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Abstract 
 
Pulmonary Hypertension (PH) is a rare but devastating illness which results in 
progressive right ventricular (RV) failure and early death.  RV function determines 
survival in all patients with PH but it is difficult to measure accurately using existing 
clinical techniques.  The choice and design of the experiments in this thesis was 
driven by a desire to improve our understanding of the reasons for right, and left, 
ventricular dysfunction in this context.  Cardiovascular magnetic resonance (CMR) 
imaging was utilized throughout as it allows the non-invasive, direct and accurate 
study of both ventricles; at rest and during stress.  In Chapter 3, CMR imaging was 
used to identify an NT-proBNP threshold (1685 ng/l, sensitivity 100%, specificity 
94%) for the non-invasive detection of RV systolic dysfunction in patients with PH.  
In Chapter 4, contrast-enhanced-CMR was utilized for the first time in PH patients 
and revealed previously unidentified areas of myocardial fibrosis within the RV 
insertion points and interventricular septum. The extent of these areas correlated 
inversely with RV ejection fraction (r = -0.762, p < 0.001). Septal contrast 
enhancement was particularly associated with bowing of the interventricular septum. 
Finally, in Chapter 5, dobutamine stress-CMR was used to determine the individual 
reasons for right and left ventricular stroke volume impairment during exercise in PH 
patients. ∆ RV stroke volume appeared limited by diminished contractile reserve as ∆ 
RVEF was lower in PH patients (27%) compared to controls (38%) and ∆ RVEF 
correlated with ∆ RV stroke volume (r = 0.94, p < 0.001). ∆ LV stroke volume 
appeared limited by impaired filling, probably due to reduced LV preload as RV 
stroke volume and LV end-diastolic volume remained closely related at rest (r = 
0.821, p < 0.001) and stress (r = 0.693, p = 0.003).  
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1. General Introduction 
 
Pulmonary Hypertension (PH) results from a variety of conditions which affect the 
pulmonary circulation.  A progressive rise in pulmonary vascular resistance (PVR) 
results from obliteration or obstruction of the pulmonary vascular bed.  This rise in 
PVR leads to a rise in pulmonary arterial pressure (PAP) and eventually results in 
right ventricular (RV) failure and early death in the majority of patients.  Prognosis in 
PH is largely dictated by RV function.  Data recorded in the 1980s by the US 
National Institutes of Health Registry indicate that, without treatment, median 
survival in Pulmonary Arterial Hypertension is only 2.8 years from diagnosis with 
equivalent 1-year, 3-year and 5-year survival rates of only 68%, 48% and 34%, 
respectively.  (1) 
 
Nevertheless, the twenty years that have elapsed since the collection of these data 
have been marked by steady and significant scientific advance.  We have seen a 
complete re-classification of the numerous conditions that result in PH and there has 
been a sea change in our conception of the processes that mediate vascular 
remodelling and the development of pulmonary arterial hypertension (PAH).  We 
have moved away from the vasoconstrictive hypothesis originally proposed regarding 
the origins of PAH and now acknowledge the primarily vasoproliferative origin of 
this condition. New intracellular therapeutic targets have thus been identified in PAH 
and other causes of PH.  This progress has driven the development of new breed of 
targeted antiproliferative therapies for the treatment of PAH (e.g. Prostanoids, 
Endothelin antagonists, and Phosphodiesterase inhibitors) and increasingly, PH 
associated with other diseases.  As a direct result of this progress survival rates in 
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PAH now approach 90% at 1 year and are over 60 % at 5 years in selected groups (2, 
3). 
 
The advent of these new therapies brings with it new challenges for physicians 
managing patients with this heterogeneous group of conditions.  The pulmonary 
circulation is largely hidden from clinical examination and conventional imaging 
technologies.  As a result the acquisition of accurate measurements within it has 
always been difficult and fraught with error.  Even now, at the dawn of the twenty-
first century, physicians remain reliant for an assessment right ventricular function, 
which is the principal determinant of survival in PH patients, upon techniques that are 
either prohibitively invasive, as is the case with right heart catheterisation or 
technically flawed, albeit non-invasive, in the case of transthoracic echocardiography. 
The need for an accurate diagnostic method with which to identify, and accurately 
document, prognostically significant RV dysfunction in PH patients has, therefore, 
never been greater.  In addition, our understanding of the reasons for RV failure in PH 
remains incomplete.  Novel approaches to filling this gap in our knowledge base are 
essential.  Furthermore, considerable importance has been placed, by both expert 
clinician bodies and organisations asked to fund clinical research trials, upon the 
development of novel imaging technologies and new techniques which provide a 
more accurate and less invasive assessment of the pulmonary circulation in patients 
with PH. 
 
Over the last decade Cardiovascular Magnetic Resonance (CMR) imaging has 
become accepted as the gold standard technique for the assessment of the proximal 
pulmonary circulation and the morphology and function of the right ventricle.  CMR 
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technology offers tremendous further potential as a non-invasive, multiplanar method 
capable of providing a more complete assessment of the right ventricle in PH patients 
than that currently available. 
 
The general aim of this thesis is to generate new and clinically relevant information 
regarding RV function in PH using CMR imaging.   The premise on which this aim is 
based is RV function dominates prognosis in patients with PH and that a better means 
of detecting, measuring and understanding RV function in PH might result in an 
improved outcome for patients. Before contemplating the diseased pulmonary 
circulation in PH a review of the structure and function of the normal pulmonary 
circulation and right ventricle is appropriate. 
 
1.1. Structure and function of the normal pulmonary circulation 
 
1.1.1 Normal pulmonary vascular anatomy 
 
Unlike the systemic vasculature, which is optimised to maintain oxygen delivery to 
the tissues, the pulmonary circulation is designed to facilitate gas exchange with the 
environment.  It must be able to function under a variety of conditions and adjust 
rapidly to changes in ambient atmospheric and haemodynamic pressure.  In terms of 
both anatomical structure and physiological function, the pulmonary circulation is 
supremely adapted to meet these demands. The vessels of the human pulmonary 
circulation, like those within the systemic circulation, are comprised of an intima, a 
media and an adventitia.  In the normal pulmonary circulation a single sheet of 
endothelial cells constitutes the intimal layer, outside of which lies a medial layer of 
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smooth muscle cells which thins and eventually disappears from normal arteries 
beyond the level of the respiratory bronchioles.  Internal and external elastic lamina 
envelop this medial smooth muscle layer, outside of which lies an adventitia 
comprised of a protein matrix secreted by resident fibroblasts. The adventitial layer of 
the pulmonary circulation, like the media, thins and disappears from pulmonary 
arteries as they subdivide and coalesce to form the dense pulmonary capillary 
network. 
 
In comparison with equivalently sized systemic vessels, the medial layer of smooth 
muscle cells within vessels of the pulmonary circulation is significantly thinner for 
any given calibre of vessel examined, e.g. the wall of a healthy main pulmonary artery 
is up to 30% thinner than that of a healthy ascending aorta.  This relative amuscularity 
reflects the lower pressures normally prevalent within the lung circulation. 
 
1.1.1.1 The pulmonary macrocirculation 
 
Following ejection from the right ventricle, the structure and function of which is 
discussed in detail in Section 1.1.4, mixed venous blood crosses the pulmonary (semi-
lunar) valve and enters the main pulmonary artery (or pulmonary trunk).  After around 
5 cm of travel this vessel bifurcates to form right and left pulmonary arteries (RPA 
and LPA).   The RPA travels horizontally behind the ascending aorta to the root of the 
right lung.  It then further sub-divides into two branches; the smaller upper branch 
accompanies the right upper lobe bronchus and subdivides within this area of lung. 
The larger, lower branch of the RPA accompanies Bronchus Intermedius and delivers 
mixed venous blood for saturation within the middle and lower lobes of the right lung.  
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The left main pulmonary artery runs horizontally in front of the descending aorta and 
on reaching the left hilum undergoes similar bifurcation with the upper branch 
supplying the left upper lobe and the lower branching providing desaturated blood to 
the left lower lobe. 
 
Unlike the systemic circulation in which the subsequent branching of the vasculature 
can be summarised by subdivision into large conducting arteries, arterioles, 
capillaries, venules and veins, the pulmonary arterial tree branches in a manner which 
appears more unfamiliar to the non-specialist.  Arterioles and venules do not exist in 
the pulmonary vascular bed.  Instead unique transitional vessels transmit blood 
between conducting pulmonary arteries and alveolar capillaries.  These transitional 
pulmonary vessels are termed pre-capillary arteries and post-capillary veins. 
 
Large conducting pulmonary arteries enter the wedge shaped units of the lung 
parenchyma (either lobules or acini) associated with a bronchus/bronchiole and 
surrounded by a loose connective tissue sheath.  The fibrous insertion points of the 
alveolar septae, which constitute the crucial, gas exchanging portions of the lung 
parenchyma, insert radially into this connective tissue sheath.  This arrangement is 
crucial to gas exchange function within the normal pulmonary circulation and will be 
discussed later. 
 
Following transmission into the lung parenchyma, the conducting pulmonary arteries, 
which whilst they run alongside a bronchiole are termed axial spawn subjugate 
supernumerary arteries at apparently random intervals and angles.  These 
supernumerary arteries far outnumber their axial progenitors.  Supernumerary 
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arteries, instead of remaining alongside their parent bronchioles penetrate directly into 
the adjacent alveolar parenchyma, subdividing further into smaller arteries and 
eventually entering the alveolar capillary network which surrounds the alveoli. 
 
This supernumerary branching pattern means that a single lobule or acinus, although 
oxygenated by the bronchus or bronchiole at its apex, is not necessarily perfused 
solely by blood within the conducting pulmonary artery that enters its own apex.  
Instead each wedge shaped unit can be partly perfused by supernumerary branches of 
the conducting pulmonary arteries which originally perfused one or more of several 
adjacent sections of lung parenchyma.  No pulmonary artery (whether axial or 
supernumerary) is ever exposed directly to atmospheric (or alveolar) air pressures, 
and all are surrounded by the thin connective tissue sheath alluded to earlier.  These 
vessels (which include both the arteries and accompanying veins) are unique to the 
lung in their configurations and are termed the extra-alveolar vessels (4). 
 
1.1.1.2 The pulmonary microcirculation 
 
1.1.1.2.1 Extra-alveolar vessels 
 
The term extra-alveolar vessels was first coined in 1961 by Howell and describes all 
of the arteries and veins within the pulmonary circulation that are surrounded by a 
connective tissue sheath (4).  Larger, axial, vessels share their connective tissue sheath 
with a bronchus, whilst smaller, supernumerary, vessels have a sheath of their own. 
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As described previously, this connective tissue sheath not only transmits the 
pulmonary arteries, veins and lymphatics into the lung parenchyma, it also accepts the 
radially arranged fibrous insertion points of the alveolar septae.  It is now accepted 
that this fibrous sheath constitutes a fibrous continuum that extends from each lung 
hilum to the corresponding parietal pleural surface, surrounding all extra-alveolar 
vessels and bronchi in between (5).  It has been demonstrated previously that the 
interstitial pressure within this connective tissue sheath is sub-atmospheric, or 
negative (6).  It has also been established that this pressure becomes more negative 
with increasing chest wall expansion as the fibrous mesh transmits the expansive 
forces generated across the thoracic cage during inspiration.  The radial arrangement 
of the insertion points of the alveolar septae into the connective tissue sheath ensures 
that these forces result in an increase in extra-alveolar vessel diameter and length 
during inspiration.  This configuration facilitates maximal capillary blood flow during 
inspiration. 
 
1.1.1.2.2 Alveolar vessels 
 
At the termination of the conducting bronchioles, both air and blood (within the 
accompanying, terminal, axial arteries) enters the (alveolar) gas exchange 
parenchyma.  Air is transmitted along the alveolar ducts which are lined by alveolar 
septae.  These organs constitute the primary gas exchange apparatus of the lung.  
Blood capillaries constitute over 90% of the substance of these septae.  The 
accompanying terminal axial arteries undergo further final subdivision and join the 
alveolar capillary network within the alveolar septae.  There, blood from the axial 
arteries is mixed with blood from supernumerary vessels which have already been 
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assimilated into this dense capillary network. At this point, alveolar air and pulmonary 
capillary blood are separated by an extremely thin membrane, which at its minimum 
is comprised of a single vascular endothelial cell, an associated alveolar epithelial cell 
with a fused basement membrane in between.  It is across this membrane that gas 
exchange can occur. 
 
Corner vessels are unique amongst the alveolar capillaries.  Due to their anatomical 
location, at the corners of each alveolus, they alone are able to withstand increases in 
alveolar air pressure, e.g. during inspiration.  Other alveolar vessels, residing within 
the walls of the alveolar septae are forced to collapse under these conditions.  The 
corner vessels thus provide the sole constant mechanism for gas-exchange within the 
lung, even in the face of high alveolar air pressures.  Serial microsectioning of these 
corner vessels has demonstrated that they are perfused on one side by a pre-capillary 
artery and drained on the other by a post-capillary vein (7).  They therefore also 
provide a rapid and efficient gas exchange short-cut between the right and left sides 
of the pulmonary circulation when the rest of the pulmonary vascular bed is collapsed, 
e.g. within the lungs of a ventilated patient using high Positive End-Expiratory 
Pressure (PEEP) settings.  This concept is discussed in more detail in section 1.1.3.1, 
entitled Passive regulation of pulmonary haemodynamics. 
 
Unlike the systemic circulation, in which the terminal, perfusing capillary bed is 
formed by the final branching of an arteriole and then drained by reconstitution of the 
capillaries to form a venule, the pulmonary capillary bed forms a seemingly chaotic 
network of intertwining capillaries with no obvious beginning or end.  This 
configuration has prompted much debate as to the exact nature and pattern of blood 
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flow within the pulmonary vascular bed.  Weibel argues that this blood flow is 
governed by the tubular shape of the pulmonary arteries and capillaries and so PVR 
can be computed by Poiseuilles law (8).  In contrast, Fung and Sobin have proposed 
an alternative model suggesting lamellar (sheet-like) flow between fibrous posts 
within the hexagonal capillary network mesh (9-11).  Others have suggested that both 
flow conditions may co-exist depending on the prevailing atmospheric and 
haemodynamic conditions (12). 
 
1.1.2 Normal pulmonary vascular function 
 
The anatomical configuration of the pulmonary circulation described above provides 
much of the apparatus necessary for normal pulmonary function and efficient gas 
exchange.  In health, the pulmonary circulation is a compliant, high flow, low 
resistance system.  Unlike the systemic circulation the pulmonary circulation is nearly 
maximally vasodilated at rest.  Healthy pulmonary arteries exhibit very low basal 
smooth muscle tone and normal PVR is approximately one-fifteenth of normal 
systemic vascular resistance (13). This allows the pulmonary circulation to 
accommodate the entire cardiac output, which flows through the lungs at pressures far 
lower than those seen in the systemic circulation. These low pressures prevent fluid 
migrating into the interstitial space, optimizing the conditions for gas exchange and 
allowing the RV to operate at minimum energy cost (14). 
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1.1.3 Normal regulation of pulmonary haemodynamics 
 
1.1.3.1 Passive regulation of pulmonary haemodynamics 
 
Pulmonary blood flow is greater in the dependant regions of the lung; the upright 
human lung is approximately 30 cm in height and so the influence of gravity cannot 
be underestimated.  Gravity-dependant relationships between the transmural pressures 
of air, arterial blood and venous blood exert tremendous influence over the shape, and 
therefore, the function of the alveolar septae and the microvasculature they contain. 
These three determinants of the net transmural alveolar pressure are present in various 
combinations depending on the location of an individual alveolus within the upright 
lung.  These combinations have been reproduced in the laboratory and, following 
fixation of the vasculature, used by West to describe the three zones within the 
upright human lung (15). 
 
Zone 1  Alveolar air pressure is higher than both arterial and venous pressures 
 Upper zones of the upright lung 
Zone 2  Arterial pressure is highest, followed by alveolar air pressure.  Venous 
pressure is lowest. 
 Mid- zones of the upright lung 
Zone 3  Both arterial and venous pressures are higher than alveolar air pressure 
 Lower zones of the upright lung 
 
In Zone 1 high alveolar air pressure produces perfectly smooth alveolar septal 
surfaces with collapse of all but the corner capillary vessels.  This configuration 
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rarely, if ever, exists in vivo except in the very apices of the lung and perhaps in the 
setting of profound hypovolaemia.  Although Zone 1 conditions are detrimental to gas 
exchange, it has been demonstrated previously that the corner vessels, which are the 
sole capillaries open within this environment remain capable of maintaining gas 
exchange. 
 
Zone 2 conditions are commonly encountered throughout the lungs of patients 
ventilated mechanically using high PEEP settings.  As in zone 1 the relatively high 
alveolar pressures cause collapse of many of the septal capillaries.  Those that remain 
open appear as slit-like vessels although, as in Zone 1, the majority of capillary blood 
flow is through corner vessels (or corner pleats, which are formed by infoldings of the 
alveolar wall where at least three alveolar septae, containing open corner vessels, 
meet).  Although these conditions would, again, appear to compromise gas exchange, 
the corner pleats perform extremely efficiently in this regard. 
 
Under Zone 3 conditions the optimum conditions for gas exchange exist.  The 
relatively low alveolar air pressure allows distension and engorgement of the majority 
of the alveolar septal capillaries.  Assuming alveolar ventilation is adequate and well 
distributed avid gas exchange across this huge surface area will be possible. 
 
This zonal model of gas exchange function is clearly not strictly geographical or 
anatomical.  Instead, Wests model provides a useful basis for discussions regarding 
pulmonary circulation function under various environmental and haemodynamic 
conditions.  In addition to these powerful passive regulatory mechanisms which are 
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endowed upon the pulmonary circulation through its unique configuration, additional 
active regulatory mechanisms also exist. 
 
1.1.3.2 Active regulation of pulmonary haemodynamics 
 
In healthy individuals, the active regulation of the pulmonary circulation is far less 
important than the passive mechanisms discussed in the previous section.  Neuro-
humeral factors play a fairly minor role in control of the healthy pulmonary 
circulation; however, Hypoxic Pulmonary Vasoconstriction (HPV) remains a 
powerful and important influence upon pulmonary haemodynamics under the 
appropriate conditions. 
 
1.1.3.2.1 Hypoxic pulmonary vasoconstriction 
 
The systemic and pulmonary circulations differ diametrically in their response to 
hypoxia.  Whilst the systemic vasculature vasodilates in an attempt to maintain local 
tissue oxygenation the pulmonary circulation vasoconstricts.  HPV is initiated by an 
unidentified oxygen sensor, which is probably located in the airways and is effected 
by shortening of the smooth muscle cells within the small (200-600 µm diameter) 
pulmonary arteries in the precapillary circulation.  HPV is triggered within two 
minutes of a fall in inspired alveolar oxygen concentration below a threshold of 
around 10%.  This reflex diverts deoxygenated blood away from under- or un-
ventilated alveoli in an attempt to maintain ventilation/perfusion (V/Q) matching and 
arterial oxygen saturation. 
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The HPV reflex was first described by Bradford and Dean in the 1890s and more 
completely defined by von Euler and Liljestrand in the cat in 1946 (16).  This reflex is 
found in all mammalian species although its intensity varies between species and 
individuals.  The components and intracellular pathways which mediate HPV have 
been the subject of much research over recent years.  Although significant progress 
has been made in animal models, the exact nature of the human HPV response is not 
yet fully understood.  It is known that hypoxia causes an increase in both the influx 
and intracellular generation of calcium within pulmonary artery smooth muscle cells 
probably signalling through altered intracellular potassium channels (e.g. Kv2.1 and 
Kv1.5 which have been identified in rat pulmonary arteries). 
 
HPV is most effective in response to localised V/Q mismatch when it can preserve 
arterial oxygen saturation without any rise in PAP.  However, in the context of 
widespread V/Q mismatch or persistent inspired alveolar hypoxia, HPV results in the 
PH associated with Chronic Hypoxic Lung Disease and continuous residence at high 
altitude, respectively. 
 
1.1.3.2.2 Neural influences upon pulmonary haemodynamics 
 
Although the pulmonary circulation is suffused with both adrenergic and cholinergic 
nerve endings, this innervation is predominantly proximal and is not thought to be of 
great significance in the control of normal pulmonary vascular function.  Adrenergic 
pathways have been shown to produce both vasodilatation (ß agonists) and 
vasoconstriction (α agonists) depending on the receptor subtypes stimulated.  
Stimulation of the sympathetic nervous system has been shown to produce both 
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vasodilatation and vasoconstriction, whilst the parasympathetic nervous system 
appears to have no significant effect on the healthy pulmonary circulation. 
 
1.1.3.2.3. Humeral influences upon pulmonary haemodynamics 
 
Various circulating and endothelium derived-humeral factors have been shown to 
influence both the healthy and the diseased pulmonary circulation.  Nitric Oxide and 
Prostacyclin, both derived from endothelial cells, have both been shown to 
consistently cause pulmonary vasodilatation and to inhibit cell replication and growth 
within the pulmonary circulation.  In contrast, Thromboxane A2 and Endothelin-1 
which again are derived from the endothelium are potent constricting agents and 
growth factors.  Disregulation of the production of these endothelium derived humeral 
factors appears central to the pathogenesis of various pulmonary vascular disorders 
including Pulmonary Arterial Hypertension.  A large number of other mediators, e.g. 
histamine, serotonin, angiotensin II, acetylcholine have been shown to affect 
pulmonary vascular tone although none of these have shown consistent 
haemodynamic effects. 
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1.1.4 Normal right ventricular structure and function 
 
1.1.4.1 Anatomical considerations 
 
1.1.4.1.1 The location and shape of the right ventricle 
 
The term right ventricle is really a misnomer.  The rightness of the RV reflects the 
natural orientation of the explanted heart as it lies on the dissection table.  In this 
position the RV, which is more accurately termed the anterior, or pulmonary, 
ventricle, lies on the operators right with the interventricular septum (IVS) in the 
midline and the cardiac apex pointing away.  In the normally connected in vivo human 
heart the RV is an anterior structure lying almost in the midline. 
 
The shape of the human RV is complex and has been likened to a truncated ellipsoid 
pyramid, draped around the cylindrical left ventricle (LV).  The left posterior and left 
lateral borders of the RV cavity are therefore concave and formed by the IVS, whilst 
the tricuspid (or atrioventricular) valve plane forms the right posterior border.  The 
basal surface of the RV lies upon the right hemi-diaphragm over the left lobe of the 
liver whilst the convex antero-superior surface, often termed the RV free wall 
extends from right atrium to the apex and forms a large part of the sterno-costal 
surface of the heart.   The upper left corner of the RV, as it resides in the chest, forms 
a conical pouch termed the Infundibulum (or Conus Arteriosus) from which the main 
pulmonary artery arises  (see figure 1.1, overleaf). 
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Figure 1.1 
Surface anatomy of the human RV as it lies in the thoracic cavity. Reproduced from 
the 20th edition of Grays Anatomy of the Human Body, originally published in 1918 
(copyright expired). 
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Figure 1.2 
Cut-away diagram of the normal RV cavity.  The RV outflow tract lies immediately 
inferior to the pulmonary valve.  The moderator band is visible, but not labelled, at the 
bottom right of the RV cavity which it crosses to attach to the RV free wall (cut 
away). Reproduced from the 20th edition of Grays Anatomy of the Human Body, 
originally published in 1918 (copyright expired). 
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1.1.4.1.2 Topography of the right ventricular cavity 
 
The RV cavity is, by convention, divided into inlet and outlet (or sinus) portions 
separated by the supraventricular ridge (see figure 1.1 on page 40).  The inlet portion 
of the RV is comprised of the tricuspid valve, the papillary muscles and their 
associated chordae tendinae, and the coarsely trabeculated myocardium that supports 
the tricuspid valve.  The well defined muscle bands of the supraventricular ridge form 
an almost circular orifice separating this inlet portion of the RV from the contiguous 
outlet (or outflow) tract.  Note: the RV outflow tract is sometimes referred to as the 
Infundibulum or the Conus Arteriosus (as it is in Figure 1.1). While the term 
Infundibulum more specifically refers to the muscular component of the RV that 
surrounds the outflow tract the terms, Infundibulum and RV outflow tract are often 
used inter-changeably.  Conus Arteriosus is a term generally now confined to anatomy 
text books although it describes the same structure as Infundibulum. 
 
The RV outflow tract is unique in that it is the only component of the RV cavity that 
has a smooth endocardial surface.  It runs superiorly from the tricuspid valve plane to 
the pulmonary valve which lies at its summit.  It is visible, but not labelled, 
immediately inferior to the pulmonary valve on figure 1.2 (page 41).  The endocardial 
surface of the remainder of the RV cavity is coarsely trabeculated.  These 
trabeculations appear straighter and fewer in number than those found within the LV 
cavity; some are simple ridges, others are more developed and although fixed at their 
ends, free in the middle.  A further population of trabecullae are more heavily 
muscled and collectively form the papillary muscles, supporting the three leaflets of 
the tricuspid valve.  The papillary muscles of the RV are more complex in there 
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arrangement than those supporting the mitral valve in the LV (17).   A single large 
anterior papillary muscle arises from the RV free wall.  In addition, multiple smaller 
papillary muscles attach partly to the postero-inferior RV free wall and partly to the 
septum and a further group of smaller papillary muscles arise from the interventricular 
septum.  The uppermost of these septal papillary muscles is called the medial (conal) 
papillary muscle, also described as the Muscle of Lancisi or the Muscle of Luschka.  
Again these structures are visible in Figure 1.2 in which they are labelled simply as 
the papillary muscles. The septomarginal trabeculation is a particularly well 
developed trabeculation that extends apically along the interventricular septum from 
the Supraventricular Ridge.  Just before this structure meets the RV free wall at the 
RV apex, a prominent ridge of muscle extends from it and crossed the RV cavity to 
meet the approaching RV free wall.  This structure may assist in preventing over-
distension of the RV, hence its name; the Moderator Band.  The moderator band is 
visible, but not labelled at the bottom right corner of the RV cavity in figure 1.2. 
 
1.1.4.1.3 The layering and myoarchitecture of the right ventricular wall 
 
The human heart is supported by a flexible, fibrous skeleton fixed around the two 
atrioventricular (tricuspid and mitral) and the two arterial (pulmonary and aortic) 
valve orifices.  Myocardial muscle fibres from all four cardiac chambers attach into 
this skeletal frame in a fashion that facilitates coordinated chamber and valve 
function. 
 
Within the LV of the human heart a characteristic pattern of subepicardial (or 
superficial), middle and subendocardial (or deep) muscle layers can be identified.  
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This is in contrast to the RV in which only two identifiable muscle layers exist, a 
superficial layer and a deep layer (18, 19). Whether within the LV or the RV these 
muscles layers are not separated by myofascial planes but are instead defined by 
changes in the orientation of their constituent fibres.  These orientations are, by 
convention, described relative to the plane of the atrioventricular grooves.  Therefore, 
circumferential fibres run parallel to the atrioventricular grooves whilst longitudinal 
fibres run perpendicular to this plane.  Oblique muscle fibres run in a direction 
interposed between these two axes (18). 
 
The myocardial muscle fibres of the superficial (subepicardial) layer of the RV are 
anchored to the fibroskeleton of the heart around the tricuspid valve ring.  These 
superficial fibres run obliquely from the base of the heart towards the apex.  Some 
cross the anterior and posterior interventricular sulci on the sternocostal and 
diaphragmatic surfaces of the heart and merge with LV superficial fibres running 
longitudinally from around the mitral valve ring.  On approaching the cardiac apex 
these superficial fibres, from both left and right ventricles, wind into tight vortices 
(one on the left and one on the right).  These vortices eventually invaginate at the 
cardiac apex. 
 
The wound fibres of this superficial layer, tucked in at the right and left cardiac 
vortices at the apex of the heart then give rise to the fibres of the deep 
(subendocardial) muscle layer of the RV and LV respectively.  The deep fibres of the 
RV run longitudinally back towards the atrioventricular and pulmonary valve anulli 
and the papillary muscles, into which they insert and are anchored to.  A significant 
component of the deep muscle layer of the RV also arises from the invagination of 
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some superficial fibres at the anterior and posterior interventricular sulci.  These fibres 
form the right hand side of the interventricular septum before continuing basally.  
They ultimately become fixed to similar endocardial structures as those fibres that 
originated at the cardiac apex. 
 
The fibres within the deepest of this deep RV layer are arranged in sheets that loop 
around both cardiac ventricles.  This arrangement of the deep fibres and in particular 
the anchoring of these fibres to key structural elements within the heart is believed to 
facilitate normal synchronised ventricular function and coordinated atrio-ventricular 
valve closure in the normal human heart. 
 
1.1.4.1.4 The layering and myoarchitecture of the left ventricular wall 
 
As indicated earlier the LV, which includes the interventricular septum, contains an 
additional, middle, layer of muscle fibres.  These fibres are arranged circumferentially 
and have no specific points of origin, termination or anchorage.  The middle layer of 
the LV has been shown to be preferentially thickened in patients with systemic 
hypertension (20) and in those with congenital heart disease (19).  Within the LV the 
superficial and deep muscle layers are arranged in a similar fashion to those within the 
RV, however, the superficial fibres of the LV must penetrate the middle, 
circumferential, layer to reach and become confluent with the deep muscle layer. 
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1.1.4.1.4. Right ventricular blood supply 
 
In general, the Right Coronary Artery (RCA) supplies the RV myocardium.  The sino-
atrial node branch supplies the sino-atrial node in the RA, whilst other marginal 
branches of the RCA supply the RV free-wall.  Inevitably there is some variability in 
this arrangement in humans, for example, in approximately 10% of individuals, 
branches of the circumflex artery, arising form the Left Coronary Artery (LCA), 
supply the posterior RV wall (21).  In the majority of individuals the interventricular 
septum is supplied predominantly by four to six perpendicular branches of the Left 
Anterior Descending Artery, arising from the LCA.  Detailed histopathological 
studies have however demonstrated a considerable contribution to septal blood 
supply, particularly within the postero-inferior portions of the septum from 
perpendicular branches of the Posterior Descending Artery (PDA) (21).  In 85 % of 
individuals this vessel arises from the RCA (a right dominant coronary circulation) 
whilst in the remaining 15% the PDA arises from the Left Coronary Artery (LCA) (a 
left dominant coronary circulation).  In this latter 15 % of individuals the 
interventricular septum will therefore receive almost all its blood supply from the left 
coronary circulation. 
 
1.1.4.2 Normal right ventricular function 
 
The RV under normal circumstances is a low pressure volume pump that moves 
desaturated blood out across the pulmonary valve into the pulmonary circulation.  
Desaturated blood returns from the systemic circulation via the vena cavae and the 
RA, finally crossing the tricuspid valve and entering the inlet portion of the RV 
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cavity. The normal RV ejects an equivalent volume of blood per contraction as the left 
ventricle (LV). Since resting pulmonary vascular resistance (PVR) is, however, only 
one-fifteenth of normal systemic vascular resistance the RV is able to operate at a far 
lower energy cost than the LV, per contraction.  The low pressure environment within 
the pulmonary circulation is advantageous in that it prevents fluid migrating into the 
interstitial space and so provides optimal conditions for gas exchange.  These low 
pressures do however make the pulmonary circulation in general, and the thin-walled 
RV in particular, poorly adapted to cope with rapid changes in pulmonary vascular 
resistance and rising pulmonary artery pressures (14). 
 
1.2 The pulmonary circulation and right ventricle in Pulmonary 
Hypertension  
 
1.2.1 The aetiology of pulmonary hypertension 
 
The term Pulmonary Hypertension describes a syndrome characterised 
haemodynamically by elevated PVR and PAP, and clinically by complaints of 
breathlessness, fatigue, chest pain and ankle swelling.  The detection of Pulmonary 
Hypertension (PH) is therefore, in itself, not an adequate diagnosis as the syndrome 
can be caused by a variety of diseases which vary not only in origin but also in 
response to treatment and prognosis. 
 
Following the 2nd WHO symposium on PH in Evian, France in 1998, a new 
classification of the diseases known to cause PH was proposed.  This re-classification 
sought to classify diseases on the basis of the pathophysiological phenotype expressed 
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in each condition; as a result the preceding arbitrary division of the causes of PH into 
primary and secondary phenomena was discarded.  It was hoped that this new 
classification would encourage the development of therapies targeted more 
specifically at the implicated and often common biological abnormalities.  In addition 
the Evian classification aimed to allow the standardisation of diagnostic methods and 
facilitate more meaningful communication about individual patients between centres.  
The Evian classification was endorsed and updated at the 3rd world symposium held in 
Venice in 2003 and is presented in Table 1.1, overleaf. 
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Table 1.1  Clinical classification of Pulmonary Hypertension (Venice 2003)  
         
1. Pulmonary arterial hypertension (PAH)     
1.1. Idiopathic (IPAH)       
1.2. Familial (FPAH)       
1.3. Associated with (APAH):       
1.3.1. Connective tissue disease      
1.3.2. Congenital systemic to pulmonary shunts     
1.3.3. Portal hypertension       
1.3.4.HIV infection        
1.3.5. Drugs and toxins       
1.3.6. Others, e.g. thyroid disorders, glycogen storage disease, HHT, splenectomy  
1.4. Associated with significant venous or capillary 
involvement    
1.4.1. Pulmonary veno-occlusive disease (PVOD)     
1.4.2. Pulmonary capillary haemangiomatosis (PCH)    
1.5. Persistent pulmonary hypertension of the newborn (PPHN)   
         
2. Pulmonary hypertension associated with left heart diseases   
2.1. Left-sided atrial or ventricular heart disease     
2.2. Left-sided valvular heart disease      
         
3. Pulmonary hypertension associated with lung respiratory diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease     
3.2. Interstitial lung disease       
3.3. Sleep disordered breathing      
3.4. Alveolar hypoventilation disorders      
3.5. Chronic exposure to high altitude      
3.6. Developmental abnormalities      
         
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease  
4.1. Thromboembolic obstruction of proximal pulmonary arteries   
4.2. Thromboembolic obstruction of distal pulmonary arteries    
4.3. Non-thrombotic pulmonary embolism, e.g. tumour, parasites, foreign material  
         
5. Miscellaneous        
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary 
vessels 
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1.2.2 The pathophysiology of Pulmonary Arterial Hypertension 
 
The unique functional configuration of the pulmonary circulation is maintained by a 
fine balance of locally synthesised and rapidly active modulators of cellular growth 
and pulmonary vascular smooth muscle tone.  This balance maintains the 
microcellular structure of the vessels in the pulmonary circulation and is necessary to 
facilitate rapid responses to changes in atmospheric, haemodynamic or ventilatory 
conditions.   However, this balance is disrupted in Pulmonary Arterial Hypertension 
(PAH), in which, aberrant intracellular signalling and functional abnormalities have 
been demonstrated within all three layers of the vascular wall.  PAH is considered the 
prototype for the majority of primary disorders affecting the pulmonary vasculature 
including Idiopathic PAH (previously termed Primary Pulmonary Hypertension) and 
PAH associated with various conditions including connective tissue diseases, HIV 
infection and congenital systemic-to-pulmonary shunts.  These intracellular 
abnormalities include: 
 
1. Endothelial cell dysfunction (22-25) within the intima 
2. Increased expression of 5-hydroxytryptamine transporter proteins (26, 27) and 
abnormal voltage-dependant potassium channels (28, 29) within pulmonary 
artery smooth muscle cells (PASMCs) 
3. Abnormalities of adventitial metalloproteases and serine elastases (30-32) 
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1.2.3 Pulmonary vascular remodelling 
 
Current evidence suggests that these aberrant intracellular processes, in combination, 
promote cellular proliferation and vasoconstriction and result in the typical 
histopathological abnormalities seen in PAH.  These changes, often summarised by 
the term vascular remodelling, are characterised by the obliteration of pulmonary 
arterioles by intimal fibrosis, often with associated in-situ thrombosis and hypertrophy 
of the medial smooth muscle cells and adventitial fibroblasts.  The classic plexiform 
lesion is seen in up to two-thirds of patients with PAH (33, 34). This ominous mass of 
tangled vessels, endothelial cells and fibroblasts has been demonstrated in patients 
with idiopathic PAH (33, 34), PAH associated with scleroderma (35) and in PH 
secondary to congenital heart disease (34) and chronic thromboembolism (36).  It has 
been demonstrated recently that endothelial cell proliferation within plexiform lesions 
is monoclonal in Idiopathic PAH but polyclonal in PH secondary to other causes (37).  
Plexiform arteriopathy is thought to represent an angiogenic response to local tissue 
ischaemia and/or hypoxia, occurring as a result of proximal vascular obstruction (38).  
Several authors have observed that the earliest stages of PH are characterised 
pathologically by medial hypertrophy alone (33, 34, 39), without plexiform 
arteriopathy, which would be in keeping with this hypothesis. 
 
Our greater understanding of the intracellular mechanisms underlying vascular 
remodelling and recognition of the vasoproliferative origins of PAH has prompted 
development of the current, growing breed of anti-proliferative or de-remodelling 
therapies.  Despite the progress that has been made over the last decade, the triggers 
involved in the initiation and perpetuation of these complex remodelling processes are 
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not yet fully understood.  Genetic (40, 41), haematological (42), inflammatory (43) 
and numerous other potential mechanisms have been implicated, and it appears likely 
that the underlying aetiology is multifactorial, perhaps involving a second-hit upon a 
genetically susceptible individual. 
 
1.2.4 Right ventricular failure in PH 
 
As alluded to in the General Introduction, RV function is the principal haemodynamic 
determinant of survival in PH of all aetiologies.  Of the numerous physiological 
variables that have prognostic significance in PH patients the vast majority are direct 
correlates of RV performance.  These include cardiac output and index (1, 3, 44, 45), 
mixed venous oxygen saturation (45) and VO2 max and peak oxygen pulse (46, 47), 
all of which outperform pulmonary arterial pressure as prognostic indicators in PH.  
Furthermore, RV failure before treatment initiation is associated with a poor outcome 
in patients with PAH (48) and is associated with increased morbidity and mortality 
related to Pulmonary Thromboendarterectomy for Chronic Thromboembolic PH (49, 
50).  This powerful prognostic influence reflects the fact that progressive RV failure is 
the usual, and unfortunately, inevitable cause of death in the vast majority of patients 
who develop PH. 
 
The prognostic impact of poor RV function suggests an obvious clinical role as a 
means of detecting at risk patients at presentation with PH.  However, its clinical 
usefulness in this manner is greatly reduced by the limited means currently available 
to detect it.  RV dysfunction, without overt RV failure (suggested by an elevated 
jugular venous pressure, peripheral oedema) is almost impossible to detect clinically.  
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Physicians are therefore overly reliant on diagnostic aids for the identification of RV 
failure in PH patients.  The methods currently available for this purpose have 
significant limitations which will be discussed in detail in the sections that follow.  
One of the principal aims of this thesis was the establishment of a novel non-invasive 
means of detecting RV dysfunction in PH patients using NT-proBNP.  This 
experiment is described in Chapter 3.   Additionally, I hoped through the studies 
reported in Chapters 4 and 5 to uncover new information regarding the development 
of RV failure and the effect of RV failure on exercise capacity in PH patients.  These 
goals are all based upon the supposition that RV failure is the catalyst for clinical 
decline and death in PH patients and that a better means of detecting and 
understanding it, are essential if the outcome for patients is to be improved. 
 
1.3 Current methods of assessment of the pulmonary circulation and 
right ventricle 
 
In contrast to the advances in therapy that have been seen over recent years, there has 
been little change in the tools used to assess the pulmonary circulation since the 
introduction of cardiac catheterisation in the 1970s and the deployment of portable, 
inexpensive transthoracic echocardiography machines in the 1980s.  This lack of 
progress means that physicians remain reliant on these two techniques for the 
assessment of RV function in patients with PH.  Unfortunately, neither method is 
ideally suited for this purpose. 
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1.3.1 Echocardiography 
 
Medical echocardiography was developed in the years following World War II.  
During the war, pre-war experimentation with ultrasound technology had been 
intensified, resulting in the introduction of SONAR which was successfully used 
during the conflict to track submarines underwater.   In the 1950s, the Swedish 
physician and physicist, Inge Edler, subsequently dubbed the Father of 
Echocardiography (51), modified these techniques to produce moving images of the 
human heart for the first time (52).  By the 1970s and 80s echocardiography had 
become established as a useful clinical tool.  Thirty years on from this, it is the most 
commonly performed cardiovascular investigation after electrocardiography and chest 
radiography (51).  Echocardiography (a term which refers to trans-thoracic 
echocardiography throughout this thesis) has two principal uses in the assessment of 
patients with PH, 1) the detection of suspected PH in a symptomatic individual and 2) 
the measurement of RV dimensions and the quantitative assessment of RV function in 
patients already known to have PH. 
 
1.3.1.1 Detection of Pulmonary Hypertension 
 
Using echocardiography, Doppler-derived measurements of the peak velocity of 
blood traversing orifices, such as valves, within the cardiovascular system allows an 
estimation of the pressure gradient driving blood flow across such areas.  This method 
employs a simplified version of Bernoullis equation where the driving pressure 
gradient = 4 x (peak velocity of blood flow) 2.  Although jets of pulmonary valve 
insufficiency and blood flow across atrial or ventricular septal defects can be used in 
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the estimation of pulmonary arterial pressure (PAP), tricuspid valve regurgitant jets 
are the most ubiquitous and easily acquired haemodynamic phenomena used for this 
purpose in patients with PH (53).  In the absence of pulmonary valve stenosis, systolic 
PAP can therefore be calculated as the tricuspid valve pressure gradient (= 4(Peak 
tricuspid valve jet velocity) 2) + estimated right atrial pressure (RAP).  RAP can be 
estimated by various methods including the Inferior Vena Cava Collapsibility Index 
and the extent of jugular venous pressure elevation detected clinically. 
 
The reliability of these methods has been extensively investigated over the last twenty 
years (53-56).  Impressive correlation has been demonstrated on numerous occasions 
with invasive measurements of systolic PAP (r = 0.89-0.97) (53-56).  Doppler 
Echocardiography has, therefore, become established as the non-invasive screening 
investigation of choice in suspected cases of PH.  Doppler Echocardiography studies 
do, however, also report relatively high standard errors of estimation (between 4.9 and 
8 mmHg)  (53, 56) making the accurate estimation of systolic PAP within a particular 
individual more unreliable.  The Echo-Doppler method described is also subject to 
inevitable operator dependence and is particularly difficult to employ in obese patients 
and those with lung hyperinflation, e.g. patients with Chronic Obstructive Lung 
Disease (COPD) (in one cohort of COPD patients only 25% of examinations were 
successful (55)), who are at significant risk of developing PH. 
 
1.3.1.2 Quantitative assessment of RV function 
 
In patients in whom a diagnosis of PH has already been secured an accurate 
measurement of RV function is desirable, not least because of its powerful prognostic 
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influence.  As we have discussed in earlier sections, RV function is the principal 
haemodynamic determinant of outcome in patients with PH (57), in whom RV failure 
remains the commonest mode of death (1, 58). Unfortunately, although 
echocardiography, being cheap and portable, is a convenient method for the 
assessment of RV function it is not a particularly accurate one.   The geometric 
assumptions that echocardiography software employs to generate three dimensional 
ventricular volume measurements from data acquired in two-dimensions become 
increasingly flawed as the diseased RV dilates (59, 60) and fails.  As we have 
discussed in Section 1.1.4, the RV is a complex structure and it is extremely difficult 
to model mathematically.  Echocardiography is therefore an imprecise method of 
measuring RV dimensions and function in the setting of RV failure, limiting its 
usefulness in patients with established PH.  RV ejection fraction (RVEF) can only be 
estimated indirectly from measurements acquired in two dimensions using 
echocardiography.  Furthermore, variables derived from echocardiography that reflect 
RV function and provide useful prognostic information in PH are either complicated 
to define and therefore reliant upon an experienced operator (e.g. the Tei index) (61) 
or detected most frequently in patients in whom RV failure is already clinically overt 
(e.g. a pericardial effusion) (44). 
 
1.3.2        Right heart catheterisation 
 
Right heart catheterisation (RHC) is the current gold standard for haemodynamic 
assessment in patients with proven or suspected PH.   Standard diagnostic algorithms 
require RHC for diagnosis (PH is defined as a mean PAP, which can only be 
measured at RHC, of > 25 mmHg at rest or > 30 mmHg on exercise). Since André 
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Cournand first demonstrated that PAP could be safely and accurately measured at 
RHC in humans in 1945 (62), simple techniques have been developed that allow the 
determination of additional important variables.  These include: 
 
1. Cardiac output (CO), which is most commonly measured using a 
thermodilution technique first described 1971 by Swan and Ganz (63) 
2. Pulmonary artery occlusion pressure (PAOP) (and the related pulmonary 
capillary wedge pressure (PCWP) which provides an approximation of left 
atrial pressure by recording pressure measurements with a balloon-tipped 
pulmonary artery catheter wedged, with the balloon inflated, within a branch 
pulmonary artery (64) 
3. Right atrial pressure (RAP) 
4. Pulmonary artery (or mixed venous) oxygen saturation (PAOP or MVO2) 
 
Integration of Mean PAP, PAOP and CO allows the calculation of resistance to blood 
flow within the resistance vessels of pulmonary circulation (termed pulmonary 
vascular resistance (PVR)): 
 
PVR   =   Mean PAP-Pulmonary Artery Occlusion Pressurre 
Cardiac Output 
 
PVR provides a simple mathematical descriptor of the lung circulation that can be 
used to quantify pulmonary vascular disease.  The computation of PVR from both 
pressure and flow makes this value a powerful index of disease severity.  In health, 
the capacity for recruitment within the pulmonary circulation is large.  On exercise, as 
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CO rises, PVR should therefore fall allowing the lung circulation to accommodate the 
increased CO with only a minimal rise in PAP.  This feature of normal physiology is 
important as the earliest stages of pulmonary vascular remodelling are characterised 
by a relatively small reduction in the cross-sectional area of the pulmonary vascular 
bed, and therefore, a curtailed recruitable lung circulation.  In this setting, PH may 
only be proven by either an abnormal rise in PVR and/or PAP on exercise. CO, RAP 
and PAOP have all been shown to predict a poor outcome in patients with Pulmonary 
Arterial Hypertension (65). 
 
Acute Vasodilator testing can also be undertaken at RHC. Inhaled Nitric Oxide is the 
most commonly used vasodilator although alternative methods such as intravenous 
Prostacyclin and Adenosine have been successfully employed (65).  A positive acute 
vasodilator test is defined as reduction of mean PAP of ≥ 10 mmHg to reach an 
absolute value of mean PAP ≤ 40 mmHg with an increased or unchanged cardiac 
output (65).  In uncontrolled studies it has been shown that patients who demonstrate 
an acute vasodilator response at RHC derive sustained haemodynamic and survival 
benefit from long-term treatment with Calcium Channel Antagonists (66). Therefore, 
RHC provides important indices of pulmonary vascular disease.  Nevertheless, the 
technique has significant limitations in PH patients, these include: 
 
1. It is invasive 
2. It is generally only performed at rest making the detection of early PH difficult 
and resulting in a loose correlation with symptoms in PH (67). 
3. RHC does not seem to yield variables that correlate tightly with clinical 
improvement on therapy (67).  Invasive haemodynamics (mean PAP, CO, and 
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PVR), although crucial to diagnosis, and usually responsive in terms of pure 
statistic significance, rarely improve in great physiological terms with 
apparently successful treatment (as defined by other means, e.g. exercise 
performance, symptom scores).  This may reflect dissociation between the 
cath. lab environment (lying supine, at rest) and real life but also suggests 
that resting RHC is too simple a tool to adequately describe the physiological 
changes that occur in PH. 
 
1.3.3        The six-minute walk test 
 
An assessment of function, or exercise capacity, is important in the assessment of all 
patients with PH.  This is because functional capacity, or WHO class correlates with 
survival in PH patients and exercise capacity is a useful surrogate of the day-to-day 
symptoms experienced by patients.  The six-minute walk test (6MWT) is the most 
widely employed tool available for this purpose.  If recorded at presentation and at 
subsequent clinic visits, six-minute walk test (6MWT) distance can be used to monitor 
patients on therapy and as a means of detecting clinical deterioration.  6MWT 
distance probably reflects RV function to some extent as it has been shown to 
correlate strongly with peak oxygen pulse measured by Cardiopulmonary Exercise 
Testing (46), which is a direct correlate of RV stroke volume.  Furthermore, 6MWT 
distance at presentation  has been shown to predict survival (46) in patients with 
idiopathic PAH and to correlate with clinical improvement with various therapies, 
including intravenous Epoprostenol (68-70).  The 6MWT is easy to undertake, cheap 
and reproducible, it also the only measure of exercise capacity that has been approved 
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by the US Food and Drug Administration for use in clinical trials of therapy for PAH 
(67). 
 
Nevertheless, the 6MWT is not specific to either the pulmonary circulation or RV.  
Deterioration in a patients 6MWT performance can occur for reasons other than the 
progression of pulmonary vascular disease or the development of RV failure, e.g.  
arthralgia or muscle weakness.  A recent study has also reported poor correlation 
between 6MWT and cardiopulmonary exercise test results in patients enrolled in 
clinical trials of therapy for PH (71). Therefore, an alternative means of assessing 
disease severity in PH at presentation and over a period of time is desired. Recent 
research conducted in patients with diseases of the systemic circulation has 
established a potential role for natriuretic peptide hormones in the detection and 
monitoring of RV dysfunction in PH patients. 
 
1.3.4 Natriuretic peptides 
 
The natriuretic peptides share a common 17-amino acid ring structure.  Atrial 
Natriuretic Peptide (ANP) was discovered first, in the early 1980s (72), followed by 
Brain Natriuretic Peptide (BNP), now termed B-type natriuretic peptide and C-type 
Natriuretic Peptide (CNP). Both ANP and BNP bind to Natriuretic Peptide Receptor-
A (NPR-A) and promote salt and water loss (natriuresis and diuresis) (73).  CNP 
binds to NPR-B and is a potent vasodilator; however, it has no practical clinical role. 
ANP and BNP are synthesised within cardiac myocytes as high molecular weight 
precursor proteins which are then cleaved into an active hormone and an inactive N-
terminal component.  BNP, for example, is secreted as proBNP 1-108, which is 
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cleaved by enzymes such as Prohormone Convertase and Corin within cardiac 
myocytes into proBNP 1-76 (known as N terminal-pro Brain Natriuretic Peptide (NT-
proBNP)), which is inactive and BNP 32 (known simply as BNP), which is the active 
hormone  (74, 75). 
 
BNP is secreted from both cardiac ventricles in response to raised chamber pressure 
or volume overload (76).  In contrast, ANP release is dictated by atrial, rather than 
ventricular, filling pressures.  The secretion of both ANP and BNP is influenced by 
other physiological factors, most notably blood pressure, salt intake and renal 
function.  The secretory mechanisms of the two peptides dictate the effect these 
variables have on serum levels.  ANP can be released rapidly in response to 
physiological stimuli because it is stored in secretory granules within atrial myocytes 
(77).  In contrast, the secretion of BNP is constitutive because ventricular myocytes 
do not contain secretory granules (78).  Therefore, serum ANP levels are more easily 
influenced by other physiological factors than BNP, making the former less attractive 
as a potential biomarker.  The assay required to measure serum ANP levels is also 
extremely complex and expensive and so ANP is not used in clinical studies.  Because 
the secretion of BNP is more predictable and its measurement is more straightforward, 
both BNP and NT-proBNP have become established as useful biomarkers in various 
cardiovascular diseases. 
 
1.3.4.1 Natriuretic peptides and left heart disease 
 
Elevated serum BNP levels have been reported in patients with LV systolic 
dysfunction (79), acute myocardial infarction (MI) (80), systemic hypertension (81) 
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and valvular heart disease (82).  BNP and NT-proBNP concentrations below assay-
specific thresholds have a powerful negative predictive value for a subsequent 
diagnosis of heart failure in patients presenting with symptoms suggestive of the 
diagnosis (83-85).  In addition, serum BNP and NT-proBNP levels have proven useful 
as population-wide screening tests for LV systolic dysfunction in asymptomatic 
individuals (86).  This diagnostic utility has led to the incorporation of natriuretic 
peptide testing into the standard diagnostic algorithms for heart failure recently 
published by both The National Institute for Clinical Excellence (NICE) (87) and the 
European Society of Cardiology (88).  Furthermore, the provision of NT-proBNP 
results, in addition to clinical findings and the results of ECGs and echos resulted in a 
significant improvement in diagnostic accuracy in patients referred to their general 
practitioner with symptoms suggestive of heart failure (89). 
 
1.3.4.2 Natriuretic peptides and Pulmonary Hypertension 
 
The natriuretic peptide system is known to be up-regulated in PH patients (90, 91). 
For example, serum levels of BNP have been shown to correlate with invasive 
pulmonary haemodynamics and RV function (91, 92) in earlier studies.  A close 
relationship has also been identified between NT-proBNP concentration and 
pulmonary haemodynamics (134), RV systolic function (163) and survival (135) in 
patients with PH. However, the diagnostic utility of NT-proBNP has yet to be tested 
in PH patients.  In contrast to LV systolic dysfunction,  where the large volume of 
data summarised above has been collected on the negative predictive value of NT-
proBNP levels below certain thresholds, no attempt has yet been made to identify an 
NT-proBNP threshold indicates RV failure in PH.  As a direct result, although high 
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NT-proBNP levels are considered a bad sign in PH patients, conclusions regarding 
RV systolic function cannot yet be drawn from NT-proBNP measurements made in 
individual patients. Rather, clinicians remain reliant on invasive (right heart 
catheterisation) and potentially inaccurate (echocardiography) tools for an objective 
assessment of RV function.  This makes the identification of at risk patients with RV 
failure difficult and appears fertile ground for further study in PH patients.  This topic 
is the subject of Chapter 3 of this thesis. 
 
1.3.5  Summary 
 
The methods used to assess RV function in PH have changed little over the last three 
decades.  The significant limitations of these techniques reduce either their usefulness, 
their accuracy, or both in routine clinical practice.  A novel alternative to the existing 
methods is now required.  Such an alternative should be accurate, reproducible and, 
most importantly, non-invasive.  A capacity to perform measurements during stress 
would an additional, and considerable, advantage.  The ability of Cardiovascular 
Magnetic Resonance (CMR) imaging to deliver these qualities in PH patients is tested 
throughout this thesis.   In the next section, the evidence that has established CMR as 
the gold standard for non-invasive RV assessment in PH is presented.  This is 
preceded by a review of basic MR theory and the factors that dictate tissue contrast on 
CMR images. 
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1.4 Cardiovascular Magnetic Resonance (CMR) imaging 
 
1.4.1 Magnetic resonance theory 
 
1.4.1.1 Nuclear magnetic resonance fundamentals 
 
Magnetic resonance imaging is based upon the principle of nuclear magnetic 
resonance which was discovered in 1946 by Bloch and Purcell.  Working 
independently in the US, they discovered that certain atoms absorbed and then 
released radiofrequency (RF) energy when moved in and out of a magnetic field. 
They demonstrated that individual atomic elements responded to RF energy of the 
same frequency that their own nuclei naturally spun at.  The term resonance was 
used to describe this effect as it is defined as an amplified response to a stimulus of 
the same natural frequency. 
 
MR images are constructed using energy absorbed and then emitted by the spinning 
nuclei of hydrogen atoms.  Hydrogen is a suitable element for this purpose because it 
is absorbs energy within the RF range and is abundant in the human body.  The 
average 70kg male contains 45 litres of water, comprised, of course, of two hydrogen 
atoms bound to a single atom of oxygen.  Proteins and lipids contain even more 
hydrogen atoms, albeit within a different molecular environment. Each hydrogen 
atom is made up of a nucleus, containing a proton but no neutron, and an orbiting 
electron.  Since the electron is redundant in this context and no proton exists, 
hydrogen nuclei will be referred to simply as protons in this thesis.  Each proton has a 
positive charge, and therefore, spins naturally around its own tiny magnetic axis.  The 
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orientation of proton spins is normally entirely random, see figure 1.3 overleaf. 
However, in the presence of a strong magnetic field protons will align themselves 
parallel to the direction of the field (identified by the symbol BØ), and are said to 
precess at a characteristic frequency (the precession frequency).  Precession 
frequency is dependent on the element, its environment and the strength of the 
surrounding magnetic field.  This relationship is described by the Larmor equation: 
 
µ = δ x B 
 
where µ is the precession frequency, δ is the gyromagnetic constant (a characteristic 
of a nucleus in a given environment) and B is the magnetic field strength.  For 
example, hydrogen protons in water have a precession frequency of 63 megahertz in a 
1.5 Tesla magnet.  Under these conditions, the majority of protons spin, or precess, in 
the same direction as the magnetic field (BØ), while a slightly smaller number line up 
in the opposite direction to the field, see figure 1.4 on page 67. Those protons lined up 
with the magnetic field are said to be in a low energy state while those lined up 
against it are said to be in a high energy state.   By applying a radiofrequency pulse at 
the precession frequency the low energy protons can be made to absorb energy and 
move to the high energy state (against the magnetic field).  Then, when the RF pulse 
is switched off these protons will relax back to the low energy state (with the 
magnetic field) emitting detectable RF energy.  Thus, the alignment of hydrogen 
protons spins, in hydrogen atom-rich tissue, placed within a strong magnetic field is a 
source of detectable RF energy.    This is the basis of nuclear magnetic resonance, or 
magnetic resonance imaging (MRI) as it has come to be known. 
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Figure 1.3    
Random natural orientation of hydrogen proton spins. Reproduced with the 
permission of Dr. John Foster 
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Figure 1.4  
Precession of protons within a strong magnetic field (the direction of which is 
indicated by the standard nomenclature: BØ). The majority of protons line up parallel 
to the magnetic field. Reproduced with the permission of Dr. John Foster. 
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1.4.1.2 Magnetic fields and magnets 
 
The purpose of the strong magnetic field in all diagnostic MRI systems is to produce 
precession of the protons within the target tissue.  Although a minority of protons will 
line up anti-parallel to the magnetic field, the net alignment of protons under these 
conditions will always be in the direction of the magnetic field and arranged 
longitudinally.  Therefore, the overall effect of the magnet on the tissue, at 
equilibrium (i.e. before any RF pulse is applied to excite protons), is to generate a 
small secondary magnetic field, described as the net tissue magnetisation vector, see 
figure 1.5 overleaf. 
 
Modern MRI systems use resistive electromagnets (as opposed to permanent magnets 
containing ferromagnetic material) to generate an electrical field perpendicular to an 
electrical current, flowing around a central coil.  The orientation of the resulting 
magnetic field and its relationship to a patient is shown in figure 1.6 on page 70. 
 
The magnetic field strength that a resistive magnet can generate greatly exceeds that 
of a permanent magnet but is limited by the resistance of the material in which the 
current flows.  This can be reduced by the use of modern filaments to carry the current 
(e.g. Niobium) and by super-cooling the coil, e.g. by bathing it in pressurised, liquid 
Helium at approximately -250ûC.  Using these techniques contemporary MRI systems 
can generate field strengths of up to 7 T (Tesla) (70,000 times stronger than the 
earths magnetic field), although most clinical systems operate at 1.5 T. 
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Figure 1.5  
The net magnetisation vector (in yellow) of protons within a strong magnetic field 
(BØ) is produced because the majority of protons line up parallel with the main field 
(i.e. pointing north; in red), while the rest of the protons line up anti-parallel (i.e. 
pointing south; in green)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BØ 
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Figure 1.6  
Magnetic field orientation (B0) in a superconducting electromagnet.  Note the 
orientation of the longitudinal and transverse magnetisation vectors relative to the 
patient (lying within the bore of the electromagnet). 
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1.4.1.3 Radiofrequency pulses and transverse magnetisation 
 
Radiofrequency pulses are used to stimulate tissue protons and alter net tissue 
magnetisation.  This process is described as excitation.  The RF energy released by 
the excited protons when the RF pulse is switched off can then be used to construct 
MR images. However, with the net tissue magnetisation vector in the longitudinal 
plane (i.e. aligned with the main magnetic field) changes in tissue proton alignment 
cannot be detected because they are dwarfed by the strength of the main magnetic 
field.  MRI systems circumvent this problem by producing magnetisation in tissue 
protons in the transverse plane by the following method, which is presented 
graphically overleaf in figure 1.7. 
 
An appropriate RF excitation pulse (delivered at the precession frequency of the tissue 
protons in that strength of MR field) causes the protons in the tissue to resonate and 
results in rotation of the axis around which they spin.  This rotation out of the 
longitudinal plane has the effect of tipping a component of the net magnetisation 
vector out of the longitudinal plane into the transverse plane.  When the excitatory RF 
pulse is switched off, any RF energy released from the excited tissue protons in this 
transverse plane will produce a change in flux in a receiver coil in this orientation.  
This produces a voltage and thus a detectable signal from the tissue protons.  This 
signal is relatively pure as it is unaffected by the background noise of the main 
(longitudinal) magnetic field.  The strength (or amplitude) of the RF pulse and the 
length of time it is applied for determine how far out of the longitudinal plane the net 
tissue vector is tipped.  A 90û pulse will covert all longitudinal magnetisation into 
detectable transverse magnetisation, as shown in figure 1.7. 
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Figure 1.7 
Schematic representation of a 90û excitation pulse which converts all longitudinal 
magnetisation in the imaged protons into transverse magnetisation.  At equilibrium, 
shown on the left, the net magnetisation vector of the tissue protons is orientated in 
the same plane as the main magnetic field (BØ).  Once a RF excitation pulse is 
applied, as shown on the right, the net magnetisation vector is tipped out of the 
longitudinal plane, into the transverse plane, in which the transverse receive coil is 
located. 
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1.4.1.4 Relaxation 
 
Once the excitatory RF pulse is turned off, the tissue magnetisation vector drifts back 
from the transverse plane into the longitudinal plane, under the influence of the main 
magnetic field.  This process is described as relaxation; during relaxation RF energy is 
released and results in a MR signal in the transverse receive coil.  The rate of 
relaxation is an important determinant of tissue contrast in MR imaging and is 
dependent on the molecular environment of the water protons that were excited.  
Relaxation is rapid in highly cellular tissues containing a lot of bound water.  This is 
a term used to describe water molecules in close proximity to macromolecules (e.g. 
intracellular organelles, proteins, DNA).  These larger molecules restrict the 
movement of the smaller water molecules.  However their juxtaposition makes energy 
transfer more efficient in bound water compartments. 
 
Conversely, relaxation of transverse magnetisation is slower in free water solutions 
containing randomly orientated and rapidly tumbling water molecules because energy 
transfer is less efficient in this less structured environment.  Thus, the molecular 
environment of water protons has a profound influence on the rate of RF energy 
release and therefore the MR signal received from different tissues.   For example, 
free water solutions (e.g. cerebrospinal fluid, urine, glandular structures or cysts) look 
different to bound water solutions (e.g. brain, liver) on MR images. This is, 
however, an oversimplification of the factors involved in MR tissue contrast.  The 
return of tissue magnetisation from the transverse to the longitudinal plane, and the 
release of RF energy (and an MR signal) are dictated by two further characteristics of 
the imaged tissue.  These are defined as T1 and T2 relaxation.  T1 relaxation describes 
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the recovery of longitudinal magnetisation, while T2 relaxation describes the decay of 
transverse magnetisation.  Clearly, these processes are related but they are not 
interchangeable and are completely independent. 
 
1.4.1.4.1 T1 relaxation 
 
T1 relaxation describes the recovery of longitudinal magnetisation after an excitatory 
RF pulse is switched off, see figure 1.8 overleaf.  Therefore, it can also be described 
as T1 recovery or longitudinal relaxation. The time required for T1 relaxation is 
dependent on the efficiency with which RF energy can be dissipated from the excited 
protons to surrounding tissues, and the strength of the main magnetic field.  The 
dependence of T1 upon the surrounding environment allows the alternative 
description of T1 relaxation as spin-lattice interaction.  T1 relaxation time is defined 
as the time taken for 63% of longitudinal magnetisation to recover to its original 
value; it is a constant for any given tissue, within a given MR field. Examples of T1 
relaxation times for different tissues in a 0.5 T and a 1.5 T MR field are given in table 
1.2. 
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Figure 1.8 
Schematic representation of T1 relaxation. Once the excitatory RF pulse is switched 
off, the net magnetisation vector of the imaged protons relaxes back from the 
transverse plane, shown on the left, into the longitudinal plane, shown on the right.  
By this process, RF energy is released in the transverse plane and can be detected by 
the transverse receive coil.  T1 relaxation time is defined as the time taken for 63% of 
longitudinal magnetisation to recover. 
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Table 1.2  T1 relaxation times (msecs) of commonly imaged tissues 
 
      
Tissue  T1 @ 0.5T T1 @ 1.5T  
      
      
Fat  215 260   
Liver  323 490   
Muscle  600 870   
Grey Matter 656 920   
CSF  >4000 >4000   
      
      
 
Pure free water has the longest T1 relaxation time because it dissipates RF energy 
slowly (around 3 seconds, depending on magnetic field strength).  Conversely, the T1 
relaxation time of adipose tissue is extremely short.  This reflects the restricted 
movement of fatty acids protons, which translates into extremely efficient energy 
transfer. Protons within protein macromolecules dissipate energy so quickly, because 
of their organised structure and size, that most MR scanners cannot detect signals 
directly from them.  However, biological tissues are not comprised of pure protein and 
it is the effect of the protein content on water protons around them that determines the 
T1 relaxation times of tissues other than free water and fat.  For example, viscous 
protein-rich solutions, e.g. pus, have a shorter T1 relaxation time than pure free water 
because of the increased amount of bound water protons (i.e. protons lying adjacent to 
protein macromolecules).  Muscle, liver and brain contain variable proportions of free 
and bound water protons.  This is reflected in the individual and characteristic T1 
relaxation times of these, and all other tissues, which lie in the spectrum in between 
those of free water and adipose tissue. 
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In practice, this means that it will take a long time to receive an adequate signal back 
from a pure water solution.  Since most MR sequences aim to detect a signal in less 
than a second, free water solutions (e.g. cerebrospinal fluid) appear dark and adipose 
tissues (e.g. brain) appear bright on images that rely on T1 contrast, see figure 1.9 
overleaf for an example.  This type of image is known as a T1-weighted image which 
will be discussed in more detail in section 1.4.1.8. 
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Figure 1.9  
T1 weighted sagittal image of the lumbar spine.  Note that cerebrospinal fluid, which 
is a free water solution, appears dark because of its long T1 relaxation time resulting 
in a low MR signal at the time of image acquisition. Adipose tissue, in contrast, 
appears bright reflecting its short T1 relaxation time. 
 
Vertebral Bodies
Cerebrospinal 
Fluid
Adipose 
Tissue
Spinal Cord
 
 
 
 79
1.4.1.4.2 T2 relaxation 
 
T2 relaxation describes the decay (or dephasing) of transverse magnetisation 
produced by an excitatory RF pulse.  Contrast this with T1 relaxation which describes 
the recovery of longitudinal magnetisation after the same event.  If T2 relaxation (also 
described as T2 decay) was automatically translated into T1 recovery the use of 
individual terms to describe these processes would be unnecessary.  However, the rate 
at which transverse magnetisation is lost (T2 decay) is greater than the rate at which 
longitudinal magnetisation returns (T1 recovery) in most tissues because of energy 
dissipation amongst individual protons (described as spin-spin interaction, contrast 
this with T1 relaxation, or spin-lattice interaction, which is largely dependant on the 
dissipation of RF energy to surrounding tissues).   A schematic representation of T2 
relaxation is presented overleaf in figure 1.10. T2 relaxation rate is described by T2 
relaxation time.  Individual tissues have a characteristic T2 relaxation time, see Table 
1.3 overleaf for examples. 
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Figure 1.10  
Schematic representation of T2 relaxation which describes the dephasing of transverse 
magnetisation once the excitatory RF pulse is switched off.  Note that this process 
results in the release of RF energy. 
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Table 1.3 T2 relaxation times (msecs) of commonly imaged tissues 
     
Tissue  T2 @ 1.5T  
     
     
Fat  85   
Liver  43   
Muscle  47   
Grey Matter 100   
CSF  1400   
     
     
 
In contrast to T1 relaxation times, T2 times are relatively independent of magnetic 
field strength and influenced by different factors when compared with T1.  T1 and T2 
relaxation times are similar for pure free water and for adipose tissue because the 
unstructured arrangement of water protons in these environments makes energy 
transfer between individual protons (spin-spin interaction) inefficient.  Therefore, the 
majority of transverse magnetisation decay is converted directly into longitudinal 
magnetisation recovery.   In more organised molecular environments, particularly 
those containing a significant proportion of bound water (i.e. water molecules closely 
associated with protein macromolecules), spin-spin interaction is more efficient.  This 
results in T2 relaxation times for tissues such as muscle and liver that are significantly 
shorter than their T1 relaxation times 
 
Additional T2 decay occurs if there is any inhomogeneity in the magnetic field.  In 
practice, tiny inconsistencies in the structure of the electromagnet are inevitable, even 
in modern superconducting systems, but also occur around paramagnetic material 
implanted in the imaged tissue.  Common examples include ferrous metal joint 
replacements and foreign bodies.  The term T2* relaxation is used to describe the total 
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decay of transverse relaxation as a result of both tissue relaxation and these local 
inhomogeneities. 
 
Because significant T2 decay results in incomplete recovery of longitudinal 
magnetisation it is easy to consider T2 decay a form of energy loss.  This is not the 
case as a) RF energy is still released during T2 decay and is, therefore, detectable and 
b) longitudinal magnetisation never, in practice, recovers completely because the 
logarithmic scale on which it is plotted makes 100% recovery a theoretical 
impossibility.  Rather, T1 and T2 decay should be considered independent processes 
of RF energy release following cessation of an excitatory RF pulse. 
 
1.4.1.5 Tissue contrast 
 
Contrast in MR imaging results from the different T1 and T2 characteristics of 
adjacent tissues.  Detailed understanding of T1 and T2 relaxation and the effect on 
tissue magnetisation of different RF excitation pulses allows the design of sequences 
that optimise tissue contrast and maximise signal intensity.  Before discussing these 
concepts it is useful to first review basic MRI sequence structure:  Most MRI 
examinations require a repeating cycle of RF excitation pulses (producing multiple 
echoes from tissue protons) to generate a data set rich enough for image 
construction.  Each cycle is comprised of an excitation pulse, a time delay of varying 
length (during which precessing protons relax back into the longitudinal plane and 
release RF energy) and a period of data collection, immediately preceding a further 
excitatory pulse.  Various parameters within this basic structure can be altered to 
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accentuate differences between the T1 (or T2) relaxation times of adjacent tissues, 
producing T1 (or T2) contrast and T1- (or T2-) weighted images.   
 
1.4.1.5.1 T1 contrast 
 
T1 contrast results from differences between the T1 relaxation times of adjacent 
tissues.  These differences can be accentuated, and T1 contrast increased, by reducing 
the Repetition Time (TR) of the excitatory RF pulse, which describes the time gap in 
between excitation pulses.  When the TR is short, tissues which have a short T1 time 
will have recovered more longitudinal magnetisation than those with a long T1 time 
by the time data is collected (immediately before the next excitatory RF pulse).  Thus, 
shortening the TR of a pulse sequence enhances contrast between tissues that have a 
difference in T1 relaxation time. However, shortening the TR of the pulse sequence 
reduces the time available for the recovery of longitudinal magnetisation, energy 
release and data collection.  This has the effect of reduced overall signal intensity on 
images with a short TR.   While this is helpful in producing T1 contrast it can result in 
poor image quality if compensations are not made in other aspects of the pulse 
sequence.  The most important of these is the Flip Angle’, which describes how far 
out of the longitudinal plane the net tissue magnetisation vector is tipped (a 90û flip 
angle converts all longitudinal magnetisation to transverse magnetisation).  The flip 
angle is a product of the strength and duration of the excitatory RF pulse.  A lower 
flip angle tips less of the net magnetisation into the transverse plane.  This has the 
effect of further lowering signal intensity on resulting MR images because energy can 
only be detected from protons precessing in the transverse plane.  However, 
increasing the flip angle too much on a T1 weighted MR image can also be 
 84
detrimental.  A large flip angle will convert a large proportion of longitudinal 
magnetisation into transverse magnetisation, e.g. a 90 û pulse tips the net 
magnetisation vector completely into the transverse plane.  While this produces a 
large amount of potential MR signal on the first RF pulse, it means that longitudinal 
magnetisation will only have time to partially recover if the TR is short. Therefore, 
there will be little longitudinal magnetisation for subsequent excitatory pulses to tip 
out into the transverse plane and signal intensity ultimately decays.  Thus, there is an 
optimum flip angle for each tissue, based on its T1 time, which produces optimum 
signal intensity and compensates for the TR reduction necessary for T1 contrast.  This 
is known as the Ernst angle.  Ernst angles tend to be small for tissues with long T1 
times (because any transverse magnetisation takes a long time to recover) and larger 
for those with short T1 times. 
 
Therefore, for T1 weighted imaging, where contrast between tissues with different T1 
times is the goal, a short TR and a small flip angle should be used.  The flip angle 
should be above the (small) Ernst angle of the long T1 tissue and ideally around the 
Ernst angle of the short T1 tissue.  This ensures high signal intensity from tissues with 
a short T1 time and low signal intensity from tissues with a long T1 time. 
 
1.4.1.5.2 T2 contrast 
 
For various reasons, transverse magnetisation cannot be measured immediately after 
its creation by an excitatory RF pulse.  Rather, an echo must be produced of the 
original signal using magnetic field gradients (see next section).  The resulting delay 
between the creation of transverse magnetisation and signal measurement is called the 
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Echo Time (TE).  The TE is defined as the time from the RF excitation pulse to the 
resulting echoes used as the MR signal.  It is an important determinant of tissue 
contrast, particularly, T2 contrast. 
 
Inevitably, transverse magnetisation decays during this interval, at a rate defined by 
the T2 relaxation time of each tissue in the image block.  This results in reduced 
signal intensity from tissues with short T2 times as a significant proportion of their RF 
energy potential is released before signal measurement.  Sequences with TEs long 
enough to allow significant T2 decay from tissues with short T2 times, but short 
enough to minimise decay from tissues with long T2 times result in T2 contrast, or, 
T2-weighted images.  TE is, however, constrained by the progressive nature of T2 
decay; if TE is too long, little or no signal will remain when measurements are made 
and signal intensity will be low.  Contrast on sequences with TEs shorter than the T2 
of any of the tissues of interest will be determined by other factors, e.g. T1 contrast. 
T2 weighted images, therefore, tend to have a long TE.  Since TR is a component of 
the TE, they also tend to have a long TR. 
 
This concept of contrast weighted can be appreciated by comparison of T1- and T2-
weighted images of the brain, presented overleaf in figure 1.11. 
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Figure 1.11, below 
Comparative T1- and T2 -weighted images of the brain.  The T1-weighted image, acquired using a short repetition time (TR), results in contrast 
between white (T1 = 780 msecs at 1.5 T) and grey matter (T1 = 920 msecs at 1.5 T) but no signal from the surrounding cerebrospinal fluid (T1 > 
4000 msecs at 1.5T).  The T2-weighted image, acquired using a long TR and long echo time (TE) results in a bright signal from the 
cerebrospinal fluid (T2 = 500-1400 msecs) but a lower signal from the white (T2 = 90 msecs) and grey matter (T2 = 100 msecs). 
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Figure 1.11 
 
T1-weighted image of the brain T2-weighted image of the brain
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1.4.1.6 Magnetic field gradients and spatial localisation of tissue 
 
So far we have discussed, in broad terms, how an MR signal is produced from 
different tissue samples and explored the basic reasons behind tissue contrast on MR 
images.  The MRI signal used to form these images is, however, a radio-wave, which 
carries no directional information.  A number of complicated techniques are therefore 
used to resolve the location of individual tissue protons and produce a useful MR 
image.  The most important of these are the three magnetic field gradients or imaging 
gradients.  These are weak supplementary magnets embedded in the inner core of the 
main electromagnet.  Relative to the patient they are arranged in the sagittal, coronal 
and axial planes.  They are used as a) slice selection gradients; to identify the block of 
tissue to be excited by the RF pulse and b) as phase and frequency-encoding 
gradients; to resolve the source of the MR signal detected and localise it to an 
individual voxel within the tissue block. 
 
For the purpose of this discussion, we can assume that all of the tissue protons 
surrounded by the main magnetic field are spinning, or precessing, at the same 
frequency (since their precession frequency is directly proportional to the magnetic 
field strength they experience, as described earlier by the Larmor equation earlier, see 
section 1.4.1.1). If an additional, graded magnetic field is applied to these protons the 
total magnetic field they experience is altered; protons at the stronger end of the 
gradient field (which, therefore, experience the strongest total magnetic field) are 
made to spin faster than those at the weaker end.  This effect of a gradient field can be 
used in two ways, as indicated above. 
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1.4.1.6.1 Slice-selection gradients 
 
A magnetic field gradient can be applied at the same time as an excitation RF pulse to 
alter the precession frequency along a section of tissue protons.  The excitation RF 
pulse will then only produce transverse magnetisation (and an MR image) in a small 
section of tissue protons which have been made to precess at exactly the right 
frequency, see figure 1.12 overleaf.  Thus, a slice-selection gradient is combined 
with the excitatory RF pulse to define the tissue to be imaged.   This block can be 
selected in almost any plane using either, one of the gradients directly for axial 
imaging, or several of them in combination, for oblique imaging. 
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Figure 1.12   
Diagrammatic representation of a slice-selection gradient.  Protons at the stronger end of the gradient field precess at a higher frequency, 
proportional to the strength of gradient field.  An excitation pulse frequency is chosen that matches the precession frequency of protons in the 
desired tissue slice (126 MHz in the example shown below) resulting an axial slice selection 
 
Main Magnetic Field
Slice-selection Gradient 
Field
Resulting Precession 
Frequency of protons in 
that slice of tissue
130 128 126 124 122 120 118 116 114 112 (MHz)
RF excitation pulse delivered at 126MHz  excites or 
selects only protons precessing at 126 MHz
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1.4.1.6.2 Frequency and phase encoding gradients 
 
Magnetic field gradients can also be used for the spatial localisation of tissue within 
the selected, one-dimensional, tissue slice.  If a magnetic field gradient is applied 
along one axis of this tissue slice during MR signal measurement (contrast this with 
the slice-selection gradient which is applied during the excitation pulse) it will cause 
protons at the stronger end of the magnetic field to precess more rapidly than those at 
the weaker end.  By this method the previously selected protons, which can already be 
localised in one-dimension via the slice-selection gradient, are encoded in a second 
direction by their precession frequency during image measurement.  This method is 
known as Frequency encoding. 
 
For a useful MR image a means of localising tissue in a third dimension is required.  
The method used for this purpose is known as Phase encoding.  It alters the phase 
(i.e. the position of individual protons as they spin around their axis at any one point, 
for example, 90û 180û, 270û) of a portion of protons and uses this to identify their 
location within the tissue slice.   The necessary alteration in phase is achieved by 
applying a brief gradient pulse in an axis perpendicular to the slice-selection and 
frequency encoding gradients.  This produces a brief increase in the precession 
frequency of protons at the stronger end of the magnetic field and relative decrease in 
the precession frequency of those at the weaker end.  Although these protons return 
back to a uniform precession frequency when the phase-encoding gradient is switched 
off, the phase of each one will be slightly different.  The shift in phase produced is 
proportional to the strength of phase encoding gradient.   Phase encoding pulses, or 
steps, are repeated for each column of tissue along this third dimensional plane to tag 
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each individual voxel of tissue.  Strong frequency encoding gradients are a powerful 
method of resolving spatial differences between adjacent structures.  Therefore, they 
play an important part in the production of the high fidelity, detailed images that MRI 
has become known for. 
 
Thus, the combination of the slice selection (applied during the excitatory RF pulse), 
frequency encoding and phase encoding gradients (applied during MR signal 
measurement) provides a method uniquely tagging each proton in the imaged tissue 
block.  This raw data that results must then be reconstructed to produce an actual MR 
image. 
 
1.4.1.7 K-space 
 
K-space can be described as temporary image space, in which digitalised data is 
deposited and stored during an MRI examination prior to image construction.  K-
space can be represented as a two-dimensional grid of points, on which the x-axis 
represents the frequency encoding gradient and y-axis is the phase encoding gradient 
see figure 1.13 on page 94-95.  Although the two-dimensional K-space grid resembles 
a two-dimensional image of physical space it is essential to remember that K-space 
does not correspond directly to physical space.  The analogue signal received during 
an MR examination is converted into digital information and encoded into grey scale 
blocks.  Data is collected and deposited in K-space in horizontal lines, starting at the 
centre of the grid.  Each line represents data collected during a single phase encoding 
step, or repetition time.  As phase encoding steps are repeated with an alternating 
increases or decreases in the strength of the phase encoding gradient, a complete data 
 93
set is collected.  Although the two-dimensional K-space grid resembles a two-
dimensional MR image, individual data points in K-space do not correspond to 
individual image voxels.  Rather, each data point in K-space contains information 
about every voxel of the tissue.  Data points towards the periphery of K-space contain 
information on fine detail and edge detection, while those in the centre of K-space 
contain information on overall image intensity and tissue contrast.  This reflects the 
fact that strong phase- and frequency-encoding gradients, which are represented at the 
extremes of the phase and frequency encoding axes in K-space are required to detect 
fine detail.  Therefore, the data collected using these strong (positive or negative) 
phase encoding steps are laid down around the edges of K-space as data collection 
begins in the centre of the matrix and fans outwards. Once K-space has been filled, 
i.e. all of the required digital information has been collected, a detailed mathematical 
method known as Fourier Transform Image Reconstruction is used to convert the 
digitalised into a recognisable MR image.   
 
The arrangement of data in K-space has implications for clinical MR imaging, 
particularly concerning spatial resolution and field of view (FoV).  Higher spatial 
resolution requires an increased amount of data to be collected in the periphery of K-
space. This is achieved by increasing the number of phase encoding steps and results 
in an increased size of K-space.  Somewhat counter-intuitively, increasing the size of 
K-space does not result in an increased FoV.  Rather, an increased FoV is achieved by 
filling K-space more densely, or reducing the space between data points. Since no 
data any further away from the centre of K-space are collected spatial resolution is 
unaffected. 
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Figure 1.13, below  
Diagrammatic representation of K-space.  On the K-space grid, shown on the left, the x-axis represents the frequency encoding gradient and y-
axis represents the phase encoding gradient.  Data is deposited in K-space in horizontal lines, i.e. with consecutive phase encoding steps, starting 
the centre of the image.  Fourier transform image reconstruction converts the digitalised data into a recognisable MR image. 
 95
Figure 1.13  
K-space formalism before Fourier 
Transform Image Reconstruction
Resulting MR image
Grey-scale digital encoding of the analogue MR signal 
received during an MRI examination.  Each line in K-space 
represents a different phase-encoding step 
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1.4.1.8 Pulse sequences 
 
So far, the basic components of the pulse sequences used to create MR images have 
been discussed.  In the following sections the two most basic types of pulse sequences 
used in clinical MRI, and throughout this thesis, will be introduced. 
 
1.4.1.8.1 Gradient echo 
 
A gradient echo pulse sequence is comprised of an initial excitation RF pulse, 
executed in synchrony with a slice selection gradient, followed by measurement of an 
MRI signal or echo.  The time between the creation of transverse magnetisation by 
the excitatory pulse and the measurement of this signal is known as the Echo time 
(TE) of the sequence. The MR signal is measured, within a receiver coil lying on the 
patients chest, immediately after a brief frequency encoding gradient and the signal is 
collected as the phase encoding gradient is pulsed repeatedly to localise the source of 
the signal. The time between two consecutive excitation pulse is known as the 
repetition time (TR). 
 
Gradient echo techniques are able to achieve fast imaging times by using short TRs.  
They are, therefore, popular in CMR and are used in various forms in the experiments 
in this thesis. However, their short TR means that tissues retain transverse 
magnetisation (and thus produce a bright image) if either they have a short T1 or a T2 
similar to, or longer than, the TR of the pulse sequence.  Because T1 and T2 times of 
different tissues often run in parallel, simple gradient echo sequences, known as 
unspoiled sequences result in images with both T1 and T2 contrast (known as T2/T1 
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weighting).  All gradient echo sequences are sensitive to inhomogeneities in the main, 
and local, magnetic fields.  They are therefore sensitive to T2*, rather than true T2, 
contrast.  Fluids and adipose tissue have the highest signal intensity on T2/T1 
weighted images with all other tissues producing intermediate signal intensity.    The 
Siemens unspoiled gradient echo sequence used in the experiments in this thesis is 
known as TrueFISP (Fast Imaging with Steady-state Precession). 
 
If true T1 contrast is desired it is necessary to disrupt or spoil any persisting 
transverse magnetisation prior to the next excitation RF pulse.  Thus, spoiled 
gradient echo sequences have been designed to incorporate an additional, spoiler, 
gradient pulse to dephase any residual transverse magnetisation and eradicate T2 
contrast from the resulting image.  The spoiler pulse is applied immediately after data 
collection and immediately before the next excitation pulse.  The Siemens product 
used in the experiments in this thesis is known as TurboFLASH (Fast Low Angle 
Shot). 
 
Gradient echo sequences are usually used for T1 contrast weighting.  For this to be 
optimised TE should be kept as short as possible, to minimise T2 contrast from tissues 
with short T2.  TR should also be short as it must be similar to, or shorter than, the T1 
time of the tissues to be distinguished.  However, as TR decreases, there is less time 
available to allow recovery of longitudinal magnetisation.  Therefore, if signal 
intensity is to be maintained, the flip angle of the excitation pulse must also be 
reduced (to around the Ernst angle for that TR).  Thus, gradient echo sequences tend 
have short TRs and TEs and relatively low flip angles.  This makes them ideally 
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suited to CMR imaging which requires rapid pulse sequencing to allow acquisition of 
detailed cine images of the moving heart. 
 
1.4.1.8.1 Spin Echo 
 
Spin echo pulse sequences are very similar to simple unspoiled gradient echo 
sequences except for an additional refocusing RF pulse which is applied in the 
middle of the TE.  The purpose of this pulse is to reverse the phase difference in 
protons spins created by the slice selection gradient.  This results in subsequent 
rephasing, or refocusing of protons spins.  If signal measurement is timed to coincide 
with this event signal intensity can be maximised.  Another advantage of spin echo is 
that it is more tolerant than gradient echo of main magnetic field inhomogeneity and 
that created by local imperfections (e.g. metal implants). Thus, spin echo is truly 
sensitive to T2 contrast, rather than T2*.  The principal disadvantage of spin echo is 
the time required to incorporate the refocusing pulse.  This tends to lengthen imaging 
times and limits the use of spin echo in cardiac MR.  In other settings, the TR and TE 
of spin echo sequences can adapted to produce T1 or T2 contrast. 
 
1.4.2 Components of a modern CMR scanner 
 
A detailed diagram of the components of a modern CMR scanner is provided in figure 
1.14 (page 101) and the most relevant elements are summarised below.  The scanner 
itself is comprised of a superconducting resistive electromagnet (made of Niobium, 
low resistance wire) bathed within supercooled liquid Helium (circulating at around -
250û).  The smaller gradient magnet coils are housed on the inner circumference of the 
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main magnet and the whole apparatus is enclosed within a copper lined room 
designed to deflect commercial radio waves that might interfere with its operation.  
Copper lined channels in one wall of this box allow transmission of tubing from 
infusion pumps in the control room and the delivery of drugs or oxygen to the patient 
during scanning.  The floor beneath the MR scanner must be reinforced to 
accommodate the weight of the main electromagnet.   
 
The MR signal is received by a phased array chest coil.  This is a dedicated receiver 
coil that lies on top of the chest.  It contains several component coils, the arrangement 
of which is designed to maximise MR signal strength but minimise interference from 
tissue movement and system noise (i.e. optimise the signal to noise ratio). ECG-gating 
is used to synchronise imaging cycles with the motion of the heart.  The R wave of a 
3-lead ECG, recorded continuously, is used to trigger the excitatory RF pulse.  
Gradient echo sequences, which have a short TR, can be used to generate video-
quality cine loops.  This capability has revolutionised cardiac imaging as end-diastolic 
and end-systolic phases can be defined on the resulting cine images and end-diastolic 
and end-systolic volumes can be accurately measured using methods that will be 
described in the sections that follow.  Individual lines of K-space (representing 
individual phase encoding steps) are filled during consecutive heart beats; therefore 
each cine loop takes at least 5 cardiac cycles to complete, depending on the sequence 
being used.  To minimise motion artefact on the resulting images, patients are asked 
to hold their breath in expiration during most gradient echo cine sequences.  In longer 
pulse sequences this is not possible and the patient must be allowed to breathe freely, 
but they are asked to do so as smoothly as possible. 
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Once the predetermined K-space volume has been filled, the digital data is fed into a 
Reconstructor computer which performs the Fourier Transform Image 
Reconstruction and generates pixelated grey-scale data that is presented to the user on 
a flat screen monitor as a completed MR image.  During any MR examination the user 
can alter the operation of the gradient coils and select a variety of pulse sequences 
using a modified keyboard and mouse.  Individual parameters within these sequences, 
e.g. TR, TE, flip angle, can be modified as the operator desires.  Images can be saved 
to an internal database and to external compact disc and floppy disc drives.  The same 
PC workstation can be used for image analysis using the necessary software. 
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Figure 1.14  
Components of a modern MRI scanner 
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1.4.3 Previous application of CMR in patients with PH 
 
Recent years have seen the publication of numerous studies demonstrating the 
capabilities of CMR imaging in the assessment of patients with PH. 
 
1.4.3.1 Right ventricular volumes, function and mass 
Using CMR, image acquisition is possible in almost any plane, at almost any angle.  
Rapidly acquired gradient echo sequences allow description of the complicated RV 
cavity by a series of short axis cine images extending from the atrioventricular valve 
plane to the cardiac apex.  Planimetry of the end-diastolic and end-systolic images in 
these cine series, and summation of the resulting end-diastolic and end-systolic 
volumes allows direct, accurate and reproducible measurements of RV volume to be 
recorded (97, 98).  RV end-diastolic (RVEDV) and end-systolic volumes (RVESV) 
can then be used to determine ejection fraction ((RVEF) = RVEDV-
RVESV/RVEDV).  These CMR measurements have been shown to be more accurate 
than similar values determined using echocardiography in patients with PH (99, 100).  
The superiority of CMR imaging reflects the flawed modelling assumptions regarding 
RV shape that echo relies on to extrapolate three-dimensional results from two-
dimensional data. 
RV mass can also be determined using CMR imaging with great accuracy.  The high 
fidelity images generated by CMR allows the thin volume of tissue between the 
endocardial and epicardial surfaces of the RV to be defined and measured by a similar 
planimetric method used for ventricular volumes.  The accuracy of CMR-derived RV 
mass has been verified against subsequently explanted bovine hearts (101).  In 
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humans with PH, RV mass is increased (101), and correlates with mean pulmonary 
artery pressure measured invasively (102). Thus, CMR is the gold standard method of 
measuring RV volumes, ejection fraction (103) and mass (101) in patients with PH. 
 
1.4.3.2 Contrast enhanced-CMR imaging 
 
Studies conducted in the 1980s and 90s demonstrated that areas of myocardial injury 
(usually ischaemic injury in the models used) exhibited higher signal intensity on 
CMR images than regions of normal myocardium.  This was true for T2-weighted 
images which did not require contrast enhancement and T1-weighted images after 
administration of a paramagnetic contrast agent such as Gadolinium.  Gadolinium has 
the effect of shortening the T1 time of injured, or abnormal, myocardium, resulting in 
T1 contrast on appropriately timed T1-weighted gradient echo images. 
 
The early non-contrast T2-weighted images used Spin Echo techniques and image 
quality was severely degraded by respiratory motion artefact which was unavoidable 
because the sequences took too long to acquire for the patient to breath-hold.  
Superior image quality and better contrast between areas of normal and injured 
myocardium was found when faster, gradient echo sequences were combined with 
Gadolinium contrast administration.  Various contrast enhanced gradient echo 
sequences have been tested in patients with a variety of myocardial abnormalities.  
Most of the evidence has been collected in ischaemic injury models in which (in both 
animals and humans) the breath-hold segmented inversion recovery TurboFLASH 
(Fast Low Angle Shot) technique used in Chapter 4 of this thesis has performed best. 
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Using this technique, contrast enhanced images are acquired 5-10 minutes after the 
administration of intravenous Gadolinium to allow the contrast agent to perfuse the 
relevant tissues.  Images are only acquired during diastole; minimising cardiac motion 
artefact.  Importantly, an inversion pulse is applied before image acquisition to tip the 
net magnetisation vector of the myocardial tissue protons out of the longitudinal plane 
(where it resides at equilibrium) a full 180û, rotating the vector through the transverse 
plane (where signals can be detected, but are not sampled during this manoeuvre) 
back into the longitudinal plane facing in the opposite direction.  A variable time 
delay (known as the Inversion Time) is then allowed during which the net 
magnetisation vector rotates back into the transverse plane (T1 recovery) on its way 
back to equilibrium.  A TI is chosen to produce nulling (i.e. minimum signal and, 
therefore minimum image intensity) within areas of normal myocardium, at which 
point as many K-space lines as possible are sampled before the onset of ventricular 
systole.  The appropriate TI can be estimated from a series of test images acquired 
using a range of TIs.  This process is repeated during consecutive heart beats until the 
required K-space volume is filled, hence the segmented nature of the sequence.  In 
most patients 8-12 heart beats, per breath-hold, are required to allow enough time for 
collection of the necessary K-space volume.  Tissue contrast on the resulting images 
is determined by the T1 characteristics of the tissues being imaged and length of the 
TI.   Gadolinium is avidly retained in abnormal myocardial regions resulting in a 
shortened T1 and increased signal intensity.  The bright areas on the resulting images 
are described as areas of delayed contrast enhancement (DCE) (because of the time 
delay between contrast administration and image acquisition). 
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Delayed contrast enhancement (DCE) is not biologically specific and has been 
described in a variety of illnesses using similar CMR sequences to the one described 
above.  Myocardial infarction, fibrosis and inflammation have all been shown to result 
in delayed contrast enhancement using Gadolinium as an intravenous CMR contrast 
agent (104-108).  The physiological mechanism(s) responsible for DCE are the 
subject of much ongoing debate and investigation.  Gadolinium (as Gadolinium-
diethylene triaminepentaacetic acid (Gd-DTPA)) is a large molecule (> 800 kDa) and 
following intravenous injection it remains within the extracellular fluid compartment 
(109).  DCE is therefore thought to result from delayed clearance of gadolinium from 
a relatively expanded extracellular volume within fibrotic or necrotic myocardial 
compartments (110, 111).  This lack of biological contrast specificity necessitates 
histopathological correlation with areas of DCE at ce-CMR to be sure of the substrate 
within these areas.  This has been achieved in Myocardial Infarction (112) and 
Hypertrophic Cardiomyopathy (113) (see the following sections for details) but in 
situations where such evidence is not available a hypothesis on the significance of 
DCE must be constructed based on other evidence. 
 
1.4.3.2.1 Myocardial infarction 
 
DCE in acute myocardial infarction is usually localised to a coronary artery 
distribution and characteristically involves the subendocardial portion of the 
myocardium, extending transmurally depending on the size of the infarct (see figure 
1.15 on page 107 for an example).  The total volume of enhancing tissue corresponds 
closely to infarct size at autopsy (104, 108, 114), serum NT-proBNP (115) and 
Troponin concentrations (116), the extent of associated LV systolic dysfunction (116) 
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and the subsequent prognosis of the patient (107, 117).  Recent research has 
demonstrated that DCE that extends to over 50% of the thickness of the ventricular 
wall is likely to be non-viable, i.e. it is unlikely to recover contractile function (118). 
The biological significance of DCE following myocardial infarction has been debated 
over recent years.   Most researchers agree that DCE in this context reflects an 
increased volume of distribution for gadolinium as a result of disrupted cell 
membranes due to cellular necrosis (119). The intensity DCE tends to decrease 
following acute myocardial infarctions.  Chronic myocardial infarction can be 
distinguished by associated thinning of the infracted wall. 
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Figure 1.15  
An example of sub-endocardial delayed contrast enhancement (DCE) in a patient with acute inferolateral myocardial infarction. The post 
contrast image on the right was acquired using a breath-held segmented inversion recovery TurboFLASH (Fast Low Angle Shot) technique 
similar to that used in Chapter 4 of this thesis. 
Pre-contrast short axis CMR image 
showing thinning of the infracted 
lateral LV wall (arrowed)
Post-contrast short axis image at the same 
slice position showing inferolateral sub-
endocardial DCE (arrowed)
RV
LV
RV
LV
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1.4.3.2.2 Hypertrophic cardiomyopathy 
 
DCE has been described in several studies of patients with Hypertrophic 
Cardiomyopathy (HCM) using ce-CMR (106, 113, 120).  These studies demonstrate 
typically patchy, mid-wall (as opposed to subendocardial) contrast enhancement in 
various areas throughout the heart.  Common sites for DCE include the RV insertion 
points and the interventricular septum (120).  These correlate with earlier autopsy 
findings in patients with HCM which reported gross muscle fibre disarray and 
destruction of the circumferential, mid-wall component of the ventricular myocardium 
at the RV insertion points (121).  The biological significance of DCE has also been 
confirmed prospectively in patients with HCM by the comparison of ce-CMR images 
with histology from subsequently transplanted hearts.  These studies confirm that 
DCE in HCM correlates with areas of increased myocardial collagen (113).  An 
example of DCE in HCM is presented overleaf in figure 1.16. 
 
1.4.3.2.3 Myocarditis 
 
Myocarditis results from a variety of infectious or inflammatory insults, although the 
cause in individual patients is often unknown.  Typically patients present with central 
chest pain, an abnormal ECG and, often, a rise in Troponin and/or evidence of 
ventricular dysfunction. As a result, differentiation between myocarditis and acute MI 
can be difficult on clinical grounds alone.  Ce-CMR allows reliable discrimination 
between these two entities (105).  Myocarditis typically produces diffuse, mid-wall 
DCE in a distribution not typical of a coronary artery territory.  An example of DCE 
in a patient with acute myocarditis is presented in Figure 1.17 on page 110. 
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Figure 1.16  
An example of patchy, mid-wall delayed contrast enhancement (DCE) in a patient with Hypertrophic Cardiomyopathy (HCM). The post contrast 
image on the right was acquired using a breath-held segmented inversion recovery TurboFLASH (Fast Low Angle Shot) technique similar to 
that used in Chapter 4 of this thesis. 
Pre-contrast short axis image showing 
hypertrophy of both RV and LV 
myocardium in a patient with HCM
Post-contrast image at the same slice 
position showing diffuse mid-wall DCE in 
various areas including the RV insertion 
points (arrowed)
LV
RV
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Figure 1.17  
An example of mid-wall delayed contrast enhancement (DCE) in a non-coronary artery distribution in a patient with acute myocarditis.  These 
images were acquired using a breath-held segmented inversion recovery TurboFLASH (Fast Low Angle Shot) technique similar to that used in 
Chapter 4 of this thesis. 
RV
LV
Post-contrast short axis image showing 
bright mid-wall DCE typical of acute 
myocarditis
Post-contrast horizontal long axis image 
showing further evidence of acute 
myocarditis in the same patient
RV
LV
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1.4.3.3  Right ventricular stroke volume and Pulmonary Artery Flow 
Mapping 
 
RV stroke volume can determined using CMR imaging by simply subtracting RVESV 
from RVEDV.  This technique can, however, result in overestimation of RVSV in 
patients with PH.  This is because Tricuspid valve Regurgitation (TR) is common in 
PH and results in a significant proportion of the ejected blood volume travelling 
backwards through the incompetent tricuspid valve. Velocity encoded (or phase-
contrast) flow mapping is a more precise means of measuring RVSV in PH patients.  
Protons within a moving column of blood acquire a difference in their phase of 
rotation as they move through a magnetic field gradient (because the strength of the 
magnetic field is higher at one end than it is at the other). The amount of the phase 
difference acquired is directly proportional to the velocity of blood flow.   This 
principle can be used to encoded moving protons within large vessels with velocity 
information which can be read using a phase-contrast MR sequence.  Blood flow can 
be determined by integrating velocity within each tissue voxel and time.  RV stroke 
volume can thus be computed by integrating blood flow data from the proximal main 
pulmonary artery with the area of the vessel.  The necessary information is encoded 
within two sets of images, a set of velocity images containing the phase-contrast 
data and a set of anatomical cine images which are used to define the area of the 
target vessel using planimetry.  This method has been shown to be accurate and 
reproducible in PH patients (122, 123).  An identical flow map acquired across the 
proximal aorta can be used to quantify LVSV in the same patient.  Velocity encoded 
flow mapping is used to precisely define right and left ventricular stroke volume 
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during dobutamine stress-CMR imaging in Chapter 5 of this thesis.  The sequences 
used are discussed in more detail in the methods section. 
 
1.4.3.4  Dobutamine stress-CMR imaging 
 
Uniquely, CMR facilitates high quality imaging of right and left ventricles 
simultaneously.  This capability provides an excellent opportunity to study cardiac 
physiology and the interaction between the two ventricles during exercise. However, 
true exercise-CMR images are degraded by movement artefact during physical 
activity, meaning that accurate images can only be acquired immediately following 
exercise.  Dobutamine stress-CMR (ds-CMR) offers an alternative approach; it allows 
true stress measurements to be made and avoids potential errors relating to exercise 
recovery.  Dobutamine approximates physiological conditions during exercise in PH 
patients by increasing cardiac output (124).  It is a pure inotrope with no flow-
independent effects on pulmonary vascular tone (125). In earlier studies, ds-CMR has 
been used successfully in patients with congenital heart disease (126-128)  However, 
it has yet to be used in patients with PH due to other causes. 
 
1.5 Hypotheses and aims of this thesis 
 
The overriding aim of this thesis was to generate new and clinically relevant 
information regarding RV function in PH using CMR imaging.  To this end, three 
separate, but related experiments were performed; see Chapters 3, 4 and 5. The 
hypothesis of each study is explained below. 
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Chapter 3:  Definition of an NT-proBNP threshold for the non-invasive detection of 
RV systolic dysfunction in pulmonary hypertension.  A close correlation between 
BNP/NT-proBNP concentration and RV systolic function has been demonstrated 
before in patients with PH (91, 92, 135, 163).  In earlier studies, a similar relationship 
with LV systolic function (79) was described in patients with left heart failure, in 
whom a threshold value for NT-proBNP, indicative of LV systolic function has been 
defined (83-85).  As a result, NT-proBNP has been incorporated, as a simple, non-
invasive test for heart failure in recent diagnostic algorithms (87, 88).  The principal 
hypothesis of this study was that a similar NT-proBNP threshold could be identified 
for RV systolic dysfunction in patients with PH using CMR imaging as the reference 
method for RV systolic function. 
 
Chapter 4: Contrast enhanced-Cardiovascular Magnetic Resonance imaging in 
patients with severe Pulmonary Hypertension.  Delayed contrast enhancement 
(DCE), detected using contrast enhanced-CMR (ce-CMR), is a well established 
marker of myocardial abnormalities myocardial infarction, fibrosis and inflammation 
(104-108).  The principal hypothesis of this study was that discrete myocardial 
abnormalities would exist in patients with PH and that this information might provide 
some new insight into the mechanisms of RV failure in this condition. 
 
Chapter 5: Dobutamine stress-Cardiovascular Magnetic Resonance imaging (ds-
CMR) in patients with Pulmonary Hypertension. Exercise limitation is common in 
patients with PH (129). Earlier studies clearly demonstrate that poor exercise 
tolerance in PH is related to an inability to increase cardiac stroke volumes (47, 130).  
However, the reasons for this are not well understood. The principal hypothesis of this 
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study was that ds-CMR imaging could be used to identify reason(s) for right and left 
ventricular stroke volume impairment during exercise in PH patients. 
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Chapter 2 
Materials and Methods 
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2.1 Patient Recruitment 
 
The patients involved in the studies in this thesis were recruited during the course of 
their routine diagnostic assessment for suspected PH at the Western Infirmary, 
Glasgow, UK.  All patients had been assessed first in an out-patient pulmonary 
vascular clinic; those in whom a diagnosis of PH was suspected were offered a one-
week elective admission for further assessment. All subjects were asked to participate  
in the studies reported in this thesis on the Monday of their admission and those who 
agreed, gave informed written consent to a study protocol that had been approved by 
the ethics committee of the West Glasgow Hospitals University NHS Trust, see figure 
2.1 on pages 118-120.  In total, 71 patients were recruited, although only 48 
completed one or more of the experiments described herein. 8 patients did not 
undergo CMR imaging; either because they withdrew consent or because of technical 
problems with the scanner on the day of their examination. 15 patients were excluded 
before their MR images were analysed. This reflected the fact that patients were 
recruited and underwent MR imaging before a definitive diagnosis was made (after 
right heart catheterisation) and patients with a primary diagnosis other than PH were 
excluded. A flow chart describing patient recruitment and study completion is 
provided in Figure 2.2 on page 121.  Thus, inclusion criteria included a diagnosis of 
PH reached by conventional diagnostic methods (57, 64) and informed written 
consent.  Additional specific exclusion criteria were used for each experiment 
performed.   These will be discussed in the relevant chapters and a demographic 
description of each study population will be provided.  For all studies, CMR-related 
exclusion criteria were applied.  These included an indwelling cardiac pacemaker, 
claustrophobia and pregnancy. 
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In all three of the experiments in this thesis, control subjects, with no history of any 
cardio-respiratory disease underwent CMR imaging to provide local control values for 
ventricular dimensions and function.  All controls were staff of the Western Infirmary 
(Glasgow, UK) and were subject to the same exclusion criteria as the PH patients in 
each study.  Controls were approached individually and asked to participate.  All 
controls gave informed written consent but did not undergo right heart catheterisation 
or any other tests 
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Figure 2.1 
Information sheet and consent form used in recruiting patients to the studies in this 
thesis 
 
Brief Title of Project 
 
The Non-invasive assessment of Pulmonary Hypertension using Cardiac MRI 
Background 
 
Pulmonary Hypertension is a rare and potentially serious condition.  It is often difficult to 
diagnose and to treat.   The major problem in Pulmonary Hypertension is high blood pressure 
in the lungs; this often leads to excessive stress being exerted on the right hand side of the 
heart.  Sometimes, as a result of this, the right side of the heart becomes unable to pump blood 
into the lungs, as it should.  This obviously can make the patient feel very unwell. 
 
We usually make the diagnosis after a number of tests have been carried out; the most 
important of these currently is a Right Heart Catheter.  This involves passing a plastic 
catheter into the heart through a vein in the neck or groin.  Through this catheter we can 
measure the blood pressure in the lungs and assess how well the heart is pumping.   We can 
also assess how likely that patient is to respond to treatment. 
 
This test is very useful and generally safe, but some patients find it unpleasant and it there are 
some risks involved.  We therefore do not tend to repeat it to see how well or badly a patient is 
doing unless it is absolutely necessary.  Instead, we use a test that measures how far a patient 
can walk in six minutes.  We then compare this measurement to the last one to say whether 
they are better or worse.  This test is useful but can sometimes be misleading. 
 
Because the catheter is done with you at rest it can also not pick up very early problems. Doing 
measurements whilst you are active makes the test more sensitive, but this is difficult to do 
accurately and safely with this procedure. 
 
The Study 
 
We are conducting a study looking at new ways to diagnose and monitor patients with 
Pulmonary Hypertension.  We would like to invite you to take part.  The study involves the use 
of a relatively new scanning technique called MRI (Magnetic Resonance Imaging). 
 
MRI allows us to get a lot of useful information about Pulmonary Hypertension.  It does not 
use any X-rays or radiation, but instead uses magnets to acquire detailed images of the 
pulmonary blood vessels and the heart.  It is therefore very safe.  We can get a lot of the same 
information using MRI that we get at right heart catheterisation.  We can combine the scan 
with a drug called Dobutamine that simulates conditions of exercise.  This drug should help 
the scanner pick up early Pulmonary Hypertension.  Gadolinium is a clear fluid like water.  It 
is used in MRI scanning as it accumulates for a short time in abnormal tissue and lights up that 
area up so that the scanner can detect this part of the body.  It is therefore useful in telling us 
 119
which part of the blood vessels and heart are affected.  After a short while Gadolinium fades 
away and is removed from your body (within a few hours). 
 
Compared with right heart catheterisation, MRI is safer, and patients tend to find it less 
unpleasant.  This means not only could MRI be used in the diagnosis of Pulmonary 
Hypertension, we would be happier to repeat it in the future.  This may allow us to better 
identify changes in the illness over time and so allow better tailoring of your treatment. 
 
In addition to the MRI we would like to measures certain proteins in your bloodstream that we 
think may go up and down depending on how well you are. 
 
 
What the study involves 
 
During your 5-day stay at the Western Infirmary you will have a number of tests, including 
blood samples and x-rays.  On the Thursday you will have your right heart catheterisation.  We 
would propose doing an MRI scan at some time during this week.  The scan would take around 
1 1/2 hours and it would not prolong your stay in hospital.  We will take some extra blood 
samples in addition (around one tablespoon in total).  These samples will be taken off at the 
same time as your routine bloods and wont involve any extra needles. 
What does the MRI involve? 
 
On arrival at the Clinical Research Initiative (CRI) a radiographer will go through a safety 
checklist and make sure that all magnetic objects (e.g. jewellery and bankcards) have been 
removed.  Following this you will be asked to sign the consent form. Once you have changed 
into a hospital gown you will then be asked to lie flat on the bed that will move into the 
scanner.  The scanner is basically tunnel shaped, like a large polo mint.  You are slid into the 
centre of the polo on an electric bed and the scans are acquired.  Some people find it a little 
enclosing, but you can come out at any time. 
 
Before you go into the scanner a small plastic cannula (similar to that used when putting up a 
drip) will be inserted into your vein.  This allows us to give you a harmless dye called 
Gadolinium and a medicine called Dobutamine.  A doctor will insert the cannula.  During the 
scan we will inject some Gadolinium dye into the drip in your arm, this will help light up your 
blood vessels and heart muscle on the pictures.  We will also run an infusion of the drug 
mentioned, Dobutamine; this will cause your heart to pump faster as if you were out walking.  
The initial dose of this drug is very small and we will only increase it slowly up if you are 
comfortable. This will allow us to assess how well the right side of your heart is pumping.  
After around 25 mins the Dobutamine will be stopped.  A doctor will be in the control room 
throughout this procedure.  When you are in the scanner you will need to wear a pair of 
headphones, allowing you to listen to music of your choice (you are welcome to bring your 
own CD) and to allow us to communicate with you throughout the scan.  The headphones are 
also necessary because of the loud knocking noise that occurs when the pictures are being 
taken.  You will be given an emergency buzzer and can very quickly be taken out of the 
scanner should you feel uncomfortable or if it is felt necessary.  During the scan you will asked 
to hold your breath at times to improve the quality of the pictures. 
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What are the risks? 
 
o The MRI scanner is very safe as long as you have no metal implants in your body 
 
o The side effects of Dobutamine tend to occur at higher doses than we are using.  These 
include changes in your heart rhythm, light-headedness and nausea.  Your heart rate 
and blood pressure will rise; this is the desired effect as this mimics exercise.  You 
will be closely monitored throughout the procedure and a senior doctor will be present 
to ensure your safety 
o The dye used is called Gadolinium.  It is generally harmless and will be washed out of 
your system by your kidneys. Rarely it can cause headaches. 
 
NB 
• You should not take part in this study if you are pregnant 
• If you wish to take part in this study, your General Practitioner will be advised 
of your participation and the clinical management that you will undergo 
• If you do not wish to participate in this study, or wish to withdraw at any time 
your care will in not, in any way, be affected 
 
If you have any questions regarding the study please contact Dr KEVIN BLYTH at 
0141 211 1812 
 
WEST ETHICS COMMITTEE 
 
FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH 
PROJECT 
 
 
Title of Project :    The Assessment of Pulmonary Hypertension using Cardiac MRI 
 
By signing this form you give consent to your participation in the project whose title 
is at the top of this page.  You should have been given a complete explanation of the 
project to your satisfaction and have been given the opportunity to ask questions.  
You should have been given a copy of the patient information sheet approved by the 
West Ethics Committee to read and to keep.  Even though you have agreed to take 
part in the research procedures you may withdraw this consent at any time without 
the need to explain why and without any prejudice to your care. 
 
Consent: 
I,......................................................................................................................(PRINT) 
of...................................................................................................................... 
give my consent to the research procedures above, the nature, purpose and possible 
consequences of which have been described to me 
by...................................................................................................................... 
 
Patient’s signature.............................................................Date....................... 
 
Doctor’s signature............................................................................................. 
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Figure 2.2   
Description of patient recruitment for the three experiments described in this thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 patients recruited 
48 patients met criteria for relevant studies and MR images were analysed 
15 patients underwent CMR imaging but were 
excluded from final analysis due to an alternative 
primary diagnosis: 
• Idiopathic pulmonary fibrosis (3) 
• COPD (2) 
• Pulmonary fibrosis related to connective tissue 
disease (5) 
• Unrepaired congenital heart disease (4) 
• No evidence of PH at right heart 
catheterisation (1) 
 
8 patients did not undergo CMR imaging: 
• Consent withdrawn (3) 
• Technical problems with scanner (5)  
Chapter 3: NT-proBNP  
25 patients 
Chapter 4: Contrast enhanced CMR 
25 patients  
(18 also took part in Chapter 3)  
Chapter 5: Dobutamine 
stress-CMR  
16 patients 
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2.2 Routine diagnostic assessment 
 
2.2.1 Non-invasive assessment 
 
During their one week stay, all patients underwent a series of tests following standard 
diagnostic algorithms for PH (57, 65).  These included routine blood tests, 12-lead 
electrocardiogram, chest radiograph, transthoracic echocardiogram, lung function and 
six-minute walk tests, ventilation/perfusion (V/Q) scan, High Resolution CT scan and 
a CT Pulmonary Angiogram (CTPA).  These investigations were performed using the 
facilities at the Western Infirmary and the adjacent Gartnavel General Hospital 
 
2.2.2 Right heart catheterisation 
 
Right heart catheterisation was performed in the laboratory at the Western Infirmary 
on the Thursday afternoon of the admission week.  In patients who were prescribed 
diuretics or Calcium Channel Blockers, these were stopped the day before.  On the 
Thursday morning an 8F introducer sheath was inserted into the right internal jugular 
vein under ultrasound guidance (Site-Rite 4, Bard Access Systems, Salt Lake City, 
USA).  Anxious patients were occasionally prescribed a short acting Benzodiazepine, 
but in general, no pre-medication was used.  Right heart catheterisation was 
performed using a 7F triple-channel thermodilution Swan Ganz catheter (Baxter 
Healthcare, Irvine, California, USA).  All measurements were recorded with the 
patient in a supine position, at rest, breathing room air. These included mean right 
atrial pressure (RAP), right ventricular pressure and systolic and diastolic pulmonary 
artery pressures (PAP).  Mean PAP was determined as the area under the PAP trace.  
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Pulmonary artery occlusion pressure was recorded with the catheter in the wedge 
position and the balloon inflated.  Cardiac output (CO) was determined by 
thermodilution, allowing the determination of pulmonary vascular resistance (PVR) 
by the following: (mean PAP  PAOP)/CO.  Cardiac index was determined as 
CO/body surface area.  If, after review of the V/Q scan and CTPA prior to 
catheterisation, suspicion remained regarding the presence of thromboembolic 
disease, selective pulmonary angiography was also performed in the catheterisation 
laboratory. 
 
2.3 Cardiovascular Magnetic Resonance imaging 
 
I performed all of the MR scans in this thesis after completing the Magnetic 
Resonance Imaging Basic Competencies course run by the Institute of Physics and 
Engineering in Medicine.  The earlier scans were performed under the guidance Ms. 
Tracey Steedman, Cardiac MR Radiographer, Western Infirmary.  All scans were 
performed a 1.5 T Siemens Sonata whole body MR scanner (see figure 2.3, overleaf). 
 124
Figure 2.3 
Ms. Tracey Steedman (Cardiac MR Radiographer) positioning a patient before a scan using the Siemens Sonata 1.5 Tesla system at the Western 
Infirmary, Glasgow.  The examination table is extended and the phased-array chest coil has been secured over the patients chest using Velcro 
straps 
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2.3.1 Patient preparation and positioning 
 
Before entry into the MR scanning room the patent was asked to complete and sign a 
safety questionnaire, see figure 2.4 overleaf.  If they reported previous injuries 
involving metal fragments, especially any to the eyes, appropriate plain radiographs 
were requested to ensure that none remained. Patients were asked to change into 
surgical blues and a 21 G intravenous cannula was placed in either the right or left 
antecubital fossa.  This was used for contrast or dobutamine administration, 
depending on the study being performed. 
 
The patient was asked to lie supine on the examination table, which had been 
remotely removed from inside the bore of the magnet, to a more accessible position, 
see figure 2.3.  Adhesive monitoring pads for the 3-lead ECG were connected, and the 
phased array chest coil was placed on the patients chest and secured in place with a 
loose fitting Velcro strap.  The patient was then supplied with an emergency buzzer 
and protective ear-defenders.  Immediately before movement of the patient inside the 
bore of the magnet, the centre of the chest coil, approximating the position of the 
heart, was defined by a laser pointer attached at the 12 oclock position of the 
magnets inner circumference.  This point of reference was used to move the patient 
to a precise point within the bore of the magnet which ensured that their heart was at 
the centre of the main magnetic field. Once the patient was inside the bore of the 
magnet, the door of the scanning room was sealed and the staff performing the scan 
retreated to the control room.  Proper functioning of the microphones and headphones 
that allow direct communication between patient and operator was verified before 
image acquisition was initiated 
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Figure 2.4 
The safety questionnaire completed by all patients before entry into the scanner room 
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2.3.2 CMR image acquisition 
 
2.3.2.1 Standard imaging 
 
The following core imaging protocol was followed in all subjects.  Fast imaging with 
steady state precession sequences (marketed as TrueFISP by Siemens) were used to 
generate the initial axial scout images (see figure 2.5 overleaf) required to localise the 
heart within the thoracic cavity and all subsequent cine images.  Vertical- and 
horizontal-long axis (VLA and HLA) cines (see figures 2.6 (page 129) and 2.7 (page 
130), respectively) were planned and acquired based on the scout images.  The first of 
a series of short axis (SA) cines (see figure 2.8 on 131) was then planned on image 
one of the HLA cine, intersecting the atrioventricular valve roots on this view.  The 
SA imaging plane was then propagated apically, covering both ventricles with 8-mm 
SA imaging slices, separated by a 2-mm inter-slice gap, see figure 2.7.  
Methodological details which are specific to this thesis, or are of particular 
importance, include the use of a traditional left ventricle (LV) short axis cine stack for 
the acquisition of both RV and LV images.  Imaging parameters, which were 
standardised for all subjects, included:  TR/TE/flip angle/voxel size/FoV = 3.14 
ms/1.6 ms/60°/2.2 x 1.3 x 8.0 mm/340 mm. 
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Figure 2.5 
Typical axial scout images used to localise the heart within the thoracic cavity during CMR scanning of a patient with PH.  Note the low 
definition images of these preliminary Fast imaging with steady state precession (TrueFISP) scout images 
 
Coronal Scout Image Transverse Scout Image Sagittal Scout Image
RV LV
RV LV
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Figure 2.6 
Image 1 of a vertical long axis Fast imaging with steady state precession (TrueFISP) 
cine acquired in a patient with PH.  The image was planned through the left ventricle 
(LV) as a standard LV protocol was used.  This image was not used for analysis. 
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Figure 2.7 
Image 1 of a horizontal long axis Fast imaging with steady state precession 
(TrueFISP) cine acquired in a patient with PH. This image was used to plan the first 
of a series of short axis (SA) cines, intersecting the atrioventricular valve roots as 
shown by the solid red line.  The SA imaging plane was then propagated apically, 
covering both ventricles with 8-mm SA imaging slices (dashed red lines), separated 
by a 2-mm inter-slice gap.  These images were not used for analysis. 
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Figure 2.8 
Image 1 of a basal short axis Fast imaging with steady state precession (TrueFISP) 
cine acquired in a patient with PH.  A stack of these imagees were acquired covering 
both ventricles from base to apex.  This stack of short axis images was used for the 
measurement of ventricular volume and mass using manual planimetry. 
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2.3.2.2 Contrast enhanced-CMR imaging 
 
Following acquisition of a complete set of short axis cine images covering both 
ventricles, contrast enhanced imaging was performed in a cohort of PH patients as 
part of an experiment described in detail in Chapter 4. 
 
Gadolinium-diethylene triaminepentaacetic acid (Gd-DTPA) was employed as an 
intravenous contrast agent.  A dose of 0.2 mmol/kg was drawn up in the scanner room 
after completion of the above images and administered to the patient manually as a 
slow intravenous bolus via the intravenous cannula inserted during patient preparation 
and positioning (see Methods Section 2.3.1).  A ten minute interval was then allowed 
before acquisition of a second complete set of short axis (SA) images.  Importantly, 
this image set was acquired using slice positions copied directly from the pre-contrast 
cines but a different, contrast sensitive, segmented inversion recovery pulse 
sequence (implemented by Siemens as an segmented inversion recovery Turbo 
FLASH (Fast Low Angle Shot)).  This technique was introduced in Section 1.4.3.2. 
 
Standardised scan settings were used for the contrast enhanced imaging in all subjects 
and specific parameters included TR/TE/flip angle/voxel size/FoV/number of 
segments = 11.6 ms/4.3 ms/20°/2.2 x 1.3 x 8.0 mm/23.  The inversion time for the 
TurboFLASH sequence was optimised on an individual patient basis.  Successful 
nulling of normal myocardium was deemed to have been achieved once the left 
ventricular myocardium appeared black and homogenous.  Generally speaking an 
inversion time of between 240 and 280 msecs was required to achieve this.  Artefact 
on the contrast enhanced images was excluded by the acquisition of swapped phase 
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images through slice planes which appeared to demonstrate intramyocardial contrast 
enhancement.  This technique involves the swapping of the phase-encoding and 
frequency-encoding directions as the phase-encoding direction is particularly prone to 
artefacts caused by cardiac or chest wall movement.  Only areas of contrast 
enhancement that persisted on these swapped phase images were included in 
subsequent quantification of areas of contrast enhancement.  Any areas of contrast 
enhancement were also compared directly with the pre-contrast cine image 
corresponding with the contrast enhanced image in terms of both slice position and 
time frame to further exclude artefact, especially that caused by partial volume effect 
and blood pool residing behind trabeculated myocardium.  See figure 4.1 for 
examples. 
 
2.3.2.3 Dobutamine stress-CMR imaging 
 
Dobutamine stress-CMR imaging was utilised in Chapter 5 of this thesis.  In the 
patients studied using this technique the standard imaging protocol described in 
Section 2.3.2.1 was used to acquire all resting measurements of right and left 
ventricular volumes.   Since this study specifically required high fidelity 
measurements of RVSV, velocity encoded flow mapping was used to precisely 
measure right and left ventricular stroke volume from flow in the main pulmonary 
artery and ascending aorta, respectively.  This methodology was introduced in Section 
1.4.3.3.  Flow maps were planned perpendicular to the target vessel in a double-
oblique plane, at least 1.5 cm distal to the pulmonary or aortic valve.  A velocity-
encoded k-space segmented gradient-echo sequence was used (imaging parameters: 
TE/TR/flip angle/slice thickness/temporal resolution /image matrix/FoV/in-plane 
 134
resolution/velocity encoding range = 3.1ms /16 ms/ 15°/ 6 mm /limited by 
TR/256/380 mm/1.9 x 1.5 mm/150 cm per second) to generate 45 matched pairs of 
anatomical and velocity images. 
 
Retrospective ECG-gating was used.   This involves continuous data collection and 
the assignment of collected data to appropriate points in the cardiac cycle 
retrospectively.  Although this means that a mean cardiac cycle must be 
interpolated, because of natural variation in R-R interval, it ensures complete 
coverage of the cardiac cycle.  Using prospective ECG-gating, late diastolic flow may 
not be measured correctly leading to inaccurate stroke volumes.  Patients were 
instructed to breath freely throughout this section of the protocol and the average time 
of acquisition was 2-3 minutes depending on the patients heart rate. 
 
2.3.2.3.1 Dobutamine infusion 
 
Dobutamine was administered using a digital syringe driver loaded with a 50 ml 
syringe containing 50 mg of dobutamine hydrochloride (Posiject, Boehringer 
Ingelheim) diluted in 0.9 % saline.  The syringe driver was located in the control room 
and attached to the subject by a length of tubing fed through a wave-guide conduit.  
The infusion was started at 5 mcg/kg/min and increased in 5 mcg steps every 3 
minutes to a maximum tolerated dose of 20 mcg/kg/min.  A 3-lead ECG trace was 
monitored throughout and systemic BP was measured every 3 minutes.  The following 
safety limits were set for each subject:  a) rise in HR > 50 %, b) rise in systolic BP > 
50 %, c) fall in systolic BP > 20 %, d) intolerable symptoms, e.g. excessive 
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breathlessness or chest pain.  If any of these tolerances were exceeded the dobutamine 
dose was reduced. 
 
2.3.2.3.2 Stress imaging 
 
Stress CMR imaging was initiated 2 minutes after the maximum tolerated dose of 
dobutamine was reached.  No specific alterations were made to the resting protocol 
for stress imaging.  However, the velocity encoding gradient was modified to 
accommodate higher stroke volume velocities (maximum 300 cm per second) in 
approximately half of the PH patients and all of the controls. 
 
2.3.2.4 Common problems encountered during CMR imaging 
 
The commonest problems related to the three lead ECG trace used to trigger 
consecutive pulse sequences and to breath-holding.  The former can be explained by 
the magnetohaemodynamic effect.  This describes the altered ECG trace recorded in a 
strong magnetic field.  It can be explained by the effect of the magnetic field on the 
ferrous metal component of red-blood cells and results in an increase in the amplitude 
of the T-wave on an ECG trace.  The effect on the T-wave is proportional to the 
strength of the magnetic field.  As a consequence, excitatory RF pulses can be 
triggered inappropriately by T-waves rather than R-waves resulting in poorly timed 
cine images and degraded image quality.   The only solution to this problem was to 
remove the patient from the MR scanner, take off the chest coil and reposition the 
ECG electrodes.  By trial and error a better ECG trace could usually be established 
and diagnostic quality images obtained.  The second common problem was that some 
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patients could not hold their breath long enough to accommodate a complete pulse 
sequence.  In extreme cases imaging was performed with the patient breathing freely.  
However, in most the TR of the sequences could be reduced by altering the flip angle 
and/or reducing the phase oversampling used as standard in the imaging sequences.  
 
Recent studies have reported adverse effects of gadolinium contrast in patients with 
chronic renal impairment (nephrogenic systemic fibrosis) (131). This was not seen in 
any patient in my thesis, reflecting the largely normal renal function of the patients 
studied. 
 
2.3.3 Data storage 
 
On completion of each MR scan, the images were saved to the hard-drive of the 
scanner and backed up onto a compact disc (CD).  Individual CDs were coded by 
number and stored in a locked filing cabinet until data analysis. 
 
2.3.4 Analysis of Cardiovascular Magnetic Resonance images 
 
All CMR images in this thesis were analysed on a satellite workstation attached to the 
main MR scanner using the Argus analysis software (Siemens, Erlangen, Germany).  
Individual CDs, which corresponded to individual patients, were retrieved and 
analysed in batches. At the time of analysis I was blinded to the haemodynamic 
results of any given patient. Although the name of the patient was visible in the corner 
of each MR image, each analysis was performed at least 6 months after their invasive 
assessment and I was unaware their haemodynamic results at the time of MR analysis.   
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2.3.4.1 Standard imaging 
 
The images for each patient were loaded into the Argus program from each CD.  
Argus automatically identified the images within each SA cine loop that had the 
largest and smallest blood volumes and defined these as end-diastole and end-systole, 
respectively.  An example of a complete image series with these images defined is 
provided in Figure 2.9 (page 139-140).  The end-diastolic image was usually the first 
image aquired after R wave deflection.  Using a trackball cursor the endocardial and 
epicardial borders of the end-diastolic and end-systolic images at each slice position 
within the SA stack were then defined by manual planimetry.   These methods are 
standard in clinical MR practice and have been published before (97, 98).  Particular 
points of note regarding the planimetry used herein include the deliberate inclusion of 
trabeculations and papillary muscles in all analyses.  This has been shown by previous 
authors to be a more accurate, but more time consuming, method (98).  By 
multiplying the individual slice areas by slice thickness (8 mm) plus the inter-slice 
gap (2mm) and applying Simpsons Rule, the Argus software automatically calculated 
RVEDV, RVESV, LV end-diastolic volume (LVEDV) and LV end-systolic volume 
(LVESV). Right and left ventricular stroke volumes (RVSV & LVSV) were 
determined as RV/LV EDV-ESV.  Ejection fraction (RVEF and LVEF) was 
determined as a percentage (%) as ((RV/LV SV/EDV) x 100) using this planimetry-
derived stroke volume measurement in Chapters 3 and 4. In Chapter 5, velocity 
encoded flow mapping was used to determine precise, forward stroke volumes for 
each ventricle, as these were the primary measurements in this experiment and we 
developed the sequences for specific use in this study. The measurements of stroke 
volumes yielded by this technique were used to calculate RV and LV ejection fraction 
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in Chapter 5.  The flow mapping technique is described in detail in Section 2.3.4.3.2. 
It circumvents the predictable measurement error in planimetry-derived stroke volume 
resulting from tricuspid valve regurgitation (see Section 3.4.4), however both methods 
are established and commonly used tools for the assessment of stroke volume and 
ejection fraction in clinical practice. 
 
RV and LV mass (RVM and LVM) were determined as the product of the difference 
between the end-diastolic and end-systolic volume for each ventricle and the quoted 
density of cardiac muscle (1.05 g/cm3).  RV mass was determined as RV free wall 
mass, with the Interventricular Septum (IVS) considered part of the LV.  These 
methods are again, common in clinical CMR practice and have published before (97, 
98).  RVM Index (RVMI) was determined as RVM/LVM, as previously shown (102).  
Throughout this thesis, all ventricular volumes are corrected for Body Surface Area 
(BSA) and reported as indexed measurements: (RVEDV Index (RVEDVI), RVESV 
Index, (RVESVI), LVEDV Index (LVEDVI) and LVESV Index (LVESVI)). 
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Figure 2.9, opposite 
An example of planimetry analysis of RV volumes and mass using the Argus analysis 
software. Each row of short axis images represents a loop of cine images acquired 
during one cardiac cycle at consecutive slice positions, beginning at the base of the 
heart, moving apically to cover both ventricles.  The first images within each row (or 
slice position) were acquired immediately after R-wave deflection.  They are therefore 
defined by the Argus software as the end-diastolic images (indicated by the yellow 
ED at the top of the left-hand column) and have the greatest total ventricular blood 
volume.  The end-systolic images were defined automatically by the Argus software 
as the column of images with the smallest total ventricular blood volume and verified 
visually. A trackball mouse and cursor was used to define the endocardial (in red) and 
epicardial (in green) surfaces of the RV at end-diastole and the endocardial surface 
only at end-systole (in red).  This allowed computation of RV end-diastolic and end-
systolic volumes and RV mass. 
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Figure 2.9 
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2.3.4.2 Contrast enhanced-CMR imaging 
 
The contrast-enhanced images for each patient were loaded into the Argus program 
from each CD.  Areas of contrast enhancement were first identified visually.  Mean 
signal intensities (± SD) for areas of contrast enhancement and for an adjacent 
reference area of non-enhancing myocardium were then determined using the 
Siemens Mean Curve software (Siemens, Erlangen, Germany).  Delayed contrast 
enhancement (DCE) was defined as an area of visually identified contrast 
enhancement with a mean signal intensity that was > two standard deviations higher 
than the mean signal intensity of an adjacent area of reference myocardium, which 
although nulled had a mean signal intensity significantly above zero.  DCE volume 
was determined by planimetry of any areas of contrast enhancement meeting these 
criteria.  An example of a set of contrast-enhanced images with areas of DCE defined 
is presented overleaf in figure 2.10.  DCE mass was calculated by multiplying DCE 
volume by myocardial density (1.05g/cm3) and is used in the subsequent correlations 
and discussion as the absolute measured value of contrast enhancing tissue seen. 
 
Although DCE has previously been described within the RV insertion points in 
conditions such as Hypertrophic Cardiomyopathy, no universally accepted definition 
of the extent of the RV insertion points has been agreed for the purposes of CMR 
imaging.  For the purpose of this study the boundaries of the RV insertion points were 
arbitrarily defined using a method described in detail and illustrated in figure 2.11, 
page 143. 
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Figure 2.10 
An example of a set of contrast-enhanced images, acquired in a patient with PH, with 
areas of DCE defined using the Argus analysis software.  Each image was acquired at 
a separate slice position, each of which was copied directly from the pre-contrast 
imaging protocol.  Only visually identified areas of DCE with a mean signal intensity 
over two standard deviations higher than the mean signal intensity of an adjacent area 
of reference myocardium were included. DCE volume was determined by planimetry 
(shown in red).  DCE mass was calculated by multiplying DCE volume by myocardial 
density (1.05g/cm3) 
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Figure 2.11 
The following method was used to define the spatial boundaries of the RV insertion 
points (RVIPs): On a short axis ce-CMR image such as this, myocardial tissue found 
at the junctions of the RV free wall and IVS was defined as being within the RVIPs if 
it was located either above (for the anterior RVIP) or below (for the posterior RVIP) 
lines drawn across the IVS from the most superior (point 1) or inferior (point 2), 
respectively, endocardial borders of the LV cavity. These lines were orientated 
perpendicularly to a single (dashed) line joining the anterior and posterior 
interventricular grooves (points 3 and 4) on the same image. Myocardial tissue lying 
either below (for the anterior RVIP) or above (for the posterior RVIP) these two lines 
was considered part of the IVS. 
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2.3.4.3 Dobutamine stress-CMR imaging 
 
2.3.4.3.1 Right and left ventricular volumes 
 
Planimetry of selected short axis images was used to measure RV and LV volumes as 
described in Section 2.3.4.1. 
 
2.3.4.3.2 Right and left ventricular stroke volume and ejection fraction 
 
Velocity encoded flow maps were used to determine RVSV and LVSV at rest and 
during stress in Chapter 5; four flow maps were therefore analysed for each patient, 
each containing 90 images. Each image set was inspected to verify accurate depiction 
of the target vessel on the 45 anatomical images and the absence of artefacts including 
aliasing on the 45 velocity images. 
 
A region of interest (ROI) was drawn around the interior surface of the target vessel 
on the first anatomical image.  This ROI was propagated throughout the 45 
anatomical images using a semi-automatic function within the Argus software.  The 
propagated ROIs were then checked visually and modified using the nudge function 
within Argus to approximate the interior surface of the target vessel throughout the 
set.  These modifications were then copied onto the corresponding 45 velocity images.   
A second, reference, ROI was then drawn on the first anatomical image and copied 
directly onto all of the other images.  This was defined within the soft tissue of the 
chest wall as close as possible to the target vessel and was used to correct for 
background movement of the thoracic contents through the imaging plane during 
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cardiac motion and normal respiration.  An example of flow map analysis illustrating 
the appropriate contour definition is presented overleaf in figure 2.12.  Four of these 
flow maps were used to define the four stroke volumes measured in each patient (RV 
rest, RV stress, LV rest, LV stress). 
 
The software automatically computed the flow during each time point (ml/sec) within 
the target vessel ROI minus the reference flow values. These data were integrated 
with the area of the target vessel and the positive values summed to produce RVSV 
and LVSV; these values were corrected for Body Surface Area and are reported as 
RVSVI and LVSVI.  Right and left ventricular ejection fraction (RVEF and LVEF) 
were determined as (stroke volume derived from flow mapping /end-diastolic volume) 
x 100, and expressed as a percentage (%). As described in Section 2.3.4.1 this is a 
different method of RVEF computation to that used in Chapters 3 and 4. 
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Figure 2.12, opposite 
Velocity encoded flow maps were used to determine RVSV and LVSV at rest and 
during stress; four flow maps were therefore analysed for each patient, each 
containing 90 images.  The resting main pulmonary artery flow map from a patient 
with PH is shown below.  The anatomical image is shown on the left with the 
corresponding velocity-encoded image, from the same time point in the cardiac cycle 
on the right.  A region of interest (ROI) was drawn around the interior surface of the 
target vessel on the first anatomical image.  This ROI was propagated throughout the 
45 anatomical images using a semi-automatic function within the Argus software.  
The propagated ROIs were then checked visually and modified using the nudge 
function within Argus to approximate the interior surface of the target vessel 
throughout the set.  These modifications were then copied onto the corresponding 45 
velocity images.  The final contours that resulted are shown overleaf in red.   A 
second, reference ROI (shown in purple) was then drawn on the first anatomical 
image and copied directly onto all of the other images.  This was defined within the 
soft tissue of the chest wall as close as possible to the target vessel and was used to 
correct for background movement of the thoracic contents through the imaging plane 
during cardiac motion and normal respiration. 
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Figure 2.12 
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2.3.4.4 Common problems encountered during CMR image analysis 
 
Definition of the most basal ventricular slice to be included in the right and to a lesser 
extent the left ventricular analysis has proven difficult in the past.  Erroneous 
definition can lead to significant errors because of the large volume of RV that is 
either excluded or included, inappropriately.  To overcome this problem the most 
basal ventricular image (RV or LV), once identified visually, was cross-referenced 
with the horizontal long axis view before its inclusion in the final analysis to ensure 
this slice was indeed ventricular and not atrial. 
 
Interventricular septal (IVS) bowing describes the paradoxical displacement of the 
IVS caused by the leftward trans-septal pressure gradient common in PH patients 
during early diastole.  This phenomenon made definition of the end-diastolic and end-
systolic images (based on blood volume) difficult for the Argus software because 
bowing tends to be most exaggerated in the mid-ventricle, and least prominent at the 
base and apex.  The resulting mid-ventricular bulge tended to maximise RVEDV and 
minimise LVEDV at this position, relative to the base and apex, making consistent 
automatic definition difficult.  The solution adopted for all scans in this thesis was to 
manually check that the maximum, and minimum, ventricular volumes (and thus the 
EDV and ESV) had been appropriately identified by Argus for each ventricle. 
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Chapter 3 
Definition of an NT-proBNP threshold for the non-
invasive detection of RV systolic dysfunction in 
pulmonary hypertension 
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3.1 Introduction 
 
As has been discussed in earlier chapters, right ventricular systolic dysfunction 
(RVSD), at baseline (i.e. pre-treatment) in PH patients, has been associated with an 
increased mortality risk in earlier studies that identified RVSD either by invasive 
haemodynamic measurements (1, 3, 44, 58, 132) or by the detection of overt clinical 
signs of RV failure (i.e. patients within Class IV of the WHO classification of disease 
severity) (1).  Accurate assessment of baseline RV function is therefore desirable in 
all patients with PH.  This information may help identify individuals in whom prompt 
invasive assessment ± the initiation of disease targeted therapy is appropriate.  
Because early RV dysfunction is difficult to detect on clinical examination, trans-
thoracic echocardiography is often used for this purpose (65).  Although inexpensive 
and widely available, RV ejection fraction (RVEF) can only be estimated indirectly 
from measurements acquired in two dimensions by this method.  Furthermore, 
variables derived from echocardiography that reflect RV function and provide useful 
prognostic information in PH are either complicated to define and therefore reliant 
upon an experienced operator (e.g. the Tei index) (61) or detected most frequently in 
patients in whom RV failure is already clinically overt (e.g. a pericardial effusion) 
(44). 
 
Cardiac Magnetic Resonance (CMR) imaging allows image acquisition in any plane 
and at almost any angle, allowing direct gold-standard measurement of RV volumes 
and RVEF in patients with PH.  At present, however, CMR imaging remains too 
expensive for routine clinical use and is not available in many PH centres.  An 
alternative non-invasive method of identifying baseline RVSD in PH that was 
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objective, operator independent and widely available would, therefore, be clinically 
useful. 
 
As indicated in Section 1.3.4, circulating natriuretic peptide levels have, as B-type 
natriuretic peptide (BNP), recently been shown to correlate with invasive pulmonary 
haemodynamics (91, 92), RVEF measured by computed tomography (CT) (91), 
survival (93, 94) and the response to therapy (95, 96) in PH patients.  NT-proBNP, 
which is biologically inactive, is more stable in vivo and in vitro than BNP (133) and 
therefore is more suitable for use as cardiovascular biomarker.   
 
In LV dysfunction an NT-proBNP threshold has been identified that can be used to 
identify patients with symptoms who are likely to have LV failure on subsequent tests 
(83-85).  Although serum NT-proBNP concentration ([NT-proBNP]) has recently 
been shown to correlate with invasive pulmonary haemodynamics (134), survival and 
echocardiography derived measures of RV function in PH (135), a similar NT-
proBNP threshold indicative of RVSD has yet to be determined.  This may reflect 
insufficient precision in the previous reference method for RV systolic function: 
echocardiography.  In this experiment I correlated serum [NT-proBNP] against RV 
systolic function measured directly by CMR imaging in patients with PH at baseline 
and hypothesised that an NT-proBNP threshold indicative of RVSD could be defined. 
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3.2 Methods 
 
3.2.1 Patients 
 
30 consecutive patients were recruited and clinically assessed as described in Methods 
Section 2.1-2.2. Specific inclusion and exclusion criteria for this experiment were 
used.  The only specific inclusion criterion was a diagnosis of either Pulmonary 
Arterial Hypertension (PAH) or Chronic Thromboembolic PH (CTEPH) reached by 
conventional diagnostic methods (57, 65).  Patients were excluded from this 
experiment (after review of their past medical history, admission blood tests and 
transthoracic echocardiogram and before CMR imaging and NT-proBNP 
measurement) if they met any of the following exclusion criteria: 
 
1.      Evidence of congenital heart disease (CHD), either at echocardiography or as 
a previous diagnosis.  This was because differing patterns of natriuretic peptide 
release have been demonstrated in conditions that cause RV volume overload, 
such as CHD, in comparison to those that cause RV pressure overload (e.g. PAH 
and CTEPH) (136). 
 
2.      A history of any other condition that might cause elevation of [NT-proBNP].  
These include: 
a.       Ischaemic heart disease (137) 
b.      Myocardial infarction (80) 
c.       LV systolic dysfunction (79) 
d.      Systemic hypertension (81) 
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e.       Left-sided valvular heart disease (82) 
f.        Chronic renal impairment (138) or an abnormal serum creatinine on 
admission (normal was defined as < 120 µmoll-1) 
g.       Diabetes Mellitus (139) or a fasting blood glucose on admission to the 
SPVU of > 6.1 mmoll-1 
 
On the basis of these criteria, 5/30 patients recruited were excluded from the final 
analysis (atrial septal defect (2/5), chronic renal impairment (1/5), significant mitral 
regurgitation (1/5) and systemic hypertension (1/5)).  The remaining 25 subjects 
underwent CMR imaging and venous blood sampling for [NT-proBNP] within 24 
hours of invasive assessment.  The final diagnoses reached in these 25 patients were, 
idiopathic PAH (IPAH) in 11/25, CTEPH in 6/25 and PAH associated with 
connective tissue disease (PAH-CTD) in 8/25.  At the time of the study no patient had 
received any disease-targeted therapy (i.e. Prostacyclin analogues, Bosentan, 
Sildenafil or calcium channel blockers) for PH. 
 
Twelve control subjects were recruited as described in Method Section 2.1.  Between 
PH patients and controls there were no significant differences in mean age (PH: 60 (± 
12), Controls: 57 (± 12), p = 0.455) or mean systemic blood pressure (PH: 95 (± 13), 
Controls: 92 (± 17), p = 0.536).  PH (17 ♀: 8 ♂) and control populations (8 ♀: 4 ♂) 
were well sex-matched. 
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3.2.2 Venous blood sampling and measurement of NT-proBNP 
 
After at least 20 minutes of recumbent rest, 5 mls of venous blood was drawn from 
the antecubital fossa of all 25 PH patients immediately prior to CMR imaging.  Blood 
samples were drawn into vacuum-sealed containers containing ethylenediamine 
tetraacetic acid and immediately centrifuged at 3000 rpm for 15 minutes using a 
PK110 centrifuge (ALC, Winchester, VA, USA).  Supernatant was then removed and 
individual samples were coded, labelled and stored at -80ûC until analysis. 
 
NT-proBNP analysis was performed on an ELECSYS 2010 bench top analyser 
utilising a chemiluminescent assay with a Coefficient of Variation < 5 % (Roche 
Diagnostics, Lewes, UK). All biochemical analyses were performed by a single 
experienced clinical biochemist in the BHF Cardiovascular Research Centre 
(University of Glasgow, UK) who was blinded to haemodynamic, CMR and clinical 
results.  NT-proBNP measurements are subsequently quoted as plasma concentration 
(ng/l). 
 
3.2.3 CMR image acquisition and analysis 
 
CMR imaging acquisition and analysis was as described in Method Section 2.3. 
 
3.2.4 Clinical assessment and right heart catheterisation 
 
Clinical assessment followed a standard diagnostic algorithm as described in Methods 
Section 2.2. 
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3.2.5 Statistical analysis 
 
For all variables a normal distribution was verified using histograms and 
Kolmogorov-Smirnov tests.  Non-normally distributed values ([NT-proBNP] and 
right atrial pressure) were logarithmically transformed and all correlation analyses 
were performed using Pearsons method.  Comparisons between PH patients and 
controls (and between sub-groups of PH patients) were made using an independent 
samples (unpaired) t-test (using Welchs correction if appropriate). 2x2 contingency 
tables were used to calculate the sensitivity and specificity of various plasma 
concentrations of NT-proBNP as a means of detecting RVSD.  RVSD was defined as 
an RVEF < 42 % (this constituted an RVEF > two standard deviations below the 
mean RVEF of the control population (66 (±7) %)).  The plasma [NT-proBNP] with 
the greatest diagnostic accuracy (that which produced the lowest number of false 
positive and false negative results) was chosen as a threshold value for the detection 
of RVSD.  Negative and positive predictive values ((NPV and PPV) for results either 
side of this NT-proBNP threshold were then calculated.  The implications of an above 
threshold result were quantified by likelihood ratios and Fishers exact test. To 
identify independent predictor(s) of circulating [NT-proBNP], variables significantly 
associated with [NT-proBNP] (RVEDVI, RVESVI, RVEF, RVMI, LVSVI, mean 
PAP, systolic PAP, diastolic PAP, cardiac index, pulmonary vascular resistance and 
mixed venous oxygen saturation (MVO2) (see table 3.3)) were entered into a 
multivariable stepwise linear regression model, in which NT-proBNP was the 
dependent variable.  Co-variables with a correlation co-efficient ≥ 0.8 were tested 
within separate regression models to avoid the effects of co-linearity.  All statistical 
analyses were performed using GraphPad Prism 4 for Windows (GraphPad Software 
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Inc., San Diego, USA), were two-sided and assumed a significance level of 5 %.  All 
values are presented as mean (±1SD) unless otherwise stated. 
 
3.3 Results 
 
3.3.1 Clinical assessment and right heart catheterisation 
 
Invasive measurements acquired in the PH patients are summarised in Table 3.1. 
 
Table 3.1  Results of right heart catheterisation in 25 patients with PH who 
underwent Cardiovascular Magnetic Resonance imaging 
       
Variable    Mean (± SD)  
       
       
PAP * (mmHg) Systolic PAP 72 (± 20)   
       
  Diastolic PAP 24 (± 9)   
       
  Mean PAP 43 (± 12)   
       
Cardiac Index (l/min/m2)   2.4 (± 0.6)  
       
PVR  (mmHg/l/min)   10 (± 6)   
       
RAP  (mmHg)   8 (± 8)   
       
MV § O2 saturation (%)   65 (± 8)   
       
       
* PAP: Pulmonary Arterial Pressure,  PVR: Pulmonary Vascular  
       
Resistance,  RAP: Right Atrial Pressure, § MV: Mixed Venous 
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3.3.2 CMR imaging 
 
Ventricular dimensions and systolic function of the 25 PH patients and 12 controls are 
presented in Table 3.2.  In summary, RVEDV, RVESV, RV mass and RVMI were 
significantly increased, and RVEF significantly depressed in PH patients relative to 
control subjects.  LVEDV and LVSV were significantly lower in PH patients 
compared with controls.  All LV measurements, in both PH patients and controls, 
were within previously published normal limits (97, 140).  Where available we have 
used CMR normal ranges determined by SSFP imaging sequences similar to those 
employed in our own study  (140). 
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Table 3.2 
Ventricular dimensions and function measured by Cardiovascular Magnetic 
Resonance imaging in 25 patients with Pulmonary Hypertension (PH) and 12 controls 
PH Controls p value
(n= 25) (n= 12)
Right Ventricle
EDV * (ml) 170 (± 57) 129 (± 46) 0.033
ESV  (ml) 99 (± 53) 45 (± 22) < 0.0001
Stroke Volume (ml) 71 (± 19) 83 (± 29) 0.126
Ejection Fraction (%) 45 (± 14) 66 (± 7) < 0.0001
Mass (g) 84 (± 34) 48 (± 18) 0.0002
RV Mass Index 0.87 (± 0.24) 0.41 (± 0.04) < 0.0001
Left Ventricle
EDV * (ml) 86 (± 25) 116 (± 36) 0.005
ESV  (ml) 28 (± 16) 31 (± 14) 0.579
Stroke Volume (ml) 60 (± 17) 85 (± 24) 0.0009
Ejection Fraction (%) 71 (± 9) 74 (± 7) 0.218
Mass (g) 94 (± 23) 120 (± 51) 0.117
* EDV; End-diastolic volume,  ESV; End-systolic Volume  
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3.3.3 Correlation analyses 
 
[NT-proBNP] was non-normally distributed in the population studied.  Median 
(interquartile range) [NT-proBNP] was 669 (94-2615) ng/l.  After logarithmic 
transformation mean (± 1SD) log 10 [NT-proBNP] was 2.71 (± 0.77).  A complete list 
of correlation co-efficients and accompanying p-values for variables compared with 
[NT-proBNP] is presented overleaf in Table 3.3.   There was a powerful negative 
logarithmic correlation between [NT-proBNP] and RVEF (see figure 3.1).  With the 
exception of LVSV, there was no significant correlation between [NT-proBNP] and 
LV measurements (see Section 3.4.4). 
 
3.3.4 Differences in log 10 [NT-proBNP] in subgroups of PH patients 
 
There were no statistically significant differences in [NT-proBNP] based on gender 
(mean log 10 [NT-proBNP] was 2.7 (± 0.6) in males and 2.7 (± 0.8) in females) or 
aetiology of PH (mean log 10 [NT-proBNP] was 2.6 (± 0.8) in PAH (2.4 (± 0.9) in 
IPH, 3.0 (± 0.7) in PAH-CTD) and 3.0 (± 0.5) in patients with CTEPH). 
 
3.3.5 RV systolic dysfunction 
 
RV systolic dysfunction (RVSD) was present in 9/25 PH patients (36 %).  The 
distribution of [NT-proBNP] values for the 9 patients with RVSD and the 16 patients 
without RVSD were normal.  Mean [NT-proBNP] was significantly higher in patients 
with RVSD (4127 (± 2951) ng/l) in comparison to those without RVSD (354 (± 435) 
ng/l) (t= 3.813, df = 8, p = 0.005). 
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Table 3.3  
Correlation co-efficients between log 10 [NT-proBNP] (ng/l) and measurements 
acquired in 25 PH patients during Cardiovascular Magnetic Resonance imaging 
Variable
Right Ventricle
EDV * (ml) 0.556
ESV  (ml) < 0.001
Stroke Volume (ml) 0.177
Ejection Fraction (%) < 0.001
Mass (g) 0.001
RV Mass Index < 0.001
Left Ventricle
EDV * (ml) 0.064
ESV  (ml) 0.705
Stroke Volume (ml) 0.009
Ejection Fraction (%) 0.115
Mass (g) 0.349
Invasive Measurements
Mean PAP  0.501 0.011
Systolic PAP  0.435 0.03
Diastolic PAP  0.622 < 0.001
Cardiac Index 0.523 0.007
Pulmonary Vascular Resistance 0.566 0.003
Mixed Venous O2 Saturation 0.541 0.009
* EDV; End-diastolic volume,  ESV; End-systolic Volume,  PAP; 
Pulmonary Artery Pressure
0.196
0.004
0.376
0.08
0.508
0.323
0.279
0.66
0.613
0.713
p-valuer co-efficient
0.655
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Figure 3.1  
 
CMR imaging and NT-proBNP measurements were acquired in 25 patients with 
Pulmonary Hypertension.  [NT-proBNP], after logarithmic transformation correlated 
powerfully with RV ejection fraction (RVEF) (r = -0.66, p < 0.001). The horizontal 
line indicates the [NT-proBNP] threshold chosen (1685 ng/l) for the detection of RV 
systolic dysfunction (RVSD).  The vertical line indicates the RVEF (42%) used to 
define RVSD.  Only one false negative result (solid triangle) was returned. 
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3.3.6 Diagnostic performance of NT-proBNP 
 
NT-proBNP performed best at a plasma concentration of 1685 ng/l, detecting RVSD 
with 100 Sensitivity % (95 % CI (63.0 % to 100 %)) and 94 % Specificity (95% CI 
(71.3 % to 99.9 %)).  1685 ng/l was therefore chosen as the threshold value for RVSD 
detection.  17/25 patients had an [NT-proBNP] below the 1685 ng/l threshold.  16/17 
of these patients were true negatives (i.e. RVEF was normal (≥ 42 %)) and one was a 
false negative.  In the false negative subject RVEF measured 34 % and [NT-proBNP] 
was 669 ng/l.  The negative predictive value of a low [NT-proBNP] was, therefore, 94 
%. 8/25 patients had an [NT-proBNP] > 1685 ng/l.  RV systolic dysfunction was 
demonstrated by CMR imaging (RVEF < 42 %) in all of these individuals.  Thus, the 
positive predictive value of a high [NT-proBNP] was 100 %.  These results are 
presented graphically in figure 1.  Based on likelihood ratio testing, individuals with 
an NT-proBNP above the 1685 ng/l threshold were 17 times more likely to have 
RVSD than those with below threshold results. 
 
3.3.7 Predictors of [NT-proBNP] 
 
Because RVEF correlated powerfully with RVMI (r = -.854, p < 0.001) these 
variables were entered into two separate multivariable linear regression models in 
which [NT-proBNP] was the dependent variable.  In these models, RVEF (Odds Ratio 
= -0.035, 95 % CI (-0.052  -0.018, p < 0.001) and RVMI (Odds Ratio = 2.254, 95 % 
CI (1.403  3.106, p < 0.001) proved the only independent predictors of circulating 
[NT-proBNP]. 
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3.4 Discussion 
 
This chapter has identified a close correlation between RVEF, measured directly by 
CMR imaging and [NT-proBNP] in patients with PH, assessed prior to any treatment.  
A previous study, reported by Nagaya et al, demonstrated a similar relationship 
between RVEF, measured by electron beam CT imaging, and BNP concentration in a 
similar cohort of patients (91).  The findings of this experiment reported herein are of 
additional interest to this previous report for three important and clinically relevant 
reasons. 
 
1)  In routine clinical practice most centres use NT-proBNP, not BNP, to aid clinical 
decision making in heart failure and a variety of other conditions.  As previously 
discussed, this is because NT-proBNP is more stable in vivo and in vitro than the 
active BNP molecule itself (133). 
 
2)  The study by Nagaya et al used EBCT imaging to measure RVEF, while this study 
utilized CMR imaging as the reference method.  Temporal resolution is better with 
CMR imaging (141) without the need for ionizing radiation or intravenous contrast 
(142).  As a result, CMR has emerged over recent years as the gold standard for 
detailed study of the RV (143-146)  and has become an established modality for the 
physiological assessment of PH patients in cross-sectional studies (102, 147, 148) 
longitudinal follow-up studies (149) and clinical trials of therapy (96).  EBCT, in 
contrast, is not used routinely to assess PH patients.  The current study is therefore 
useful as it defines the relationship between [NT-proBNP] and RV volumes and 
ejection fraction measured directly by CMR imaging. 
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3)  In addition to a correlation between [NT-proBNP] and RVEF, this study has also 
demonstrated that an [NT-proBNP] > 1685 ng/l (detected in 8/25 patients) was a 
sensitive marker of RVSD (sensitivity 100 %).  Below this threshold only one false 
negative result was returned, suggesting that RVSD is very unlikely when circulating 
[NT-proBNP] is less than 1685 ng/l, at least in patients assessed at baseline, before 
treatment initiation (negative predictive value 94 %)).  Stratifying patients either side 
of this NT-proBNP threshold may prove useful as an operator independent, objective 
means of classifying individuals at presentation based upon their probability of having 
RVSD and thus an increased risk of early death. 
 
3.4.1 Physiological determinants of NT-proBNP 
 
Several variables correlated closely with circulating [NT-proBNP] in this experiment 
(see Table 3.3).  Of these variables only RVEF and RV mass index (RVMI), analysed 
within separate regression models to avoid the effects of co-linearity, proved 
independent predictors of [NT-proBNP].  Although it has previously been shown that 
RVMI relates linearly to mean PAP in PH (102), it has not been proven to predict 
early death in patients with this condition.  For this reason we defined our primary 
goal as the detection of RVSD, not RV hypertrophy, using [NT-proBNP].   The 
influence of RV hypertrophy (as RVMI) should, however, be discussed and perhaps 
acknowledged as a potential confounder of our results.  The vast majority (7/8 (88 %)) 
of patients in our study with above threshold NT-proBNP levels indicative of RVSD 
also had RV hypertrophy (defined as a RV mass > 84 g (> 2 SDs above mean RV 
mass of the control population (48 (± 18) g)) reflecting the co-variation between 
RVMI, RVEF and [NT-proBNP] that we found.  Despite this, RVEF appeared to be 
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an important determinant of circulating [NT-proBNP] in our study.  Interestingly, a 
recent study reported by Quaife et al (150) has identified a close correlation between 
RVEF and RV wall stress.  Since RV wall stress is the principal stimulus to NT-
proBNP release in PH, this relationship may explain the usefulness of NT-proBNP as 
a means of detecting RVSD reported herein. 
 
3.4.2 Clinical implications 
 
Non-survivors in a recent PH study reported by Fijalkowska et al (135) were 
identified by an [NT-proBNP] > 1400 ng/l.  Since non-survivors with PH are likely to 
die from RV failure, and [NT-proBNP] correlated powerfully with echocardiographic 
measures of RV systolic function in this study, it seems plausible that the 1400 ng/l 
threshold reported in the Fijalkowska study and our own 1685 ng/l threshold reflect 
genuine RV systolic dysfunction in the patients studied.  However, the true clinical 
significance of the [NT-proBNP] threshold for RVSD (1685 ng/l) identified in our 
study can only be determined in a longitudinal survival analysis.  For this reason it is 
difficult to justify detailed proposals for the future use of NT-proBNP in clinical 
practice at this time.  The findings reported here indicate, however, that NT-proBNP, 
measured during a patients first consultation at a specialist PH centre could, in 
conjunction with existing means of assessing RV function (i.e. clinical examination 
and echocardiography) help identify patients with prognostically significant RVSD.  
Assuming other reasons for a high NT-proBNP were excluded patients with a high 
[NT-proBNP] could then be invasively assessed at an early stage and treatment 
initiated if appropriate.  Although there is no evidence yet that early treatment of PH 
alters prognosis per se, it is known that a history of overt RV failure before treatment 
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initiation is associated with an increased mortality risk (48). Prompt initiation of 
therapy in patients with high NT-proBNP levels and sub-clinical RVSD may, 
therefore, avoid the development of overt RV failure and reduce early mortality. 
 
3.4.3 RV ejection fraction 
 
In this chapter, RVEF was utilized to define RVSD.  Although historical data have 
suggested that RVEF does not reflect RV systolic function alone (since it is also 
dependant upon right ventricular afterload) (151-153), RVEF determined by 
echocardiography and radionuclide ventriculography has recently been shown to 
predict adverse outcomes (cardiac death or deterioration) in patients with PH (154). 
Until longitudinal survival studies are reported in which CMR-derived variables are 
assessed the true prognostic significance of CMR-derived RVEF, and the cut-off 
value of 42 % used here to define RVSD cannot, however, be known. 
 
3.4.4 NT-proBNP and LV stroke volume 
 
In this experiment a statistically significant relationship between [NT-proBNP] and 
LV stroke volume (LVSV), but no correlation between [NT-proBNP] and RV stroke 
volume (RVSV) is reported.  This apparent contradiction reflects the inaccuracy of 
CMR-planimetry in determining true (i.e. forward) stroke volume in patients with 
significant valvular regurgitation.  CMR-planimetry of a dilated RV with significant 
tricuspid valve regurgitation will always overestimate true forward RVSV because a 
proportion of the ejected blood volume will move backwards through the incompetent 
tricuspid valve.  Since forward LVSV and forward RVSV will, over several heart 
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beats, be equivalent in the absence of any communicating shunt, and since no PHT 
patient in our study had any evidence of mitral regurgitation, the statistically 
significant relationship that we found between LVSV and [NT-proBNP] likely 
reflects an underlying correlation between [NT-proBNP] and true forward RVSV that 
is obscured by this predictable measurement error.  Although CMR-planimetry may 
not always accurately determine forward RVSV in PH patents, RVEF still reflects the 
systolic contractile function of the ventricle, assessment of which was the primary aim 
of this study.  An alternative confounder to the CMR-planimetry results might be the 
trabeculation of the RV.  Despite this concern, we have found acceptable intra-
observer variation for ventricular mass and ejection fraction (3.8-7.4 % and 3.4-4.4 %, 
respectively) measured by other researchers using the same method in the Glasgow 
Cardiac Magnetic Resonance Unit (unpublished data). 
 
3.4.5 Study limitations 
 
The relatively small number of patients involved in this experiment is of concern in 
the proposal of a specific cut-off level for use in the detection of RVSD in clinical 
practice.  CMR imaging, however, represents an extremely accurate and reproducible 
gold standard of RVEF limiting the number of patients required for such studies. [NT-
proBNP] can be affected by a number of factors including renal function, left-sided 
heart disease, age, gender (155) and recent exertion.  In the current study patients who 
had other reasons for a high [NT-proBNP] were excluded and the timing and 
conditions surrounding NT-proBNP sampling were standardised.  It should be 
emphasised that the results of this study should only be applied to selected PH 
patients assessed in this manner.  In addition, it is not known whether therapies such 
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as Sildenafil, which acts directly upon the cardiac myocyte (156), will affect the 
relationship we report between RVEF and [NT-pro BNP] or whether any observed 
fall in [NT-pro BNP] during treatment will prove proportional to an improvement in 
RV systolic function.  Further insight into these issues is necessary to understand the 
clinical significance of changes in [NT-proBNP] during treatment. 
 
3.4.6 Conclusion 
 
The study reported in this chapter is the first to utilise a specific NT-proBNP 
threshold (1685 ng/l) as a means of detecting RVSD in patients with PH.  Classifying 
patients either side of such a threshold is simple, inexpensive and most importantly, 
non-invasive and may help to inform the largely subjective process of stratifying new 
patients for invasive assessment and the initiation of disease targeted therapy. 
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Chapter 4 
Contrast enhanced-Cardiovascular Magnetic Resonance 
imaging in patients with pulmonary hypertension 
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4.1 Introduction 
 
In Chapter 3 it was shown that NT-proBNP can be used to detect RV systolic 
dysfunction non-invasively in patients with PH.  Unfortunately, despite recent 
therapeutic advances, which have improved the short-to-medium term outlook for 
patients with PH, RV failure and early death remains inevitable in the majority (1, 
58).  In this chapter contrast enhanced-CMR (ce-CMR) imaging is used a means of 
interrogating the right and left ventricular myocardium in patients with PH in a 
manner not possible using any other imaging technique. The purpose of this study was 
to gain some new insight into the mechanism(s) of RV failure in PH patients.  Such 
information might facilitate better targeting of the treatments currently available and 
allow physicians to anticipate an individuals decline and the need for therapeutic 
intervention or referral for transplant. As discussed in section 1.4.3.2, delayed contrast 
enhancement (DCE) is well established as a marker of myocardial abnormalities in a 
variety of disease states.  However, ce-CMR has yet to be utilised in patients with PH.  
The experiment in this chapter tested the specific hypothesis that discrete myocardial 
abnormalities might exist in patients with PH.  It was hoped that the pattern of any 
DCE detected might provide new insight into the development of RV failure in 
patients with PH. 
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4.2 Methods 
 
4.2.1 Patients 
 
Twenty-five consecutive patients with PH were recruited and clinically assessed as 
described in Methods Section 2.1-2.2. Eighteen of these patients also took part in the 
NT-proBNP study reported in Chapter 3.  No specific selection criteria were used, 
other than a diagnosis of either Pulmonary Arterial Hypertension (PAH) or Chronic 
Thromboembolic PH (CTEPH) reached by conventional diagnostic methods (57, 65). 
The final diagnoses reached in the 25 patients studied are summarised in Table 4.1. 
 
Table 4.1  
Final diagnoses reached in 25 patients with Pulmonary Hypertension who underwent 
contrast enhanced-Cardiovascular Magnetic Resonance imaging 
          
 Diagnosis     No. of Patients  
          
          
 Pulmonary Arterial Hypertension (PAH)  19   
          
  Idiopathic PAH    12   
          
  Associated PAH    7   
          
   Connective Tissue Disease  5   
          
   Repaired Congenital Left-to-Right shunt 2   
          
 Chronic Thromboembolic Pulmonary Hypertension 6   
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At the time of the study no patient had received any specific treatment (other than 
anticoagulation with warfarin) for PH.  None of the patients had a previous diagnosis 
of ischaemic heart disease or a history of previous myocardial infarction.  Twenty 
three out of the twenty five patients underwent ce-CMR within twenty four hours of 
right heart catheterisation. The other two patients underwent ce-CMR within four 
days of invasive assessment. 
 
Twelve control subjects were recruited as described in Methods Section 2.1.   
Controls underwent CMR imaging, without contrast enhancement, to provide local 
control values for ventricular dimensions and function.  Demographic data for the PH 
and control populations are summarised in Table 4.2. 
 
Table 4.2  
Group demographics for 25 patients with Pulmonary Hypertension and 12 control 
subjects who underwent contrast enhanced-Cardiovascular Magnetic Resonance 
imaging.  Values are mean (± SD) unless stated 
        
   PH Controls p value 
        
        
        
 Age (years)    58 (± 14) 57 (12) 0.837 
        
 Sex  (♀;♂)    17;8 8;4  
        
 Systemic BP(mmHg) Systolic BP  125 (± 17) 129 (25) 0.635 
        
  Diastolic BP  78 (± 9) 74 (13) 0.252 
        
  Mean BP  96 (± 12) 92 (17) 0.403 
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4.2.2 CMR image acquisition 
 
Pre-contrast CMR image acquisition, in PH patients and controls, was performed as 
described in Methods Section 2.3.2.1. Contrast enhanced imaging was performed in 
PH patients only as described in Methods Section 2.3.2.2. 
 
4.2.3 Pre-contrast CMR image analysis 
 
Pre-contrast CMR images analysis was performed as described in Methods Section 
2.3.4.1. 
 
4.2.4 Contrast enhanced-CMR image analysis 
 
All post contrast CMR images were analysed as described in Methods Section 2.3.4.2. 
 
4.2.5 Clinical assessment and right heart catheterisation 
 
Clinical assessment followed a standard diagnostic algorithm as described in Methods 
Section 2.2. 
 
4.2.6 Statistical Analysis 
 
For all variables a normal distribution was verified using histograms and 
Kolmogorov-Smirnov tests.  For demographic, haemodynamic and ce-CMR variables 
mean values + one standard deviation (± SD) were calculated.    Correlations between 
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normally distributed CMR and haemodynamic variables were tested by Pearsons 
method, correlation involving non-normally distributed variables was assessed using 
Spearmans rho test; all tests were two-tailed.  Mean signal intensity values for areas 
of DCE versus reference areas were compared by a paired t-test.   An independent 
samples (unpaired) t-test (equal variances not assumed) was used to compare right 
and left ventricular measurements acquired in the twenty five PH patients studied with 
a) the twelve control subjects assessed in our own laboratory and b) previously 
published normal mean values.  This method was also used to compare differences in 
mean DCE mass between sub-groups of patients with different aetiologies of PH and 
gender and to compare systemic blood pressure measurements in PH patients 
compared with controls.  A significance level of 5 % was used in all tests.  No 
adjustment was made to p-values to account for multiple testing.  All statistical 
analyses were performed using SPSS 11.5 for Windows (SPSS Inc., Chicago, USA).  
All values are presented as mean (±1SD) unless otherwise stated. 
 
4.3 Results 
 
4.3.1 Right heart catheterisation 
 
Invasive measurements acquired in the PH patients are summarised overleaf in Table 
4.3. 
 
 
 
 
 175
Table 4.3  
Results of Right Heart Catheterisation in 25 patients with PH 
 
Mean (± SD)
PAP * (mmHg) Systolic PAP 72 (± 20)
Diastolic PAP 23 (± 9)
Mean PAP 43 (± 12)
Cardiac Output (l/min) 4.3 (± 1.2)
PVR  (mmHg/l/min) 9 (± 5)
RAP  (mmHg) 7 (± 5)
Mixed Venous Oxygen Saturation (%) 66 (± 8)
*PAP: Pulmonary Arterial Pressure,  PVR: Pulmonary Vascular 
Resistance,  RAP: Right Atrial Pressure 
 
 
4.3.2 Pre-contrast CMR imaging 
 
Ventricular dimensions and systolic function of PH patients and control subjects are 
presented in Table 4.4 on page 174.  In summary, LV measurements within PH 
patients were within previously published normal limits (97, 140); LVEDV and 
LVSV were, however significantly lower in the PH cohort compared with local 
controls.  Within the control population both left and right ventricular measurements 
were within previously published normal limits (97, 140). In PH patients RV volumes 
and RV mass were significantly increased, and RVEF significantly depressed in 
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comparison with both control subjects and previously published normal ranges (97).  
For both left and right ventricular measurements in controls and PH patients we have 
compared our measurements with normal ranges acquired using a SSFP CMR 
technique where these ranges are available (140). 
 
4.3.3 Contrast enhanced CMR imaging 
 
Delayed contrast enhancement was demonstrated in twenty three out of twenty five 
patients.  Median DCE mass for the population studied was 3.3g (range 0  22.2g).  
Contrast enhancement was confined to the RV insertion points (RVIPs) in seven out 
of twenty three patients.  Further contrast enhancement was demonstrated outwith, but 
still contiguous with the RVIPs, within the Interventricular Septum (IVS), in sixteen 
out of twenty three patients (examples are shown in figure 4.1 on pages 175 and 176).  
Two patients showed no evidence of contrast enhancement. 
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Table 4.4  
Ventricular dimensions and function in 25 patients with PH and 12 control subjects 
who underwent contrast enhanced-Cardiovascular Magnetic Resonance imaging. 
Values are mean (± SD) 
PHT Controls p value
n = 25 n = 12
Right Ventricle
EDV * (ml) 179 (± 60) 128 (± 46) p = 0.009
ESV  (ml) 104 (± 58) 45 (± 22) p < 0.001
Stroke Volume (ml) 75 (± 27) 83 (± 29) p = 0.383
Ejection Fraction (%) 45 (± 17) 65 (± 7) p < 0.001
Mass (g) 86 (± 34) 48 (± 18) p < 0.001
RV Mass Index 0.88 (± 0.25) 0.41 (± 0.04) p < 0.001
Left Ventricle
EDV * (ml) 90 (± 25) 116 (± 36) p = 0.01
ESV  (ml) 29 (± 17) 31 (± 14) p = 0.601
Stroke Volume (ml) 63 (± 17) 85 (± 24) p = 0.002
Ejection Fraction (%) 70 (± 11) 74 (± 7) p = 0.457
Mass (g) 97 (± 27) 120 (± 51) p = 0.178
* EDV; End Diastolic Volume,  ESV; End Systolic Volume  
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Figure 4.1, opposite  
25 patients with Pulmonary Hypertension (PH) and 12 control subjects underwent 
contrast enhanced-Cardiovascular Magnetic Resonance imaging. Images series 1 and 
2 were acquired at basal and mid-ventricular slice positions, respectively, in a patient 
with PH.  Images 1(a) and 2 (a) are pre-contrast.  Images 1(b) and 2(b) were acquired 
ten minutes after intravenous administration of Gadolinium.  Images 1(c) and 2 (c) are 
swapped phase images, which were acquired to verify areas of delayed contrast 
enhancement (indicated by blue arrows). 
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Figure 4.1 
Image series 1
Image series 2
1(a)
2(b)2(a)
1(c)1(b)
2(c)
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The mean signal intensity (SI) of areas of contrast enhancement was significantly 
higher than that of reference areas (mean SI (contrast enhancement areas) = 31.6 
(11.5), mean SI (reference areas) = 7.3 (1.8), p < 0.001).   In all patients, contrast 
enhancement, whether it was localised to the RVIPs or extended into the IVS, was 
confined to the mid-wall region of the ventricular myocardium.  No sub-endocardial 
contrast enhancement was seen.  No contrast enhancement was seen within the RV 
free wall or the LV outwith the IVS.  There were no significant differences in the 
DCE pattern or DCE mass in patients with different aetiologies of PH or different 
gender. 
 
There were a number of statistically significant correlations between the extent of 
contrast enhancement seen (DCE mass) and both invasive pulmonary haemodynamics 
and RV dimensions and function at CMR (see figure 4.2 overleaf).  Correlations not 
shown in this figure include DCE mass α RV mass/BSA (r = 0.639, p = 0.001), 
systolic pulmonary artery pressure (PAP) (r = 0.589, p = 0.002, diastolic PAP (r = 
0.538, p = 0.006) and pulmonary vascular resistance (PVR) (r = 0.459, p = 0.024) 
 
IVS bowing (displacement of the IVS towards the LV in early LV diastole) (148, 157) 
was observed in seventeen out of twenty five patients studied (see figure 4.3 on page 
183).   This phenomenon was observed in all sixteen patients in whom contrast 
enhancement was seen within the IVS.  Only one patient with IVS bowing had 
contrast enhancement confined to the RVIPs. 
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Figure 4.2, below   
25 patients with Pulmonary Hypertension (PH) underwent contrast enhanced-Cardiovascular Magnetic Resonance imaging. The extent of 
delayed contrast enhancement (DCE) within the RV insertion points and interventricular septum was quantified by manual planimetry and 
defined as DCE mass.  DCE mass was correlated against various indices of RV structure, RV function and pulmonary haemodynamics 
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Figure 4.2 
 
r = 0.587, p = 0.002 r = 0.679, p < 0.001
r = - 0.762, p < 0.001 r = 0.672, p < 0.001
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Figure 4.3  
25 patients with Pulmonary Hypertension (PH) underwent contrast enhanced-
Cardiovascular Magnetic Resonance imaging.  A single pre contrast, short axis CMR 
image is presented.  The image was acquired at a mid-ventricular level, in early 
diastole and clearly demonstrates interventricular septal (IVS) bowing (arrowed), i.e. 
leftward displacement of the IVS during diastole.  This phenomenon was observed in 
17/25 PH patients studied and all 16 patients in whom septal delayed contrast 
enhancement was detected.  The image used was acquired in the same patient used in 
figure 4.1 for ease of comparison. 
 
RV
LV
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4.4 Discussion 
 
The study described in this chapter was based upon the hypothesis that discrete, and 
detectable, myocardial abnormalities might exist in patients with PH.  Delayed 
contrast enhancement (DCE), indicative of some form of myocardial damage, was 
demonstrated in the vast majority of patients in this experiment (twenty three out of 
twenty five subjects).  The two subjects in whom DCE was not demonstrated both had 
low pulmonary artery pressures at invasive assessment (mean PAP 30 mmHg and 34 
mmHg respectively) and normal RV anatomy and function at CMR (RV ejection 
fractions 68 % and 71% respectively).  All areas of DCE detected were in the mid-
wall of the ventricular myocardium at either the RV insertion points (RVIPs), in 
isolation (in seven patients), or both the RVIPs and the IVS (in the remaining sixteen 
patients).  The extent of DCE, defined by DCE mass, correlated with various 
haemodynamic variables.  Septal contrast enhancement was particularly associated 
with the presence of IVS bowing, i.e. in all sixteen patients in whom septal contrast 
enhancement was demonstrated, bowing of the IVS was also seen.  Only one patient 
demonstrated IVS bowing without significant septal contrast enhancement (in this 
subject contrast enhancement was present but was confined to the RVIPs). 
 
There were no significant differences in DCE mass in patients of different genders or 
different aetiologies.  The numbers of patients in these sub-groups were, however, 
small making it difficult to draw significant conclusions from these results. 
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4.4.1 Potential mechanisms of contrast enhancement 
 
The physiological mechanism(s) responsible for the contrast enhancement observed 
are unknown.  In general, DCE is thought to result from delayed clearance of 
gadolinium from a relatively expanded extracellular volume within fibrotic or necrotic 
myocardial compartments (110, 111).  Potential biological mechanisms for the 
contrast enhancement seen in this experiment are explored below. 
 
4.4.1.1 Myocardial ischaemia 
 
The exclusive and consistent mid-wall contrast enhancement pattern demonstrated is 
not typical of ischaemic injury.  DCE in acute and chronic myocardial infarction 
characteristically involves the subendocardium and extends transmurally depending 
on the size of the infarct (104, 108).  Furthermore, earlier studies found no evidence 
of reversible myocardial ischaemia within either the RVIPs or the IVS using stress 
myocardial scintigraphy in patients with PH (158). 
 
4.4.1.2 Myocardial fibrosis 
 
The mid-wall contrast enhancement pattern observed appears most similar to that 
recently described in several studies of patients with Hypertrophic Cardiomyopathy 
(HCM) using ce-CMR (106, 113, 120).  These studies have demonstrated similar 
contrast enhancement to that seen in this experiment in both the RVIPs and other foci 
throughout the heart, including the IVS (120).  Contrast enhancing foci in HCM have 
recently been shown to correlate histologically with areas of increased myocardial 
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collagen (113) and while autopsy studies of the hearts of patients with HCM had, in 
the past, demonstrated gross muscle fibre disarray and destruction of the 
circumferential, mid-wall component of the ventricular myocardium within the RVIPs 
(121) it is only since the publication of the more recent CMR studies referenced above 
that this distribution of fibrosis has become recognised as the pattern typical of HCM.  
Despite an extensive review of the literature we have, however, been unable to find 
any similar autopsy studies which describe the histopathological appearances seen 
within the RVIPs and IVS of human subjects with PH.  This makes any speculation 
that similar mechanisms of delayed contrast enhancement might exist in patients with 
PH uncertain. 
 
4.4.1.3 Elevated RV afterload 
 
One possible precipitant for myocardial abnormalities in the setting of PH is elevated 
RV afterload.  DCE mass in this experiment correlated positively with RV mass and 
RVMI; both variables which have been associated with the degree of RV hypertrophy 
present in patients with PH (101, 102).  Pure afterload-induced myocardial 
hypertrophy seems, however, an unlikely cause of the fibrosis suggested by the 
contrast enhancement seen here.  It is difficult to see how such a global insult to the 
RV myocardium could explain the consistent and exclusive deposition of contrast 
within the RVIPs and IVS.  This localised contrast enhancement pattern suggests an 
additional precipitant of what appears most likely to be fibrotic change within the 
areas described. 
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4.4.1.4 Mechanical wall stress 
 
The RVIPs are regions of a particular mechanical stress, even under normal 
physiological conditions.  In severe PH, these mechanical stresses are amplified as 
elevation of RV chamber pressures results in the generation of a physiologically 
abnormal leftward trans-septal pressure gradient.  This gradient is manifested 
physiologically as the paradoxical, leftward displacement of the IVS seen during early 
LV diastole (i.e. late RV systole) (148, 157) in a proportion of patients with PH (see 
figure 4.3).  It is of note that in our study, all sixteen patients in whom there was 
evidence of septal contrast enhancement also showed clear evidence of IVS bowing.  
Furthermore, animal studies have shown that the middle, circumferential layer of the 
LV myocardium, which by conventional CMR terminology includes the areas 
identified within the RVIPs and IVS in this experiment, are subject to maximal hoop 
stress (defined as force generated per unit area of myocardium) during the course of 
normal ventricular contraction (159).  Finally, in a rodent model of hypobaric-hypoxic 
PH the RVIPs (within three days of hypoxia) and later the IVS were identified by 
McKenzie and co-workers as the earliest sites of immunoreactive-Atrial Natriuretic 
Peptide expression.  The authors concluded that these areas were subject to the 
earliest and most intense increases in mechanical wall stress as a result of developing 
PH and rising RV chamber pressures (160). 
 
4.4.1.5 Summary of potential mechanisms of DCE 
 
At the current time, it is only possible to speculate on the true reasons for the contrast 
enhancement pattern demonstrated in our study.  However, based upon the evidence 
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available from earlier studies, it appears most likely to reflect altered contrast kinetics 
due to myocardial fibrosis (113) within the mid-wall, circumferential muscle 
compartment of the RVIPs and IVS.  Elevated mechanical wall stress in these areas 
appears a likely precipitant of this fibrosis.  Definitive proof will require correlation 
between areas of DCE at CMR and autopsy specimens from patients with PH. 
 
4.4.2 Study Limitations 
 
None of the patients in this study underwent coronary angiography to formally 
exclude ischaemic heart disease (IHD) which is an important cause of DCE.  
However, the contrast enhancement pattern observed is not typical of ischaemic 
myocyte injury and a diagnosis of IHD was not considered likely in any patient 
studied based on the presenting clinical picture. 
 
4.4.3 Clinical implications 
 
Contrast enhanced-CMR imaging provides a novel method of identifying and 
quantifying myocardial abnormalities in patients with PH, abnormalities which have 
thus far gone undetected. This study, in combination with the work of others (147, 
148, 157) emphasises the importance of interventricular septal dysfunction in the 
evolution of RV failure in PH. Given the correlations of DCE mass with existing 
markers of disease severity in PH, this measure may prove useful in the prognostic 
classification of patients presenting with PH. 
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Chapter 5 
Dobutamine stress-Cardiovascular Magnetic Resonance 
imaging in patients with pulmonary hypertension 
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5.1 Introduction 
 
In Chapter 4 it was shown that discrete myocardial abnormalities exist within the RV 
insertion points and interventricular septum of patients with PH.  The nature of these 
could not be proven but the available evidence supports a hypothesis that they 
represent areas of myocardial fibrosis precipitated by mechanical wall stress 
associated with interventricular septum bowing.  In this chapter the intimate 
relationship between the right and left ventricles of patients with PH is explored in 
more detail.   
 
Exercise limitation is common in patients with PH (129) and appears related to an 
inability to appropriately increase cardiac output by increasing right and left 
ventricular stroke volumes during physical activity (47, 130).  However, the reasons 
for stroke volume limitation in PH are not well understood, and are probably different 
for each ventricle. For example, the blunted LV stroke volume response seen in PH 
has been attributed to impaired LV filling as a result of low RVSV and low LV 
preload in some studies (161, 162), but related more to direct ventricular interaction, 
mediated by leftward displacement of the interventricular septum, in others (163-165). 
 
Detailed study of cardiac physiology during exercise in PH patients is not easy.  
Ideally one would like to compare invasive cardiac filling pressures, during exercise, 
with accurate right and left ventricular volume measurements.  However, the invasive 
nature of these studies makes them unattractive to both patients and investigators.  An 
alternative, non-invasive approach is, therefore, preferable.  As has been discussed in 
earlier chapters, CMR imaging can be used to directly and accurately measure 
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ventricular volumes and function and can also quantify right and left ventricular 
stroke volumes based on forward flow measured in the main pulmonary artery and 
aorta, respectively (166).  Therefore, exercise-CMR imaging seems to offer obvious 
potential as a means of enhancing our understanding of the reasons for stroke volume 
limitation during exercise in PH.  Unfortunately, true exercise-CMR images are 
degraded by movement artefact during physical activity, meaning that accurate 
images can only be acquired immediately following exercise.  Dobutamine stress-
CMR (ds-CMR) circumvents these difficulties and allows true stress measurements to 
be made, thus avoiding potential errors relating to exercise recovery.  Dobutamine 
approximates physiological conditions during exercise in PH patients by increasing 
cardiac output.  It is a pure inotrope with no flow-independent effects on pulmonary 
vascular tone (125).  In earlier studies, ds-CMR has been used successfully in patients 
with congenital heart disease.  However, it has yet to be used in patients with PH due 
to other causes.  The primary hypothesis of the following experiment was that ds-
CMR could be used to identify the reason(s) for right and left ventricular stroke 
volume impairment during exercise in PH patients. 
 
5.2 Methods 
 
5.2.1 Study participants and clinical assessment 
 
Sixteen patients with PH were recruited and clinically assessed as described in 
Methods Section 2.1-2.2.  None of these patients were recruited to the other studies in 
this thesis.  Two specific exclusion criteria were used during recruitment for this 
study.  Patients with PH due to congenital heart disease were excluded, after clinical 
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assessment and transthoracic echocardiography, because of their more complicated 
cardiac anatomy and physiology.  Patients with contraindications to dobutamine were 
also excluded, e.g. aortic stenosis, hypokalaemia and dobutamine allergy. Six control 
subjects were recruited as described in Methods Section 2.1 and underwent 
dobutamine stress-CMR but no other tests.  No study participant (PH patient or 
control) was taking chronotropic cardiac medication at the time of dobutamine stress-
CMR. 
 
5.2.2 Dobutamine stress-CMR imaging 
 
Dobutamine stress-CMR was performed using the protocol described in Method 
Section 2.3.2.3 in PH patients and controls. 
 
5.2.3 Dobutamine stress-CMR image analysis 
 
All scans were coded by number and analysed using the Argus analysis software as 
described in Method Section 2.3.4.3. 
 
5.2.4 Statistics 
 
For all variables a normal distribution was verified using histograms and 
Kolmogorov-Smirnov tests.  Comparisons between resting and stress CMR 
measurements were made using a paired t-test and quantified as percentage of the 
resting value (%).  Comparisons between PH patients and controls and sub-groups of 
PH patients were made using an independent samples (unpaired) t-test (using Welchs 
correction if appropriate).  Correlation between measurements was tested using 
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Pearsons method.  All statistical analyses were performed using GraphPad Prism 4 
for Windows (GraphPad Software Inc., San Diego, USA), were two-sided and 
assumed a significance level of 5 %.  All values are presented as mean (± SD) unless 
otherwise stated. 
 
5.3 Results 
 
5.3.1 Clinical characteristics and demographics 
 
The final diagnoses reached in the 16 PH patients were, Pulmonary Arterial 
Hypertension (PAH) in 12/16 (idiopathic PAH in 8, PAH related to connective tissue 
disease in 4) and Chronic Thromboembolic PH in 4/16.   Invasive haemodynamic 
measurements are summarised overleaf in Table 5.1.  
 
PH patients were older than controls (mean age PH: 55 (± 10), controls: 37 (± 10), p = 
0.001) and 12/16 of the PH patients were female; all 6 controls were male.  The two 
populations were well matched for systemic BP (systolic BP in PH: 123 (± 16), in 
controls: 114 (± 8), p = 0.215), diastolic BP in PH: 80 (± 12), in controls: 73 (± 6), p = 
0.1586), mean arterial BP in PH: 98 (±13), in controls: 87 (± 6), p = 0.053). 
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Table 5.1  
Invasive haemodynamic measurements acquired in 16 patients with Pulmonary 
Hypertension who underwent dobutamine-stress Cardiovascular Magnetic Resonance 
imaging 
 
Variable mean (±1SD)
Pulmonary artery pressure (mmHg)
Systolic 84 (24)
Diastolic 27 (9)
Mean 50 (14)
Cardiac index (l/min/m2) 2.3 (0.5)
Mean right atrial pressure (mmHg) 7 (5)
Pulmonary artery occlusion pressure (mmHg) 8 (2)
Pulmonary vascular resistance (mmHg/l/min) 12 (5)
Mixed venous oxygen saturation (%) 63 (6)
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5.3.2 Symptoms 
 
During dobutamine stress testing, 6/16 PH patients experienced breathlessness, 1/16 
reported pounding in the chest, 1/16 reported light-headedness and 1/16 reported 
headache.  None of these symptoms were intolerable or necessitated a reduction in 
dobutamine dose.  However, 7/16 patients exceeded the safety tolerances set for the 
study (HR increment > 50 % in 5/16, fall in systolic BP > 20 % in 2/16).  In these 
seven patients, the dobutamine infusion rate was reduced to 15 mcg/kg/min during 
stress CMR imaging.  5/7 of these patients experienced symptoms. 
 
The average dose and total time spent on Dobutamine during measurement were 
similar in controls and PH patients (19.1 (1.4) vs. 18.1 (2.3) mcg/kg/min, (p = 0.363) 
and 26 (3) vs. 28 (7) minutes (p = 0.450), respectively). 
 
5.3.3 CMR results 
 
All PH patients and controls completed the CMR imaging protocol, which took an 
average of 35 minutes to complete.  There was excellent internal agreement between 
RVSVI and LVSVI at rest and during stress in both PH patients and controls.  Results 
are presented in detail below and are summarised overleaf in Table 5.2. 
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Table 5.2  
Right and left ventricular measurements at rest and during dobutamine infusion in 16 
patients with Pulmonary Hypertension and 6 controls who underwent dobutamine-
stress Cardiovascular Magnetic Resonance imaging 
Rest Stress % Change Rest Stress % Change
Right Ventricle
SVI (ml/m2) 43 (± 8) 52 (± 13)* + 23 26 (± 10) 29 (± 11)
EDVI (ml/m2) 75 (±14) 63 (± 13) 92 (± 24) 86 (± 29)
ESVI (ml/m2) 32 (± 9) 14 (± 6)**  56 58 (± 24) 48 (± 30)*  17
EF (%) 61 (± 19) 84 (± 10)* + 38 30 (± 13) 38 (± 19)* + 27
Left Ventricle
SVI (ml/m2) 44 (± 9) 53 (± 15)* + 20 27 (± 10) 30 (± 10)
EDVI (ml/m2) 78 (± 12) 67 (± 15) 48 (± 15) 42 (± 12)*  13
ESVI (ml/m2) 25 (± 6) 10 (± 4)**  60 16 (± 6) 8 (± 5)**  50
EF (%) 57 (± 12) 79 (± 15)* + 39 57 (± 10) 72 (15)** + 26
Heart Rate (bpm) 62 (± 13) 97 (± 21)** + 56 75 (± 12) 105 (± 20)** + 41
SVI = stroke volume index, EDVI = end-diastolic volume index, ESVI = end-systolic volume 
index, EF = ejection fraction. * = p < 0.05, ** = p < 0.01 for stress vs. rest within groups,
 p < 0.05 for PH patients vs. controls at rest,  p < 0.05, right vs. left within groups
Controls PH
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5.3.3.1 Resting analyses 
 
RV volumes were larger and RVSVI and RVEF were lower in PH patients compared 
to controls.  15/16 PH patients had RV systolic dysfunction based on previously 
published normal ranges. LV volumes and LVSVI were also lower in PH patients; 
however LV systolic function was normal (140). All measurements were normal in 
controls (140). 
 
5.3.3.2 Stress analyses 
 
In control subjects dobutamine resulted in statistically significant and matched 
increments in mean right and left ventricular stroke volume index (23 % and 20 %, 
respectively) and ejection fraction (38 % and 39 %, respectively).  As a result, mean 
right and left ventricular end-systolic volume fell in a similar co-ordinated manner (by 
56 % and 60 %).  In controls, mean right and left ventricular end-diastolic volume was 
unchanged and heart rate rose significantly.  These findings represent a normal 
physiological response to dobutamine as demonstrated in earlier studies (126, 167). 
 
In PH patients, the co-ordinated response to dobutamine seen in controls was lost.  
RV stroke volume index did not increase overall and fell in 3/16 patients (see figure 
5.1 overleaf).  Although mean RV ejection fraction increased (by 27 %) and mean RV 
end-systolic volume fell (by 17 %) these changes were smaller in absolute terms than 
those observed in controls.  Mean RV end-diastolic volume was unchanged in PH 
patients but LV end-diastolic volume fell significantly (by 13 %).  HR rose by a 
similar amount in PH patients as it did in controls. 
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Figure 5.1 
RV stroke volume index (RVSVI) was measured at rest and during dobutamine stress 
by Cardiovascular Magnetic Resonance imaging in 16 patients with Pulmonary 
Hypertension and 6 controls.  Individual values are presented for PH patients (◊-◊); 
mean RVSVI did not change significantly overall (26 (10) ml vs. 29 (11) ml, p = 0.1) 
and RVSVI fell in three patients.  RVSVI rose significantly in all controls, mean rest 
and stress RVSVI (●-●) (43 (8) vs. 52 (13), p = 0.03) are presented to summarise 
these data. 
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5.3.4  Correlates of the right and left ventricular stroke volume response 
to dobutamine 
 
Right and left ventricular stroke volume responses to dobutamine were defined by ∆ 
RVSVI and ∆ LVSVI, respectively.  These responses were correlated against changes 
in right and left ventricular dimensions during dobutamine infusion (identified in the 
text by the prefix ∆) and resting CMR measurements (see Table 5.3 overleaf).  ∆ 
RVSVI correlated closely with ∆ RV ejection fraction (r = 0.94, p < 0.001) but did not 
relate to either resting or dynamic RV volumes or resting RV stroke volume index or 
ejection fraction. 
 
∆ LVSVI correlated with ∆ LV end-diastolic volume (r = 0.547, p = 0.028) and ∆ LV 
ejection fraction (r = 0.645, p = 0.007) but was not related to resting LV volumes or 
ejection fraction.  LV end-diastolic volume index correlated strongly with RV stroke 
volume index at rest (r = 0.821, p < 0.001) and stress (r = 0.693, p = 0.003) (see 
figures 5.2 (a) and (b), respectively, on page 201). 
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Table 5.3  
Correlates of the effect of dobutamine on right and left ventricular stroke volumes 
measured using dobutamine stress-Cardiovascular Magnetic Resonance imaging in 16 
patients with Pulmonary Hypertension 
Pearson r p value
∆ RV stroke volume index 
Resting RV stroke volume index -0.337 0.201
Resting RV ejection fraction -0.219 0.416
Resting RV end-diastolic volume index -0.022 0.936
Resting RV end-systolic volume index 0.012 0.657
∆ RV ejection fraction 0.94 < 0.001
∆ RV end-diastolic volume index -0.436 0.092
∆ RV end-systolic volume index -0.223 0.406
∆ LV stroke volume index 
Resting LV stroke volume index -0.297 0.263
Resting LV ejection fraction 0.012 0.965
Resting LV end-diastolic volume index -0.339 0.199
Resting LV end-systolic volume index -0.142 0.599
∆ LV ejection fraction 0.645 0.007
∆ LV end-diastolic volume index 0.547 0.028
∆ LV end-systolic volume index -0.142 0.599
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Figure 5.2  
RV stroke volume index (RVSVI) and LV end-diastolic volume index (LVEDVI) were measured at rest and during dobutamine stress-
Cardiovascular Magnetic Resonance imaging in 16 patients with Pulmonary Hypertension.  RVSVI was closely related to LVEDVI, both at rest 
(figure 5.3 (a), r = 0.821, p < 0.001) and during stress (figure 5.3 (b), r = 0.693, p = 0.003). 
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5.4 Discussion 
 
In this Chapter, dobutamine stress-CMR imaging was performed successfully in all 16 
PH patients and 6 controls.  The protocol was well tolerated, with no serious adverse 
events.  As expected there was good internal agreement between right and left 
ventricular stroke volumes both at rest and with stress in PH patients and controls.  
This provided quality assurance regarding the imaging performed. 
 
The major results of this study are as follows.  The normal, synchronised response to 
dobutamine was lost in PH patients who were unable to increase either right or left 
ventricular stroke volume.  This has been shown before in earlier studies. (47, 168, 
169) Interestingly, the reasons for stroke volume limitation were different for right 
and left ventricles.  The principal reason for RVSV limitation appeared diminished 
RV contractile reserve.  In contrast, LVSV was limited primarily by impaired LV 
filling, which, in turn, appeared due to low RVSV (i.e. preload) rather than LV 
compression due to displacement of the interventricular septum.  These findings are 
discussed in more detail below. 
 
5.4.1 Right ventricle 
 
In PH patients, mean RV stroke volume did not rise in response to dobutamine and 
individual values actually fell in 3/16 patients, see figure 5.1.  The increment seen in 
RV ejection fraction in PH patients (27 %), although statistically significant, was also 
was smaller than that observed in controls (38 %).  The extent of this change in RV 
ejection fraction (∆ RVEF) correlated strongly with the resulting change in RV stroke 
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volume (∆ RVSVI), which was not related to any other resting or stress CMR 
measurement.  RV stroke volume is determined principally by RV end-diastolic 
volume and RV ejection fraction.  However, RV end-diastolic volumes did not change 
during dobutamine infusion.  These findings suggest that the principal factor limiting 
RV stroke volume augmentation in this experiment was the ability of the PH patients 
to increase RV ejection fraction appropriately. 
 
The physiological significance of RV ejection fraction has been the subject of recent 
study.  Although it reflects RV contractility, RV ejection fraction is also influenced by 
RV afterload (151-153),  Interesting recent evidence has identified a close correlation 
between RV ejection fraction and RV wall stress in PH patients (150), indicating that 
RV ejection fraction is, in fact, a better reflection of the extent to which the RV has 
adapted to the afterload it faces (170).  Thus, the intimate relationship between RV 
ejection fraction and the capacity to appropriately increase stroke volume in this 
experiment indicates a degree of RV maladaptation, or diminished contractile reserve.  
It is reasonable to presume that the rise in pulmonary artery pressure during physical 
activity previously demonstrated, using the ambulatory pulmonary artery catheter 
(171), mediates a rise in RV afterload and stroke work, exposing this maladaptation. 
 
Previous studies have found similar evidence of RV stroke volume impairment in 
patients with PH, using exercise-CMR imaging (168), exercise-Electron Beam CT 
imaging (169) and cardiopulmonary exercise testing (47).  RV ejection fraction fell in 
both of the earlier imaging studies (168, 169), in which stroke volume was measured 
post-exercise.  These results support the conclusion that the RV contractile function, 
which reflects the level of adaptation of the RV to the afterload it faces, is the 
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principal determinant stroke volume during exercise in PH.  However, the fall in RV 
ejection fraction demonstrated in these reports contrasts with the increment, albeit 
blunted, in RV ejection fraction seen in our patients, stressed using dobutamine.  A 
similar difference between exercise-CMR and ds-CMR has been shown before in 
patients with congenital heart disease (126).  It is unclear whether this difference 
reflects the fact that measurements can only be made post-exercise in exercise-CMR.  
Nevertheless results from the two techniques cannot be directly compared in PH 
patients. 
 
5.4.2 Left ventricle 
 
As indicated above, PH patients were unable to increase LV stroke volume in 
response to dobutamine.  In contrast to the RV, the change seen in LV stroke volume 
(∆ LVSVI) correlated with both ∆ LV ejection fraction and ∆ LVEDV.  While resting 
and stress LVEF was normal (161, 172) in PH patients, LV end-diastolic volumes 
were low at rest and fell further during stress testing in this experiment and in earlier 
studies (168, 169).  Thus, reduced LV filling appeared the more important 
determinant of LV stroke volume than LVEF in the PH patients in this study.  As 
indicated in Section 5.1, the mechanisms behind this are not well understood. 
 
One potential explanation for reduced LV filling is compression of the LV within the 
enclosed pericardial sac.  Earlier studies have demonstrated that the pressure 
overloaded RV causes leftward displacement of the interventricular septum during 
early diastole (163-165).  Such a mechanism certainly seems plausible on inspection 
of CMR images in patients with PH showing an apparently squashed LV cavity.  
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Early animal studies by Elzinga and co-workers (173) first proposed that such 
pericardial constriction played an important role in right-left ventricular interaction.  
More recently, Baker (174) and Belenkie (175), using similar canine models of acute 
RV pressure overload, demonstrated that opening of the pericardium facilitated 
improved LV filling and an increase in stroke volume. Evidence that direct ventricular 
interaction may be important in human subjects with PH has recently be reported by 
Gan et al, who correlated left atrial filling rate, derived from transoesophageal 
echocardiography, against cardiac dimensions measured at rest in using CMR.  In this 
study, LV filling rate correlated with the severity of leftward interventricular septal 
displacement and the authors concluded that septal displacement was directly 
impairing LV relaxation and, therefore, filling  (163). 
 
The alternative view is that impaired LV filling reflects low RV stroke volume and 
diminished LV preload  (161, 162).  Under these conditions, septal displacement 
would still occur, but would do so more as a consequence of reduced LV filling rather 
than as the cause of it.  We found some evidence in support of this hypothesis in that 
we demonstrated a linear and consistent correlation between LV end-diastolic volume 
and RV stroke volume at rest and stress (see figures 3 (a) and (b), respectively).  This 
indicates coupling between RV output and LV filling under both conditions.   
 
This hypothesis is further supported by previous studies. Gurudevan et al 
demonstrated rapid resolution of mitral valve inflow abnormalities and normalisation 
of LV filling rates using echocardiography pre- and post-pulmonary 
thromboendarterectomy (PTE) in patients with chronic thromboembolic PH (161).  
These improvements were associated with a fall in pulmonary vascular resistance and 
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a rise in wedge pressure but no change in the M-mode appearance of the 
interventricular septum. Furthermore, Blanchard et al found, in patients with chronic 
RV pressure overload due to chronic thromboembolic PH (contrast this with the 
model of acute RV pressure overload used by Baker and Belenkie) that although the 
LV appears compressed by the RV, pericardiectomy results in no change in LV 
volume or diastolic filling (176).  These studies suggest that the human pericardium 
may be able to adapt to pressure and shape changes over time and the role of direct 
ventricular interaction due to pericardial constriction is unclear at this time. 
 
Furthermore, earlier invasive exercise studies also support the conclusion that direct 
ventricular interaction is less important than reduced RV stroke volume in limiting 
LV filling: During Operation Everest II (OE II), normal subjects were exposed to 
chronic hypoxia and exercised during a simulated ascent of Everest.   Pulmonary 
artery pressure and pulmonary vascular resistance rose in these subjects without any 
rise in pulmonary capillary wedge pressure (177), making them a reasonable 
haemodynamic model of established PH due to other diseases.  In this study, LV 
stroke volume and end-diastolic volume also fell in all subjects during exercise, 
accompanied by a decrease in pulmonary capillary wedge pressure, but with 
preservation of LV systolic function (178, 179). These invasive measurements are 
consistent with my non-invasive observations.  If septal displacement had played an 
important role in limiting LV end-diastolic volume in the OE II volunteers, a rise, 
rather than the observed fall in pulmonary capillary wedge pressure would have been 
expected. 
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5.4.3 Conclusions 
 
In this chapter it has been shown that patients with PH are unable to increase right or 
left ventricular stroke volume when given the cardiac inotrope Dobutamine.  The 
principal factor limiting RV stroke volume augmentation appears to be diminished 
RV contractile reserve, equivalent to maladaptation of the RV to the afterload it faces 
during exercise.  In contrast, the principal cause of LV stroke volume limitation 
appeared to be impaired LV filling, as a result of low RVSV (i.e. preload) rather than 
LV compression due to interventricular septal displacement. 
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Chapter 6 
General Discussion and Summary 
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6.1 Clinical background 
 
Over the last fifteen years new and effective treatments for PAH and CTEPH have 
been developed.  In patients with PAH, continuous intravenous Epoprostenol has been 
shown to improve survival in a randomised, controlled trial (180).  Although this 
cumbersome, and potentially dangerous, treatment remains necessary in patients with 
WHO functional class IV disease, easier to manage oral alternatives, such as 
Bosentan, have proven as effective in patients with Class III disease in recent clinical 
trials (181).  As a result, oral therapies are now accepted first-line treatment in 
patients with without overt evidence of RV failure (65).  In a similar vein, pulmonary 
thromboendarterectomy (PTE) has revolutionised the outlook for patients with 
CTEPH.  With increasing global experience and refinement of surgical techniques, 
post-operative care and pre-operative patient selection criteria, 5-year survival rates 
have reached almost 90% after successful PTE (182), in stark contrast to the 5-year 
survival rate of  10 % without surgery (183). 
 
If this pace of clinical progress continues, even better therapies for PH may be 
developed in the years to come and treatment algorithms will have to evolve to 
accommodate them.  In this dynamic clinical environment the development of a better 
means of quantifying and understanding RV function is essential.  For the most part, 
RV function determines survival in PH patients and its precise and prompt 
measurement is likely to aid clinical decision-making in this context. 
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6.2 The limitations of the current diagnostic method 
 
At present, PH physicians remain reliant on transthoracic echocardiography and right 
heart catheterisation for an assessment of RV function in their patients.  As discussed 
in Sections 1.3.1 and 1.3.2 these tools are not ideal for this purpose.  
Echocardiography relies on flawed geometric assumptions to extrapolate three-
dimensional RV volumes (and therefore function) from measurements acquired in 
two-dimensions and in a single plane.  These assumptions become increasingly 
incorrect as the RV dilates and fails, as is inevitable in most PH patients.  Right heart 
catheterisation is more accurate than echocardiography but it is so invasive that it 
cannot be justified in all patients.  Furthermore, measurements are made during right 
heart catheterisation in a patient lying supine, at rest, in a catheterisation laboratory.  
This environment is far-removed from the patients day-to-day activities and 
potentially distinct from their ability to exercise, on which the efficacy of subsequent 
treatments will be assessed.  It is perhaps unsurprising, therefore, that resting invasive 
haemodynamics often change little despite apparently successful treatment of PH as 
assessed by improvement in symptom scores, exercise performance and survival (71, 
184) since these values rarely reflect physiological conditions at the times that 
patients experience symptoms. 
 
6.3 The advantages of CMR imaging 
 
In Section 1.4.3 the advantages of CMR imaging in the assessment of the RV in PH 
patients were described.  The principal strength of CMR is its ability to directly 
generate high fidelity measurements of right (and left) ventricular volume (97), mass 
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(101) and systolic function (97), in any plane and at almost any angle.   These 
measurements can be made non-invasively, without the use of ionising radiation and 
are extremely reproducible, reducing the number of observations needed to test study 
hypotheses.  Chapter 3 illustrates this final point clearly.  In this experiment, CMR 
imaging was used to provide a gold-standard reference for RV systolic function.  A 
close, logarithmic relationship between NT-proBNP and RV ejection fraction was 
found and the precision and reproducibility of the MR measurements allowed the 
identification of an NT-proBNP threshold for the detection of RV failure.  As 
commented on by Groenning and co-authors in their paper on the NT-proBNP 
threshold for LV systolic function (79), the number of observations needed to define 
such a value using echocardiography would have been much greater due to the 
relative imprecision of the reference measurement 
 
In Chapter 4, contrast-enhanced CMR was successfully used to identify occult 
myocardial abnormalities within the RV insertion points and interventricular septum 
(IVS) of patients with PH.  These abnormalities, which probably reflect fibrosis 
related to IVS bowing, had gone undetected until this study.  No other imaging 
modality has the ability that CMR imaging has to describe microscopic myocardial 
structure, in addition to macroscopic ventricular dimensions and function.  The new 
information gleaned during this experiment emphasises the importance of IVS 
dysfunction in the evolution of RV failure in PH and is a potentially fertile area for 
future study (see Section 6.4). 
 
In Chapter 5, Dobutamine stress-CMR (ds-CMR) was utilized to investigate and 
describe the reasons for right and left ventricular stroke volume impairment during 
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exercise in patients with PH.  Ds-CMR was performed for the first time in PH patients 
in this experiment.  Although stress echocardiography is a less expensive alternative 
to ds-CMR it is subject to the same errors as resting echocardiography described in 
Section 1.3.1.  Stress echo is also extremely operator-dependant and pulmonary 
vascular units that do not specialise in echocardiography have had little success in 
replicating the results of the original publications by specialist stress-
echocardiography units (185).  Ds-CMR circumvents this operator dependency and 
allows high-fidelity imaging of both right and left ventricles during stress.  Unlike 
physical exercise-CMR, which suffers from image degradation due to patient 
movement inside the scanner, ds-CMR also facilitates true stress imaging of PH 
patients, avoiding potential errors related to exercise recovery. 
 
6.4 Conclusions and future work 
 
This thesis has demonstrated that CMR imaging can be performed safely and yield 
high-quality images in patients with PH.  Despite significant gas exchange problems 
the vast majority of patients studied were able to breath-hold adequately during the 
MR pulse sequences described herein. 
 
The results of the experiments conducted in this thesis are novel and clinically 
relevant.  The NT-proBNP threshold for RV failure defined in Chapter 3 has the 
potential to streamline the diagnostic pathway for patients with presenting with PH.  
In particular, the results of an NT-proBNP test may, in the future, help inform the 
largely subject process of stratifying new patients for invasive assessment and the 
initiation of disease targeted therapy.  However, any incorporation of NT-proBNP 
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testing into diagnostic algorithms for PH must be combined with rigorous exclusion 
of patients with other reasons for a high NT-proBNP result.  The strategy should be 
predated by prospective validation of the threshold identified in a larger cohort of 
patients.  This is an obvious area for further study. 
 
In Chapter 4, ce-CMR was used for the first time in PH patients.  The occult, and 
previously unknown, myocardial abnormalities demonstrated in this study are a 
potentially fruitful area for further study.  In patients with hypertrophic 
cardiomyopathy, areas of delayed contrast enhancement (DCE) within the septum and 
RV insertion points have recently been correlated with electrical instability on 
detailed ECG recordings and the incidence of life-threatening ventricular tachycardia 
(106).  These areas have been proposed as arrhythmogenic foci, and thus, may prove 
to be the visible substrate for sudden arrhythmic death in patients with this condition.  
Since patients with PH are also prone to sudden arrhythmic death (58), it would be 
interesting to test the hypothesis that the DCE identified in similar areas in PH 
patients in Chapter 4,  correlates with areas of similar electrical instability.  This 
information might help identify patients with PH who are more likely to develop 
dangerous cardiac arrhythmias, and thus, benefit from prophylactic medication. 
 
In Chapter 5, ds-CMR was performed successfully and safely in PH patients for the 
first time.  In this study, both right and left ventricular stroke volumes failed to rise in 
PH patients during simulated exercise.  The former appeared related solely to 
diminished RV contractile reserve, while the latter seemed to reflect diminished LV 
filling and the Frank-Starling mechanism.  The data reported herein support the 
conclusion that LV filling is reduced during exercise in PH patients due to reduced 
 214
LV preload rather than extrinsic compression of the LV by septal bowing during 
diastole.  This conclusion is in agreement with earlier invasive studies performed 
during Operation Everest II (178, 179) and a proportion of the latest relevant imaging 
studies performed in PH patients (161, 162).  Nevertheless, contrary evidence has also 
been published (163) and the conclusion reached in this thesis cannot be considered 
absolute.  Future studies combining ds-CMR and invasive cardiac pressure 
measurements may be able to definitively define the principal limitation to LV filling 
during exercise in PH patients.  Nonetheless, the results of Chapter 5 add considerably 
to the knowledge base in this interesting area of study.  Ds-CMR also provides a 
potentially useful assessment tool for patients with mild PH or those with risk factors 
for PH in whom a non-invasive screening test would be useful.  Amplification of any 
abnormal signals from the pulmonary circulation is these patients may be possible 
using ds-CMR and further studies should be directed in this area. 
 
Pulmonary vascular medicine is rapidly evolving clinical speciality in which huge 
progress has been made over recent years.  5-year survival has almost doubled for 
patients with PAH (from 34% in 1991 (1) to 61% in 2005 (3)) and new, and 
potentially more effective therapies, directed against well described intracellular 
targets, are the subject of ongoing clinical trials.  Patients with proximal CTEPH can 
now be effectively treated by pulmonary thromboendarterectomy and even those with 
distal CTEPH can gain some benefit from medications previously reserved for 
patients with PAH (186).  As the therapeutic armamentarium available to pulmonary 
vascular physicians grows treatment algorithms must evolve to reflect this increased 
complexity.  Standard diagnostic aids such as echocardiography and right heart 
catheterisation are likely to remain essential components in these algorithms but CMR 
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imaging offers significant advantages over both.  This thesis demonstrates that CMR 
imaging can be used to improve both the clinical management of PH patients and our 
understanding of the reasons for right and left ventricular dysfunction in this 
condition.  It is hoped that over the next decade, as the availability of CMR imaging 
increases, the considerable advantages offered by CMR imaging can be experienced 
by patients unfortunate enough to develop PH. 
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